AngioDynamics (ANGO) 10-K 1 Aug 16 2016 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	May 31, 2016	Jul. 22, 2016	Nov. 30, 2015
Document And Entity Information [Abstract]
Entity Registrant Name	ANGIODYNAMICS INC
Entity Central Index Key	1,275,187
Document Type	10-K
Document Period End Date	May 31, 2016
Amendment Flag	false
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY
Current Fiscal Year End Date	--05-31
Entity Well Known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Public Float			$ 431,798,128
Entity Common Stock, Shares Outstanding		36,442,398

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	May 31, 2016	May 31, 2015	May 31, 2014
Income Statement [Abstract]
Net sales	$ 353,890	$ 356,534	$ 354,425
Cost of sales	179,574	180,738	174,251
Gross profit	174,316	175,796	180,174
Operating expenses
Research and development	25,053	26,594	28,124
Sales and marketing	84,723	83,220	85,305
General and administrative	29,603	29,162	26,902
Amortization of intangibles	17,964	17,966	16,562
Change in fair value of contingent consideration	948	(8,096)	(1,908)
Acquisition, restructuring and other items, net	12,591	26,257	10,873
Medical device excise tax	2,416	4,142	3,829
Total operating expenses	173,298	179,245	169,687
Operating income (loss)	1,018	(3,449)	10,487
Other (expenses) income
Interest income	11	4	0
Interest expense	(3,396)	(3,197)	(3,656)
Other expense	(886)	(1,489)	(1,645)
Total other expenses, net	(4,271)	(4,682)	(5,301)
Income (loss) before income tax expense (benefit)	(3,253)	(8,131)	5,186
Income tax expense (benefit)	40,337	(4,743)	2,839
Net income (loss)	$ (43,590)	$ (3,388)	$ 2,347
Earnings per share
Basic (usd per share)	$ (1.21)	$ (0.09)	$ 0.07
Diluted (usd per share)	$ (1.21)	$ (0.09)	$ 0.07
Basic weighted average shares outstanding (in shares)	36,161,383	35,683,139	35,135,689
Diluted weighted average shares outstanding (in shares)	36,161,383	35,683,139	35,439,850

Consolidated Statements Compreh

Consolidated Statements Comprehensive Income (Loss) - USD ($) $ in Thousands	12 Months Ended
	May 31, 2016	May 31, 2015	May 31, 2014
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ (43,590)	$ (3,388)	$ 2,347
Other comprehensive (loss) income, before tax:
Unrealized gain (loss) on marketable securities	(11)	(120)	(16)
Unrealized gain (loss) on interest rate swap	257	296	(32)
Foreign currency translation gain (loss)	(112)	(264)	442
Other comprehensive income (loss), before tax	134	(88)	394
Income tax benefit (expense) related to items of other comprehensive income (loss)	(92)	(64)	18
Other comprehensive income (loss), net of tax	42	(152)	412
Total comprehensive income (loss), net of tax	$ (43,548)	$ (3,540)	$ 2,759

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	May 31, 2016	May 31, 2015
CURRENT ASSETS
Cash and cash equivalents	$ 32,333	$ 18,391
Marketable securities, at fair value	1,653	1,689
Accounts receivable, net of allowances of $4,372 and $3,043, respectively	52,867	58,428
Inventories	55,370	67,388
Prepaid income taxes	788	770
Prepaid expenses and other	3,243	4,132
Total current assets	146,254	150,798
Property, Plant and Equipment, net	48,284	54,450
Other Assets	4,696	5,398
Intangible Assets, net	166,577	181,652
Goodwill	361,252	361,252
Deferred Income Taxes, long term	0	19,508
Total Assets	727,063	773,058
Current Liabilities
Accounts payable	15,616	23,048
Accrued liabilities	21,896	18,109
Income taxes payable	46	439
Current portion of long-term debt	16,250	8,750
Current portion of contingent consideration	12,919	9,969
Other current liabilities	0	200
Total current liabilities	66,727	60,515
Long-term Debt, net of current portion	105,160	128,910
Deferred Income Taxes, long term	21,684	1,119
Contingent Consideration, net of current portion	25,356	37,415
Other Long Term Liabilities	908	0
Total Liabilities	219,835	227,959
Commitments and Contingencies
Stockholders’ Equity
Preferred stock, par value $.01 per share, 5,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock, par value $.01 per share, 75,000,000 shares authorized; 36,420,403 and 36,043,725 shares issued and 36,278,098 and 35,901,420 shares outstanding at May 31, 2016 and May 31, 2015, respectively	363	360
Additional paid-in capital	525,775	520,101
Retained earnings	(16,015)	27,575
Treasury stock, 142,305 shares, at cost	(2,104)	(2,104)
Accumulated other comprehensive loss	(791)	(833)
Total Stockholders' Equity	507,228	545,099
Total Liabilities and Stockholders' Equity	$ 727,063	$ 773,058

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	May 31, 2016	May 31, 2015
Statement of Financial Position [Abstract]
Accounts receivable, allowances	$ 4,372	$ 3,043
Preferred stock, par value (usd per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (shares)	5,000,000	5,000,000
Preferred stock, shares issued (shares)	0	0
Preferred stock, shares outstanding (shares)	0	0
Common stock, par value (usd per share)	$ 0.01	$ 0.01
Shares of common stock (shares)	75,000,000	75,000,000
Common stock, shares issued (shares)	36,420,403	36,043,725
Common stock, shares outstanding (shares)	36,278,098	35,901,420
Treasury stock, shares (shares)	142,305	142,305

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional paid in capital	Retained earnings	Accumulated other comprehensive loss	Treasury Stock
Beginning Balance at May. 31, 2012	$ 523,306
Net income	(1,051)
Ending Balance at May. 31, 2013	526,324	$ 351	$ 500,554	$ 28,616	$ (1,093)	$ (2,104)
Ending Balance, Shares at May. 31, 2013		35,060,351				(142,305)
Net income	2,347			2,347
Exercise of stock options	1,085		1,085
Tax effect of exercise of stock options	(146)		(146)
Exercise of stock options, Shares		105,676
Issuance of restricted shares, net	(1,357)	$ 1	(1,358)
Issuance of restricted shares, net, Shares		129,702
Purchase of common stock under Employee Stock Purchase Plan	2,718	$ 1	2,717
Purchase of common stock under Employee Stock Purchase Plan, Shares		146,275
Stock-based compensation	5,502		5,502
Other comprehensive income (loss), net of tax	412				412
Ending Balance at May. 31, 2014	536,885	$ 353	508,354	30,963	(681)	$ (2,104)
Ending Balance, Shares at May. 31, 2014		35,442,004				(142,305)
Net income	284
Other comprehensive income (loss), net of tax	63
Ending Balance at Aug. 31, 2014	539,585
Beginning Balance at May. 31, 2014	536,885	$ 353	508,354	30,963	(681)	$ (2,104)
Beginning Balance, Shares at May. 31, 2014		35,442,004				(142,305)
Net income	1,353
Other comprehensive income (loss), net of tax	(2)
Ending Balance at Nov. 30, 2014	543,239
Beginning Balance at May. 31, 2014	536,885	$ 353	508,354	30,963	(681)	$ (2,104)
Beginning Balance, Shares at May. 31, 2014		35,442,004				(142,305)
Net income	(2,800)
Other comprehensive income (loss), net of tax	(517)
Ending Balance at Feb. 28, 2015	543,570
Beginning Balance at May. 31, 2014	536,885	$ 353	508,354	30,963	(681)	$ (2,104)
Beginning Balance, Shares at May. 31, 2014		35,442,004				(142,305)
Net income	(3,388)			(3,388)
Exercise of stock options	4,338	$ 3	4,335
Exercise of stock options, Shares		341,446
Issuance of restricted shares, net	2	$ 2
Issuance of restricted shares, net, Shares		141,274
Purchase of common stock under Employee Stock Purchase Plan	1,416	$ 2	1,414
Purchase of common stock under Employee Stock Purchase Plan, Shares		119,001
Stock-based compensation	5,998		5,998
Other comprehensive income (loss), net of tax	(152)				(152)
Ending Balance at May. 31, 2015	545,099	$ 360	520,101	27,575	(833)	$ (2,104)
Ending Balance, Shares at May. 31, 2015		36,043,725				(142,305)
Beginning Balance at Aug. 31, 2014	539,585
Net income	1,069
Other comprehensive income (loss), net of tax	(64)
Ending Balance at Nov. 30, 2014	543,239
Net income	(4,153)
Other comprehensive income (loss), net of tax	(514)
Ending Balance at Feb. 28, 2015	543,570
Net income	(588)
Ending Balance at May. 31, 2015	545,099	$ 360	520,101	27,575	(833)	$ (2,104)
Ending Balance, Shares at May. 31, 2015		36,043,725				(142,305)
Net income	(775)
Ending Balance at Aug. 31, 2015	547,182
Beginning Balance at May. 31, 2015	545,099	$ 360	520,101	27,575	(833)	$ (2,104)
Beginning Balance, Shares at May. 31, 2015		36,043,725				(142,305)
Net income	(1,109)
Ending Balance at Nov. 30, 2015	547,726
Beginning Balance at May. 31, 2015	545,099	$ 360	520,101	27,575	(833)	$ (2,104)
Beginning Balance, Shares at May. 31, 2015		36,043,725				(142,305)
Net income	(515)
Ending Balance at Feb. 29, 2016	550,796
Beginning Balance at May. 31, 2015	545,099	$ 360	520,101	27,575	(833)	$ (2,104)
Beginning Balance, Shares at May. 31, 2015		36,043,725				(142,305)
Net income	(43,590)			(43,590)
Exercise of stock options	$ 1,297	$ 1	1,296
Exercise of stock options, Shares	145,260	101,040
Issuance of restricted shares, net	$ (331)	$ 1	(332)
Issuance of restricted shares, net, Shares		137,681
Purchase of common stock under Employee Stock Purchase Plan	1,471	$ 1	1,470
Purchase of common stock under Employee Stock Purchase Plan, Shares		137,957
Stock-based compensation	3,240		3,240
Other comprehensive income (loss), net of tax	42				42
Ending Balance at May. 31, 2016	507,228	$ 363	525,775	(16,015)	(791)	$ (2,104)
Ending Balance, Shares at May. 31, 2016		36,420,403				(142,305)
Beginning Balance at Aug. 31, 2015	547,182
Net income	(334)
Ending Balance at Nov. 30, 2015	547,726
Net income	594
Ending Balance at Feb. 29, 2016	550,796
Net income	(43,075)
Ending Balance at May. 31, 2016	$ 507,228	$ 363	$ 525,775	$ (16,015)	$ (791)	$ (2,104)
Ending Balance, Shares at May. 31, 2016		36,420,403				(142,305)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	May 31, 2016	May 31, 2015	May 31, 2014
Cash flows from operating activities:
Net income (loss)	$ (43,590)	$ (3,388)	$ 2,347
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	28,115	29,861	28,329
Amortization of acquired inventory basis step-up	0	0	150
Tax effect of exercise of stock options and issuance of performance shares	0	0	(146)
Deferred income tax provision	39,983	(5,123)	2,716
Stock based compensation	3,240	5,998	5,502
Changes in accounts receivable allowances	2,377	1,448	465
Change in fair value of contingent consideration	948	(8,096)	(1,908)
Loss on impairment/disposal of long-term assets	806	9,381	0
Loss on impairment of intangible assets	384	6,400	0
Other	90	181	130
Changes in operating assets and liabilities, net of effects of acquisitions:
Accounts receivable	3,131	2,095	(14,786)
Inventories	11,976	(5,648)	(6,114)
Prepaid expenses and other	712	(1,170)	1,208
Accounts payable and accrued liabilities	(2,956)	(6,254)	6,788
Net cash provided by operating activities	45,216	25,685	24,681
Cash flows from investing activities:
Additions to property, plant and equipment	(2,326)	(11,383)	(11,172)
Acquisition of businesses, net of cash acquired	0	0	(4,169)
Acquisition of intangible assets	(3,268)	(1,353)	(1,435)
Acquisition of warrants	(2,000)	0	0
Purchases of marketable securities	0	0	(25)
Proceeds from sale or maturity of marketable securities	25	0	353
Net cash used in investing activities	(7,569)	(12,736)	(16,448)
Cash flows from financing activities:
Repayment of long-term debt	(16,250)	(20,000)	(146,250)
Proceeds from issuance of and borrowings on long-term debt	0	15,000	146,410
Proceeds from exercise of stock options and ESPP	2,437	5,757	2,444
Payment of acquisition related contingent consideration	(9,850)	(11,222)	(15,943)
Deferred financing costs on long-term debt	0	0	(677)
Net cash used in financing activities	(23,663)	(10,465)	(14,016)
Effect of exchange rate changes on cash and cash equivalents	(42)	(198)	86
Increase (decrease) in cash and cash equivalents	13,942	2,286	(5,697)
Cash and cash equivalents
Beginning of year	18,391	16,105	21,802
End of year	32,333	18,391	16,105
Supplemental disclosure of non-cash operating, investing and financing activities:
Contractual obligations for acquisition of fixed assets	75	140	4,970
Contractual obligations for acquisition of intangibles and business	0	0	2,249
Contractual obligations for tax basis adjustment	0	779	0
Cash paid during the period for:
Interest	3,063	3,151	3,591
Income taxes	$ 332	$ 699	$ 182

Basis of Presentation, Business

Basis of Presentation, Business Description and Summary of Significant Accounting Policies	12 Months Ended
	May 31, 2016
Accounting Policies [Abstract]
BASIS OF PRESENTATION, BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	BASIS OF PRESENTATION, BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES 1. Basis of Presentation and Description of Business The consolidated financial statements include the accounts of AngioDynamics, Inc. and its wholly owned subsidiaries, (collectively, the “Company”). We design, manufacture and sell a wide range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and in oncology and surgical settings. Our devices are generally used in minimally invasive, image-guided procedures. Most of our products are intended to be used once and then discarded, or they may be temporarily implanted for short- or long-term use. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect reported amounts of sales and expenses during the reporting period. Actual results could differ from those estimates. Assets and liabilities of non-U.S. dollar functional currency entities are translated to U.S. dollars at period-end exchange rates, and the resulting gains and losses arising from the translation of those net assets are recorded as a cumulative translation adjustment, a component of accumulated other comprehensive loss on the consolidated balance sheets. All intercompany balances and transactions have been eliminated. Cash and Cash Equivalents We consider all unrestricted highly liquid investments purchased with an initial maturity of less than three months to be cash equivalents. We maintain cash and cash equivalent balances with financial institutions in the United States in excess of amounts insured by the Federal Deposit Insurance Corporation. Marketable Securities Marketable securities, which include auction rate investments, are classified as “available-for-sale securities” and are reported at fair value, with unrealized gains and losses excluded from operations and reported as a component of accumulated other comprehensive income (loss), net of the related tax effects, in stockholders’ equity. Cost is determined using the specific identification method. We hold investments in auction rate securities in order to generate higher than typical money market rate investment returns. Auction rate securities typically are high credit quality, generally achieved with municipal bond insurance. Credit risks are eased by the historical track record of bond insurers, which back a majority of this market. Sell orders for any security traded through an auction process could exceed bids and, in such cases, the auction fails and we may be unable to liquidate our position in the securities in the near term. As of May 31, 2016 and 2015 , we had $1.7 million and $1.7 million , respectively, in investments in two auction rate securities issued by New York state and local government authorities that failed auctions. The authorities are current in their interest payments on the securities. Accounts Receivable Accounts receivable, principally trade, are generally due within 30 to 90 days and are stated at amounts due from customers, net of an allowance for sales returns and doubtful accounts. We perform ongoing credit evaluations of our customers and adjust credit limits based upon payment history and the customer’s current creditworthiness, as determined by a review of their current credit information. We continuously monitor aging reports, collections and payments from customers, and a provision for estimated credit losses is maintained based upon our historical experience and any specific customer collection issues that have been identified. While such credit losses have historically been within our expectations and the provisions established, we cannot guarantee that the same credit loss rates will be experienced in the future. We write off accounts receivable when they are determined to be uncollectible. Inventories Inventories are stated at the lower of cost (using the first-in, first-out method) or market. Appropriate consideration is given to deterioration, obsolescence, expiring and other factors in evaluating net realizable value. Property, Plant and Equipment Property, plant and equipment are stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Refer below for useful lives by category: Estimated useful lives Building and building improvements 39 years Machinery and equipment 3 to 8 years Computer software and equipment 3 to 10 years We evaluate these assets for impairment periodically or as changes in circumstances or the occurrence of events suggest the remaining value is not recoverable. Expenditures for repairs and maintenance are charged to expense as incurred. Renewals and betterments are capitalized. Goodwill and Intangible Assets Intangible assets other than goodwill and acquired IP R&D are amortized over their estimated useful lives, which range between two and eighteen years, on either a straight-line basis over the expected period of benefit or as revenues are earned from the sales of the related products. We periodically review the estimated useful lives of our intangible assets and review such assets for impairment whenever events or changes in circumstances indicate that the carrying value of the assets is not recoverable. Our determination of impairment is based on estimates of future cash flows. If an intangible asset is considered to be impaired, the amount of the impairment will equal the excess of the carrying value over the fair value of the asset. Acquired IP R&D has an indefinite life and is not amortized until completion of the development of the project, at which time the IP R&D becomes an amortizable asset. If the related project is not completed in a timely manner or the project is terminated or abandoned, we may have an impairment related to the IP R&D, calculated as the excess of the asset’s carrying value over its fair value. Our policy defines IP R&D as the value assigned to those projects for which the related products have not received regulatory approval and have no alternative future use. Determining the portion of the purchase price allocated to IP R&D requires us to make significant estimates. The amount of the purchase price allocated to IP R&D is determined by estimating the future cash flows of each project or technology and discounting the net cash flows back to their present values. The discount rate used is determined at the time of measurement in accordance with accepted valuation methods. These methodologies include consideration of the risk of the project not achieving commercial feasibility. Goodwill and other intangible assets that have indefinite useful lives are not amortized, but rather, are tested for impairment annually or more frequently if impairment indicators arise. Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in each business combination. Goodwill and intangible assets have been recorded at either incurred or allocated cost. Allocated costs were based on respective fair market values at the date of acquisition. For goodwill, the impairment test requires a comparison of the estimated fair value of the reporting unit to which the goodwill is assigned to the sum of the carrying value of the assets and liabilities of that unit. If the sum of the carrying value of the assets and liabilities of a reporting unit exceeds the fair value of the reporting unit, the carrying value of the reporting unit’s goodwill is reduced to its implied fair value through an adjustment to the goodwill balance, resulting in an impairment charge. Our determination of impairment is based on estimates of future cash flows. 8. Contingent Consideration The fair value of the liability for contingent consideration recorded on the acquisition date for a business combination is based on probability weighted estimated cash flow streams, discounted back to present value using a discount rate determined in accordance with accepted valuation methods. The liability for contingent consideration is remeasured to fair value at each reporting period with changes recorded in earnings until the contingency is resolved. Revenue Recognition We recognize revenue when the following four criteria has been met: (i) persuasive evidence that an arrangement exists; (ii) the price is fixed or determinable; (iii) collectability is reasonably assured; and (iv) product delivery has occurred or services have been rendered. We recognize revenue, net of sales taxes assessed by any governmental authority, as products are shipped, based on shipping terms, and when title and risk of loss passes to customers. We negotiate shipping and credit terms on a customer-by-customer basis and products are shipped at an agreed upon price. All product returns must be pre-approved by us and customers may be subject to a 20% restocking charge. To be accepted, a returned product must be unadulterated, undamaged and have at least twelve months remaining prior to its expiration date. Charges for discounts, returns, rebates and other allowances are recognized as a deduction from revenue on an accrual basis in the period in which the revenue is recorded. The accrual for product returns, discounts and other allowances is based on the company’s history. Shipping and handling costs, associated with the distribution of finished products to customers, are recorded in costs of goods sold and are recognized when the related finished product is shipped to the customer. Amounts charged to customers for shipping are recorded in net sales. Research and Development Research and development costs, including salaries, consulting fees, building costs, utilities and administrative expenses that are related to developing new products, enhancing existing products, validating new and enhanced products, managing clinical, regulatory and medical affairs are expensed as incurred. Income Taxes In preparing our financial statements, we calculate income tax expense for each jurisdiction in which we operate. This involves estimating actual current taxes due plus assessing temporary differences arising from differing treatment for tax and accounting purposes that are recorded as deferred tax assets and liabilities. We periodically evaluate deferred tax assets, capital loss carryforwards and tax credit carryforwards to determine their recoverability based primarily on our ability to generate future taxable income and capital gains. Where it is more-likely-than-not these will not be recovered, we estimate a valuation allowance and record a corresponding additional tax expense in our statement of operations. We file income tax returns in the U.S. federal jurisdiction and various state and foreign jurisdictions. In the normal course of business we are subject to examination by taxing authorities throughout the world. Fiscal years 2012 through 2016 remain open to examination by the various tax authorities. New York State is currently auditing AngioDynamic’s franchise tax filings for 2011 through 2013, and we do not anticipate any material adjustments will result. We analyzed filing positions in all of the Federal and state jurisdictions where we are required to file income taxes, as well as all open tax years in these jurisdictions and believe that our income tax filing positions and deductions will be sustained on audit and we do not anticipate any adjustments will result in a material adverse effect on our financial condition, results of operations or cash flows. Derivative Financial Instruments We are exposed to market risks, including changes in interest rates. We periodically enter into certain derivative financial instruments to hedge the underlying economic exposure. The derivative instruments used are floating-to-fixed rate interest rate swaps, which are subject to hedge accounting treatment. Derivative instruments are presented in the consolidated financial statements at their fair value. Changes in the fair value of derivative financial instruments are either recognized periodically in income or in stockholders’ equity as a component of accumulated other comprehensive income (loss) depending on whether the derivative financial instrument qualifies for hedge accounting and, if so, whether it qualifies as a fair value or cash flow hedge. Generally, the changes in the fair value of derivatives accounted for as fair value hedges are recorded in income along with the portions of the changes in the fair value of hedged items that relate to the hedged risks. Changes in the fair value of derivatives accounted for as cash flow hedges, to the extent they are effective as hedges, are recorded in accumulated other comprehensive income (loss). Supplier Concentrations We are dependent upon the ability of our suppliers to provide products on a timely basis and on favorable pricing terms. The loss of our principal suppliers or a significant reduction in product availability from these suppliers could have a material adverse effect on us. We believe that our relationships with these suppliers are satisfactory. Recent Events On March 31, 2016, Joseph DeVivo, former President and Chief Executive Officer, decided to pursue other interests outside of the Company and on April 4, 2016, James C. Clemmer was appointed as the new President and Chief Executive Officer. As part of the separation agreement with Joseph DeVivo, his stock options, restricted stock units and performance shares will continue to vest for one year . On November 3, 2015, Mark Frost resigned as Executive Vice President and Chief Financial Officer (CFO). Michael Trimarchi, Vice President and Global Controller, assumed the responsibilities as principal accounting officer of the Company and interim CFO until his resignation on May 13, 2016. On July 22, 2016, Michael Greiner was appointed Executive Vice President and Chief Financial Officer of the Company, effective August 16, 2016. On July 27, 2016, Peter J. Kish was designated as the principal financial officer and principal accounting officer of the Company by the Board of Directors of the Company. Mr. Kish will serve in this role until Mr. Greiner begins his service as Chief Financial Officer on August 16, 2016. On December 18, 2015, President Obama signed into law H.R. 2029, the “Consolidated Appropriations Act, 2016”, which includes a two-year moratorium on the medical device excise tax, effective January 1, 2016. The 2.3 percent tax on sales of medical devices (except certain devices sold at retail) was enacted as part of the Affordable Care Act in 2010 and applied to device sales beginning on January 1, 2013. Absent further legislative action, the tax will be automatically reinstated for medical device sales starting on January 1, 2018. As presented on our Consolidated Condensed Statement of Operations we have incurred $12.0 million cumulatively since the enactment of the tax on January 1, 2013 through the May 31, 2016. In the absence of this tax, the company will seek opportunities to further invest in growth drivers to create long-term shareholder value. On November 17, 2015, the Company received a letter from the FDA closing out the warning letter the Company received from FDA in January 2011 regarding certain promotional activities related to the NanoKnife System. On November 25, 2015, the Company received letters from the FDA closing out the warning letters the Company received from FDA in May 2011 related to the Company’s Queensbury facility and in November 2014 related to the Company’s Glens Falls facility. These close out letters resolved all outstanding warning letters against the Company. During the quarter ended May 31, 2016, we made the decision to discontinue the Celerity tip location and navigation product line. The discontinuance of the product line was the result of performance and quality issues with the product and a strategic shift to focus on other product within the Vascular Access business. We recorded a write-off of approximately $5.8 million of inventory and $0.1 million of hardware assets during the fourth quarter. During the quarter ended May 31, 2016 we entered into an agreement with Merz North America where we became the exclusive sub-distributor of ASCLERA in the vein market in the United States and received the Merz customer list for the designated market territory. As part of the agreement we receive a personal, non-exclusive, non-transferable, non-assignable, non-sub licensable, license to use the trademarks, service marks and trades names from Merz. As a result of this agreement we recorded $3.3 million of intangible assets for the exclusive distribution rights and the customer lists obtained. The Asclera product is the replacement for Sotradecol. Regulatory Matters On May 27, 2011, we received a Warning Letter from the U.S. Food and Drug Administration ("FDA") in connection with its inspection of our Queensbury, NY manufacturing facility. In the Warning Letter, FDA cited deficiencies in the response letter we provided FDA pertaining to the inspection that occurred from January 4 to January 13, 2011. The deficiencies related to our internal procedures for medical device reporting, corrections and removals and complaint handling. We responded to the Warning Letter and completed corrective and preventive actions to address the observations noted. In December 2011, we initiated a comprehensive Quality Call to Action Program to review and augment our Quality Management Systems at our Queensbury facility. To accelerate implementation of the program, we engaged a team of external regulatory and quality experts and reallocated a significant number of engineering and product development resources to support this corporate initiative. From inception of the Quality Call to Action Program through fiscal 2014, we have incurred $3.2 million in direct costs associated with the program. On February 10, 2012, we received from FDA a Form 483, List of Investigational Observations, in connection with its inspection of our Queensbury facility from November 14, 2011 to February 10, 2012. The Form 483 contained 12 observations related to, among other things, our CAPA (Corrective and Preventive Action) system, MDR (Medical Device Reporting), complaint investigation, corrections and removals, acceptance criteria and training. Some of the observations contained in the Form 483 were repeat observations from the May 27, 2011 Warning Letter described above. On February 13, 2012, we received from FDA a Form 483 in connection with its inspection of our Fremont facility from January 12, 2012 to February 13, 2012. The Form 483 contained six observations related to, among other things, our CAPA system, design controls, risk management and training. We provided responses to FDA within 15 business days of our receipt of the Form 483s. On September 24, 2012, we received from FDA a Form 483 in connection with its subsequent inspection of our Queensbury, NY facility from September 6 to September 14, and September 19 to September 24. This re-inspection followed our response to the original Form 483 issued by FDA on February 13, 2012. The Form 483 contained 5 observations related to 510(k) decisions, complaint investigations, acceptance criteria, corrective and preventive actions and training. All but one of the observations in the Form 483 related to events that occurred before the date that we had indicated to FDA in our previous responses that our corrective and remediation activities related to our Quality Call to Action would be completed. We provided responses to FDA within 15 business days of our receipt of the Form 483. On February 4, 2014, FDA completed a comprehensive follow-up inspection of our Queensbury facility. The inspection began on January 14, 2014 and resulted in FDA issuing a Form 483 containing one observation. The observation related to the inconsistency of certain complaint investigation elements in certain devices that have hardware and disposable components. The Form 483 observation was annotated to reflect that during the inspection we had corrected the issue, and this correction was verified by the inspector. In addition, we provided a response to FDA within 15 business days of our receipt of the Form 483. We believe that the results of this inspection validate that all of the Quality System and current Good Manufacturing Practice issues raised in the 483s described above have been fully addressed. On March 31, 2014, FDA completed an inspection of our Glens Falls, NY facility. The inspection began on March 17, 2014 and resulted in FDA issuing a form 483 containing 3 observations. The observations were related to 1) inconsistency of a manufacturing product test process used among similar products, 2) a particular verification test of a product, and 3) non-conforming product control procedure. We responded to the FDA within 15 business days of the receipt of the Form 483. During the fourth quarter of our fiscal year ended May 31, 2014, we received Certificate to Foreign Governments ("CFGs") from the FDA covering all Vascular Access and Peripheral Vascular products manufactured in our Queensbury facility. During the first quarter of our fiscal year ended May 31, 2016, we received CFGs for our NanoKnife product. On November 5, 2014, we received a Warning Letter from the FDA relating to observations noted during FDA’s inspection of our Navilyst Medical facilities located in Marlborough, Massachusetts and Glens Falls, New York in 2014. The matters raised in the Warning Letter and observations focused on design control processes related to packaging validations and accelerated and real time aging testing in connection with our fluid management and PICC families of products, inconsistency of a manufacturing product test process used among similar valved PICC products, a particular verification test of valved PICC products and non-conforming product control procedures. On November 17, 2015, we received a letter from the FDA closing out the warning letter we received from FDA in January 2011 regarding certain promotional activities related to the NanoKnife System. On November 25, 2015, we received letters from the FDA closing out the warning letters we received from FDA in May 2011 related to the Company’s Queensbury facility and in November 2014 related to the Company’s Glens Falls facility. These close out letters resolved all outstanding warning letters against the Company. Recently Issued Accounting Pronouncements In May 2014, the Financial Accounting Standards Board ("FASB") issued ASU No. 2014-09, "Revenue from Contracts with Customers" ("ASU 2014-09"). ASU 2014-09 provides a single, comprehensive accounting model for revenues arising from contracts with customers that supersedes most of the existing revenue recognition guidance, including industry-specific guidance. Under this model, revenue is recognized at an amount that an entity expects to be entitled to upon transferring control of goods or services to a customer, as opposed to when risks and rewards transfer to a customer under existing revenue recognition guidance. ASU 2014-09 is effective for the Company beginning in its fiscal year 2018, and may be applied retrospectively to all prior periods presented or through a cumulative adjustment to the opening retained earnings balance in the year of adoption. The Company is currently in the process of evaluating the impact of ASU 2014-09 on its consolidated financial statements. In June 2014, the FASB issued ASU 2014-12, Accounting for Share-Based Payments When the Terms of the Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period, that clarified that entities should treat performance targets that can be met after the requisite service period of a share-based payment award as performance conditions that affect vesting. Therefore, an entity would not record compensation expense related to an award for which transfer to the employee is contingent on the entity’s satisfaction of a performance target until it becomes probable that the performance target is met. This ASU is effective for the Company in its first quarter beginning after January 1, 2016 and did not have a material impact on the Company’s consolidated financial statements. In April 2015, the FASB issued ASC Update No. 2015-03, Interest-Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. Update No. 2015-03 requires debt issuance costs related to a recognized debt liability to be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. Update No. 2015-03 is effective for annual reporting periods beginning after December 15, 2015 and interim periods within those reporting periods. Early adoption is permitted for financial statements that have not been previously issued. This update is not expected to impact the results of our operations. In July 2015, the FASB issued ASC Update No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. Update No. 2015-11 more closely aligns the measurement of inventory in U.S. GAAP with the measurement of inventory in International Financial Reporting Standards by requiring companies using the first-in, first-out and average costs methods to measure inventory using the lower of cost and net realizable value, where net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Update No. 2015-11 is effective for annual reporting periods beginning after December 15, 2016 and interim periods within those fiscal years. Update No. 2015-11 should be applied prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. The adoption of Update No. 2015-11 is not expected to have a material impact on our financial position or results of operations. In November 2015, the FASB issued ASC Update No. 2015-17, “Balance Sheet Classification of Deferred Taxes” as part of its simplification initiatives. This update requires deferred tax liabilities and assets to be classified as non-current on the consolidated condensed balance sheet for fiscal years beginning after December 15, 2016, and interim periods within those annual periods. Early application is permitted. An entity can elect to adopt prospectively or retrospectively to all periods presented. This update was applied retrospectively as of November 30, 2015. The current deferred tax asset balance of $4.4 million was classified as a non-current deferred tax asset for the period ended May 31, 2015 in the consolidated condensed balance sheet. In January 2016, the FASB issued ASU 2016-01, Financial Instruments - Overall (Subtopic 825-10). Update No. 2016-01 addresses certain aspects of recognition, measurement, presentation and disclosure of financial instruments. Update No. 2016-01 is effective for annual reporting periods beginning after December 15, 2017 and interim periods within those fiscal years and early application is permitted. The adoption of Update No. 2016-01 is not expected to have a material impact on our financial position or results of operations. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). ASU 2016-02 increases transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information about leasing arrangements. For leases with a term or twelve months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and liabilities. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018 and early application is permitted. The Company is currently in the process of evaluating the impact of ASU 2016-02 on its consolidated financial statements. In March 2016, the FASB issued ASU 2016-09, Compensation - Stock Based Compensation (Topic 718: Improvements to Employee Share-Based Payment Accounting. ASU 2016-09 simplifies and improves various aspects of ASC 718 for share-based payments, including income tax items and the classification of these items on the statement of cash flows. ASU 2016-09 is effective for annual periods beginning after December 31, 2016 and early application is permitted. The Company is currently in the process of evaluating the impact of ASU 2016-09 on its consolidated financial statements.

Other Assets

Other Assets	12 Months Ended
	May 31, 2016
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Other Assets	OTHER ASSETS On March 2, 2015, the Company filed an 8-K stating that it executed a non-binding letter of intent to enter into a strategic relationship with privately-held EmboMedics Inc., which develops injectable and resorbable embolic microspheres. On April 9, 2015, the Company entered into a License, Distribution, Manufacturing and Purchase Option Agreement with EmboMedics Inc, subject to certain approvals by EmboMedics shareholders. Under the terms of the agreement, AngioDynamics received an exclusive worldwide license to market and sell, upon regulatory clearances, EmboMedics’ microsphere technology. AngioDynamics has the ability to determine the manufacturing of the products. On December 7, 2015, AngioDynamics made an initial $2.0 million purchase of non-transferable warrants in a subsidiary of EmboMedics which become exercisable upon a change of control of EmboMedics. The Company does not have significant influence, or control of the subsidiary. This initial investment is recorded at cost and the Company will review for impairment at each balance sheet date. The warrants are not exercisable at the original issue date or the balance sheet date as they only become exercisable upon a change of control, termination of the agreement or delivery of an offer notice. Based on the achievement of certain development activities, the Company will make an additional $5.0 million purchase of non-transferable warrants and an additional $4.0 million in milestone payments based on regulatory approvals. In the future, AngioDynamics could execute an exclusive option to acquire this subsidiary of EmboMedics.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	12 Months Ended
	May 31, 2016
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Our financial instruments include cash and cash equivalents, accounts receivable, marketable securities, accounts payable, interest rate swap agreement and contingent earn outs. The carrying amount of cash and cash equivalents, accounts receivable, and accounts payable approximates fair value due to the immediate or short-term maturities. The marketable securities and interest rate swap agreement has been recorded at its fair value based on a valuation received from an independent third party. The contingent earn out has been recorded at fair value using the income approach. Fair value is the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. This policy establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The policy describes three levels of inputs that may be used to measure fair value which are provided in the table below. Level 1 Quoted prices in active markets for identical assets or liabilities. Level 1 assets include money market funds that are traded in an active exchange market. Level 2 Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. When quoted market prices are unobservable, we obtain pricing information from an independent pricing vendor. The pricing vendor uses various pricing models for each asset class that are consistent with what other market participants would use. The inputs and assumptions to the model of the pricing vendor are derived from market observable sources including: benchmark yields, reported trades, broker/dealer quotes, issuer spreads, benchmark securities, bids, offers, and other market-related data. The pricing vendor considers all available market observable inputs in determining the evaluation for a security. Thus, certain securities may not be priced using quoted prices, but rather determined from market observable information. Included in Level 2 assets is our interest rate swap agreement which is valued using a mid-market valuation model. Level 3 Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation. This category includes the auction rate securities where independent pricing information was not able to be obtained and the contingent consideration related to the acquisitions of Vortex, Microsulis and Clinical Devices. Our investments in auction-rate securities were classified as Level 3 as quoted prices were unavailable since these auction rate securities issued by New York state and local government authorities failed auction. Due to limited market information, we utilized a discounted cash flow (“DCF”) model to derive an estimate of fair value for contingent considerations for all periods presented. The assumptions used in preparing the DCF model included estimates with respect to the discount rate, amount and timing of future interest and principal payments and forward projections. Assumptions associated with the auction rate securities include the interest rate benchmarks, the probability of full repayment of the principal considering the credit quality and guarantees in place, and the rate of return required by investors to own such securities given the current liquidity risk. The following tables provide information by level for assets and liabilities that are measured at fair value (in thousands): Fair Value Measurements using inputs considered as: Level 1 Level 2 Level 3 Fair Value at May 31, 2016 Financial Assets Marketable securities New York State government agency obligations $ — $ — $ 1,653 $ 1,653 Total — — 1,653 1,653 Total Financial Assets $ — $ — $ 1,653 $ 1,653 Financial Liabilities Contingent liability for acquisition earn out — — 38,275 38,275 Total Financial Liabilities $ — $ — $ 38,275 $ 38,275 Fair Value Measurements using inputs considered as: Level 1 Level 2 Level 3 Fair Value at May 31, 2015 Financial Assets Marketable securities New York State government agency obligations $ — $ — $ 1,689 $ 1,689 Total — — 1,689 1,689 Total Financial Assets $ — $ — $ 1,689 $ 1,689 Financial Liabilities Interest rate swap agreements $ — $ 257 $ — $ 257 Contingent liability for acquisition earn out — — 47,384 47,384 Total Financial Liabilities $ — $ 257 $ 47,384 $ 47,641 There were no transfers in and out of Level 1, 2 and 3 measurements for the years ended May 31, 2016 and 2015 . The components of Level 3 fair value instruments as of May 31, 2016 are shown below (in thousands): Financial Assets Financial Liabilities Fair Value Measurements Fair Value Measurements Balance at May 31, 2015 $ 1,689 $ 47,384 Change in fair value of contingent consideration (1) — 948 Currency (gain) loss from remeasurement — 43 Fair market value adjustments (36 ) — Contingent consideration payments — (10,100 ) Balance at May 31, 2016 $ 1,653 $ 38,275 The components of Level 3 fair value instruments as of May 31, 2015 are shown below (in thousands): Financial Assets Financial Liabilities Fair Value Measurements Fair Value Measurements Balance at May 31, 2014 $ 1,809 $ 67,331 Change in fair value of contingent consideration (1) — (8,196 ) Currency (gain) loss from remeasurement — (529 ) Included in other comprehensive income (loss) (120 ) — Contingent consideration payments — (11,222 ) Balance at May 31, 2015 $ 1,689 $ 47,384 (1) Change in the fair value of contingent consideration is included in earnings and comprised of changes in estimated earn out payments based on projections of company performance and amortization of the present value discount. Contingent Liability for Acquisition Earn Outs Certain of our business combinations involve the potential for the payment of future contingent consideration upon the achievement of certain product development milestones and/or various other favorable operating conditions. Payment of the additional consideration is generally contingent on the acquired company reaching certain performance milestones, including attaining specified revenue levels or achieving product development targets. Contingent consideration is recorded at the estimated fair value of the contingent milestone payments on the acquisition date. The fair value of the contingent milestone consideration is remeasured at the estimated fair value at each reporting period with the change in fair value recognized as income or expense within change in fair value of contingent consideration in the consolidated statement of operations. We measure the initial liability and remeasure the liability on a recurring basis using Level 3 inputs as defined under authoritative guidance for fair value measurements. Contingent consideration liabilities will be remeasured to fair value each reporting period using projected net sales, discount rates, probabilities of payment and projected payment dates. Projected contingent payment amounts are discounted back to the current period using a discounted cash flow model. Projected net sales are based on our internal projections and extensive analysis of the target market and the sales potential. Increases in projected net sales and probabilities of payment may result in higher fair value measurements in the future. Increases in discount rates and the projected time to payment may result in lower fair value measurements in the future. Increases or decreases in any valuation inputs in isolation may result in a significantly lower or higher fair value measurement in the future. The recurring Level 3 fair value measurements of the contingent consideration liabilities include the following significant unobservable inputs as of May 31, 2016 (in thousands of dollars): Fair value at May 31, 2016 Valuation Technique Unobservable Input Range Revenue based payments $ 35,325 Discounted cash flow Discount rate 4% Milestone based payments 2,950 Discounted cash flow Discount rate 16% $ 38,275 At May 31, 2016 , the estimated potential amount of undiscounted future contingent consideration that we expect to pay as a result of all completed acquisitions is approximately $40.8 million . The milestones associated with the contingent consideration must be reached in future periods ranging from fiscal years 2017 to 2022 in order for the consideration to be paid.

Marketable Securities and Inves

Marketable Securities and Investments	12 Months Ended
	May 31, 2016
Investments, Debt and Equity Securities [Abstract]
MARKETABLE SECURITIES AND INVESTMENTS	MARKETABLE SECURITIES AND INVESTMENTS As of May 31, 2016 , marketable securities consisted of the following: Amortized cost Gross Unrealized Gains Gross Unrealized Losses Fair Value (in thousands) Available-for-sales securities New York State government agency obligations $ 1,800 $ — $ (147 ) $ 1,653 $ 1,800 $ — $ (147 ) $ 1,653 As of May 31, 2015 , marketable securities consisted of the following: Amortized cost Gross Unrealized Gains Gross Unrealized Losses Fair Value (in thousands) Available-for-sales securities New York State government agency obligations $ 1,825 $ — $ (136 ) $ 1,689 $ 1,825 $ — $ (136 ) $ 1,689 The amortized cost and fair value of marketable securities as of May 31, 2016 , by contractual maturity, are shown below. Expected maturities may differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without call or prepayment penalties. Amortized cost Fair Value (in thousands) As of May 31, 2016: Due in one year or less $ — $ — Due after one through five years — — Due after five through twenty years 1,800 1,653 $ 1,800 $ 1,653

Inventories

Inventories	12 Months Ended
	May 31, 2016
Inventory Disclosure [Abstract]
INVENTORIES	INVENTORIES As of May 31, 2016 and 2015 , inventories consisted of the following: May 31, 2016 May 31, 2015 (in thousands) Raw materials $ 21,669 $ 28,040 Work in process 10,700 11,910 Finished goods 23,001 27,438 Total $ 55,370 $ 67,388 Total inventory is reduced to net realizable value by $12.6 million compared to $7.8 million in the prior year. Of the $12.6 million in the current year, $5.8 million relates to the write-off of Celerity.

Prepaid Expenses and Other

Prepaid Expenses and Other	12 Months Ended
	May 31, 2016
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
PREPAID EXPENSES AND OTHER	PREPAID EXPENSES AND OTHER As of May 31, 2016 and 2015 , prepaid expenses and other consisted of the following: May 31, 2016 May 31, 2015 (in thousands) Deposits $ 190 $ 2,011 Other prepaid taxes 160 165 License fees 108 121 Software licenses 282 667 Trade shows 278 279 Rent 127 77 Other 2,098 812 Total $ 3,243 $ 4,132

Property, Plant and Equipment,

Property, Plant and Equipment, at Cost	12 Months Ended
	May 31, 2016
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT, AT COST	PROPERTY, PLANT AND EQUIPMENT, AT COST As of May 31, 2016 and 2015 , property, plant and equipment are summarized as follows: May 31, 2016 May 31, 2015 (in thousands) Building and building improvements $ 39,585 $ 33,853 Machinery and equipment 24,078 23,626 Computer software and equipment 24,691 24,431 Construction in progress 1,743 7,033 90,097 88,943 Less accumulated depreciation and amortization (43,536 ) (36,197 ) 46,561 52,746 Land and land improvements 1,723 1,704 $ 48,284 $ 54,450 Depreciation expense for fiscal 2016 , 2015 and 2014 was $8.2 million , $9.8 million and $8.4 million , respectively. In conjunction with the Operational Excellence Program that was announced in December 2013, we updated the estimated useful lives on certain manufacturing equipment. As a result of the change in the useful life, we recorded additional depreciation of $1.0 million, $1.5 million and $0.8 million for the years ended May 31, 2016 , 2015 and 2014 , respectively.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	12 Months Ended
	May 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL AND INTANGIBLE ASSETS	GOODWILL AND INTANGIBLE ASSETS Intangible assets other than goodwill and indefinite lived intangible assets are amortized over their estimated useful lives, which range between two and eighteen years, on either a straight-line basis or proportionately to the benefit being realized. We periodically review the estimated useful lives of our intangible assets and review such assets for impairment, based on estimated future cash flows, whenever events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. If an intangible asset is considered to be impaired, the amount of the impairment will equal the excess of the carrying value over the fair value of the asset. We consider our business to be a single operating segment entity, and a single reporting unit engaged in the development, manufacture and sale on a global basis of medical devices for vascular access, peripheral vascular disease, oncology and surgery. Goodwill and other intangible assets that have indefinite useful lives are not amortized, but rather, are tested for impairment annually or more frequently if impairment indicators arise. Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in each business combination. Goodwill and intangible assets have been recorded at either incurred or allocated costs based on respective fair market values at the date of acquisition. For goodwill, the impairment test requires a comparison of the estimated fair value of the reporting unit to which the goodwill is assigned to the sum of the carrying value of the assets and liabilities of that unit. If the sum of the carrying value of the assets and liabilities of a reporting unit exceeds the fair value of the reporting unit, the carrying value of the reporting unit’s goodwill is reduced to its implied fair value through an adjustment to the goodwill balance, resulting in an impairment charge. To determine fair value of our single reporting unit we utilized a market-based approach and an income approach. We determined the discounted cash flow as the best indicator to determine fair value and therefore assigned a weight of 75% with the remaining 25% assigned to the market approach. Under the market-based approach, we utilized information of our Company as well as publicly available information of certain peer companies within our industry to determine earnings multiples (EBITDA). Under the income approach, we determined fair value based on estimated future cash flows of the reporting unit, discounted by our estimated weighted-average cost of capital, which reflects the overall level of inherent risk of a reporting unit and the rate of return an outside investor would expect to earn. We used a discount rate of 12.5% to calculate the fair value of our reporting unit. Use of the income approach in determining the fair value of a reporting unit requires the use of significant estimates and assumptions, including revenue growth rates, operating margins, discount rates and future market conditions, among others. These assumptions are highly sensitive and changes in these estimates could result in impairment. We applied gross margin assumptions, showing improvement over historical trends, improvements over historical trends of revenue of certain product lines and used a capitalization rate of 8.5% to calculate the terminal value of our reporting unit. We completed our annual goodwill impairment test of our single reporting unit as of December 31, 2015. Our assessment of goodwill impairment indicated that the fair value of our reporting unit exceeded its carrying value and therefore goodwill was not impaired. The fair value of our reporting unit exceeded its carrying value by 9.2% . At times our stock market capitalization has been lower than our shareholders’ equity or book value. However, our reporting unit has continued to generate significant cash flows from operations, and we expect to continue to do so in fiscal 2016 and beyond. Furthermore, we believe that a reasonable potential buyer would offer a control premium for our business that would adequately cover the difference between our stock market capitalization and our book value. The implied control premium in our annual goodwill impairment test as of December 31, 2015 is comparable to premiums identified in recent acquisitions of companies of similar size and in similar industries. Even though we determined that there was no goodwill impairment as of December 31, 2015, the future occurrence of a potential indicator of impairment, such as a significant adverse change in legal, regulatory, business or economic conditions or a more-likely-than-not expectation that the reporting unit or a significant portion of the reporting unit will be sold or disposed of, would require an interim assessment for the reporting unit prior to the next required annual assessment as of December 31, 2016. We continued to assess impairment through May 31, 2016 and noted no events that would be considered a triggering event. It is not possible at this time to determine if any such future impairment charge would result or, if it does, whether such charge would be material. Events that could, in the future, result in impairment include, but are not limited to, declining sales for a significant product or in a significant geographic region. As of May 31, 2016 and 2015 , intangible assets consisted of the following: May 31, 2016 Gross carrying value Accumulated amortization Net carrying value Weighted average useful life (in thousands) (years) Product technologies $ 148,387 $ (51,313 ) $ 97,074 10.2 Customer relationships 88,389 (47,133 ) 41,256 11.9 Trademarks 28,470 (6,242 ) 22,228 10.7 In process R&D 3,600 — 3,600 Indefinite Licenses 7,931 (6,716 ) 1,215 7.6 Distributor relationships 2,150 (946 ) 1,204 5.2 $ 278,927 $ (112,350 ) $ 166,577 May 31, 2015 Gross carrying value Accumulated amortization Net carrying value Weighted avg useful life (in thousands) (years) Product technologies $ 148,776 $ (41,447 ) $ 107,329 10.2 Customer relationships 86,371 (42,813 ) 43,558 12.0 Trademarks 28,545 (3,383 ) 25,162 10.7 In process R&D 3,600 — 3,600 Indefinite Licenses 7,913 (5,910 ) 2,003 8.3 Distributor relationships 900 (900 ) — 3.0 $ 276,105 $ (94,453 ) $ 181,652 Amortization expense was $18.0 million , $18.0 million and $16.6 million for fiscal 2016 , 2015 and 2014 , respectively. Annual amortization of these intangible assets is expected to approximate the following amounts for each of the next five fiscal years (in thousands): 2017 $ 19,049 2018 $ 19,903 2019 $ 22,062 2020 $ 23,329 2021 $ 24,370 Adjustments to goodwill for the fiscal year ended May 31, 2016 and May 31, 2015 are as follows (in thousands): Total Balance, May 31, 2014 $ 360,473 Tax basis adjustment 779 Balance, May 31, 2015 $ 361,252 — Balance, May 31, 2016 $ 361,252 During fiscal 2015, goodwill and deferred tax liabilities were adjusted by $0.8 million due to the receipt of a New York State tax grant that was not correctly accounted for as part of purchase accounting in fiscal 2012. The Company has determined that this adjustment was not material to any current or prior annual or interim periods.

Income Taxes

Income Taxes	12 Months Ended
	May 31, 2016
Income Tax Disclosure [Abstract]
INCOME TAXES	-INCOME TAXES The components of income (loss) before income tax provision for the years ended May 31 are as follows: 2016 2015 2014 (in thousands) (Loss) income before tax provision: US $ (4,444 ) $ (8,965 ) $ 4,645 Non-US 1,191 834 541 $ (3,253 ) $ (8,131 ) $ 5,186 Income tax (benefit) provision analyzed by category and by statement of operations classification for the years ended May 31 is summarized as follows: 2016 2015 2014 (in thousands) Current Federal $ 34 $ (242 ) $ (133 ) State and local 103 205 99 Non U.S. 217 417 157 354 380 123 Deferred 39,983 (5,123 ) 2,716 Income tax (benefit) provision $ 40,337 $ (4,743 ) $ 2,839 The significant components of deferred income tax (benefit) expense from operations for the years ended May 31 consist of the following: 2016 2015 2014 (in thousands) Net effect of temporary differences $ 133 $ (1,916 ) $ 1,543 Adjustments for beginning-of-the-year valuation allowance balance for changes in circumstances 40,418 — — Impact of NYS tax reform legislation — — 1,173 Net operating loss carryforward (568 ) (3,207 ) — $ 39,983 $ (5,123 ) $ 2,716 Temporary differences that give rise to deferred tax assets and liabilities are summarized as follows: May 31, 2016 May 31, 2015 (in thousands) Deferred tax assets Net operating loss carryforward $ 52,593 $ 52,025 Stock-based compensation 4,135 4,468 Federal and state R&D tax credit carryforward 2,145 1,646 Inventories 4,535 2,808 Expenses incurred not currently deductible 3,018 2,107 Accrued liabilities 339 114 Gross deferred tax asset 66,765 63,168 Deferred tax liabilities Excess tax over book depreciation and amortization 46,240 42,988 46,240 42,988 Valuation Allowance (42,209 ) (1,791 ) Net deferred tax asset (liability) $ (21,684 ) $ 18,389 Our Federal net operating loss carryforwards as of May 31, 2016 after considering IRC Section 382 limitations are $151.7 million . The expiration of the Federal net operating loss carryforwards are as follows: $29.8 million between 2017 and 2023 and $121.9 million between 2027 and 2036. Our state net operating loss carryforwards as of May 31, 2016 after considering remaining IRC Section 382 limitations are $30.8 million which expire in various years from 2016 to 2036. As a result of certain realization requirements of ASC 718, the table of deferred tax assets and liabilities shown above does not include certain deferred tax assets as of May 31, 2016 and 2015 that arose directly from tax deductions related to equity compensation greater than compensation recognized for financial reporting. Equity will be increased by $0.4 million if and when such excess tax benefits are ultimately realized. At May 31, 2016 , we had a net deferred income tax liability of $21.7 million , after recording a valuation allowance of $42.2 million . The valuation allowance increased by $40.4 million in 2016. While the net deferred tax asset at May 31, 2016 before the valuation allowance was $19.9 million , the Company was required to record a valuation allowance of $40.4 million due to deferred tax liabilities related to intangibles of $20.5 million that have an indefinite reversal period and can not be used to support the deferred tax asset. A valuation allowance is provided if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company’s analysis of the need for a valuation allowance considered that the Company has incurred a cumulative loss in the U.S. over the three year period ending May 31, 2016 . A majority of the cumulative loss has been caused by the charges associated with the product recall and discontinuance and the impairment of fixed and intangible assets recorded in the quarter end February 28, 2015, From the time when the Company initially incurred a three year cumulative loss in the quarter ended February 28, 2015, and in each subsequent quarter through the quarter ended February 28, 2016, the Company could still demonstrate a recent history of core earnings , and had anticipated a return to profitability for the full fiscal year 2016. However, in the quarter ended May 31, 2016 the Company did not return to profitability for the full fiscal year and could no longer demonstrate a recent history of core earnings. Consequently after careful consideration and weighing of all the available positive and negative evidence, the weight given to the three year cumulative loss and lack of a recent history of core earnings was difficult to overcome and a full valuation allowance related to the U.S. deferred tax assets was established. Management will continue to reevaluate the positive and negative evidence at each reporting period and if future results as projected in the U.S. and our tax planning strategies are favorable, the valuation allowance may be removed, which could have a favorable material impact on our results of operations in the period in which it is recorded. Our consolidated income tax provision has differed from the amount that would be provided by applying the U.S. Federal statutory income tax rate to our income before income taxes for the following reasons: 2016 2015 2014 (in thousands) Income tax (benefit) provision at statutory tax rate of 35% $ (1,139 ) $ (2,845 ) $ 1,814 Effect of graduated tax rates 33 81 (51 ) State income taxes, net of Federal tax benefit (215 ) (21 ) 111 Impact of Non US operations (162 ) 133 (27 ) Research and development tax credit (499 ) (604 ) (236 ) Meals and entertainment 329 — — Nondeductible interest on contingent payments 262 265 540 Nontaxable gain on revaluation of contingent consideration liability (170 ) (3,102 ) (1,734 ) Tax law changes — (454 ) 1,173 Adjustment to beginning of year valuation allowance 40,685 — — Effect of elimination of stock compensation APIC pool 739 1,253 440 Nondeductible stock-based compensation — — 176 Other nondeductible expenses 207 498 384 Over (under) accrual of prior year Federal and state taxes 356 38 249 Other (89 ) 15 — Income tax (benefit) expense $ 40,337 $ (4,743 ) $ 2,839 The following table provides a reconciliation of the beginning and ending amount of unrecognized tax benefits, all of which, if recognized, would impact the effective tax rate. 2016 2015 2014 (in thousands) Unrecognized tax benefits balance at June 1 $ — $ — $ — Increase in gross amounts of tax positions related to prior years 899 — — Decrease in gross amounts of tax positions related to prior years — — — Increase in gross amounts of tax positions related to current year — — — Decrease due to settlements with tax authorities — — — Decrease due to lapse in statute of limitations — — — Unrecognized tax benefits balance at May 31 $ 899 $ — $ — The table above includes unrecognized tax benefits associated with the calculation of limitations placed on the utilization of tax attributes related to an acquired company. If recognized, $0.1 million of the balance of unrecognized tax benefits as of May 31, 2016 would affect the effective tax rate and the balance of $0.8 million would result in adjustments to other tax accounts. We recognize interest and penalties related to unrecognized tax benefits within its global operations as a component of income tax expense. There are no accrued interest and penalties recognized in the consolidated balance sheet as of May 31, 2016 and May 31, 2015. We file income tax returns in the U.S. federal jurisdiction and various state and foreign jurisdictions. In the normal course of business we are subject to examination by taxing authorities throughout the world. Fiscal years 2012 through 2016 remain open to examination by the various tax authorities. New York State is currently auditing AngioDynamic's franchise tax filings for 2011 through 2013. We do not anticipate any adjustments will result in a material adverse effect on our financial condition, results of operations or cash flows. We do not anticipate that the amount of unrecognized tax benefits will significantly change in the next twelve months. The accumulated undistributed earnings of the Company’s foreign operations were approximately $4.6 million , and are intended to remain indefinitely invested in foreign operations. Accordingly, no taxes have been provided on these earnings at May 31, 2016. If these earnings were distributed, the Company would be subject to both foreign withholding taxes and U.S. income taxes that may not be fully offset by foreign tax credits. A reasonable estimate of the deferred tax liability on these earnings is not practicable at this time.

Accrued Liabilities

Accrued Liabilities	12 Months Ended
	May 31, 2016
Payables and Accruals [Abstract]
ACCRUED LIABILITIES	ACCRUED LIABILITIES As of May 31, 2016 and 2015 , accrued liabilities consist of the following: May 31, 2016 May 31, 2015 (in thousands) Payroll and related expenses $ 9,414 $ 10,297 Royalties 2,489 2,237 Accrued severance 1,524 158 Sales and franchise taxes 565 489 Interest rate swap liability — 257 Outside services 2,063 1,522 Deferred Rent 35 808 Other 5,806 2,341 Total $ 21,896 $ 18,109

Long-Term Debt

Long-Term Debt	12 Months Ended
	May 31, 2016
Debt Disclosure [Abstract]
LONG-TERM DEBT	LONG-TERM DEBT On September 19, 2013, we entered into a Credit Agreement (the "Credit Agreement") with the lenders party thereto, JPMorgan Chase Bank, N.A., as administrative agent, Bank of America, N.A. and Keybank National Association as co-syndication agents, and J.P. Morgan Securities LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated and Keybank National Association as joint bookrunners and joint lead arrangers. The Credit Agreement provides for a $100 million senior secured term loan facility (the "Term Loan") and a $100 million senior secured revolving credit facility, which includes up to a $20 million sublimit for letters of credit and a $5 million sublimit for swingline loans (the "Revolving Facility", and together with the Term Loan, the "Facilities"). The proceeds of the Revolving Facility may be used for general corporate purposes of the Company and its subsidiaries. The Facilities have a five years maturity. The Term Loan has a quarterly repayment schedule equal to 5% , 5% , 10% , 15% and 65% of its principal amount in years one through five. Interest on both the Term Loan and Revolving Facility will be based on a base rate or Eurodollar rate plus an applicable margin which increases as our total leverage ratio increases, with the base rate and Eurodollar rate having ranges of 0.5% to 1.25% and 1.5% to 2.25% respectively. After default, the interest rate may be increased by 2.0% . The Revolving Facility will also carry a commitment fee of 0.2% to 0.35% per annum on the unused portion. Our obligations under the Facilities are unconditionally guaranteed, jointly and severally, by our material direct and indirect domestic subsidiaries (the "Guarantors"). All obligations of the Company and the Guarantors under the Facilities are collateralized by first priority security interests in substantially all of the assets of the Company and the Guarantors. We have entered in an interest rate swap agreement, (the "Swap Agreement"), with an initial notional amount of $100 million , to limit the effect of rising of interest rates. The Swap Agreement, which qualified for hedge accounting, was a contract to exchange floating interest rate payments for fixed interest rate payments of 3.26% on the outstanding balance of the loan over the life of the agreement without the exchange of the underlying notional amounts. The Swap Agreement provides for a fixed rate of 0.74% above the applicable rate provided for in the Credit Agreement. The Swap matured in May 2016. On September 19, 2013, we borrowed $100 million under the Term Facility and approximately $41.4 million un der the Revolving Facility to repay the prior credit agreement. As of May 31, 2016 , $85.0 million and $36.4 million were outstanding under the Term Facility and Revolving Facility, respectively. As of May 31, 2016 and 2015 the carrying value of long-term debt approximates its fair market value. The Credit Agreement includes customary representations, warranties and covenants, and acceleration, indemnity and events of default provisions, including, among other things, two financial covenants. The first financial covenant requires us to maintain, as of the end of each of our fiscal quarters, a ratio of (i) consolidated EBITDA minus consolidated capital expenditures to (ii) consolidated interest expense paid or payable in cash plus scheduled principal payments in respect of indebtedness under the Credit Agreement of not less than 1.35 to 1.00 . The second financial covenant requires us to maintain, as of the end of each of our fiscal quarters, a ratio of consolidated total indebtedness to consolidated EBITDA of not greater than 3.75 to 1.00 . We were in compliance with both financial covenants as of May 31, 2016 . As of May 31, 2016 , future minimum principal payments on long-term debt were as follows (in thousands): 2017 $ 16,250 2018 26,250 2019 78,910 $ 121,410

Retirement Plans

Retirement Plans	12 Months Ended
	May 31, 2016
Compensation and Retirement Disclosure [Abstract]
RETIREMENT PLANS	RETIREMENT PLANS We have a 401(k) plan under which eligible employees can defer a portion of their compensation, part of which is matched by us. Matching contributions were $3.7 million , $3.7 million and $2.8 million in 2016, 2015 and 2014, respectively. There are also various immaterial foreign retirement plans.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	May 31, 2016
Equity [Abstract]
STOCKHOLDERS' EQUITY	STOCKHOLDERS’ EQUITY 1. Capitalization On October 29, 2014, our Board of Directors approved our Amended and Restated Certificate of Incorporation (the “Amended Certificate”). Under the Amended Certificate, the authorized capital stock is 80,000,000 shares, consisting of 75,000,000 shares of common stock, par value $.01 per share and 5,000,000 shares of preferred stock, par value $.01 per share. The holders of common stock are entitled to one vote for each share held. Subject to preferences applicable to any outstanding shares of preferred stock, the holders of common stock are entitled to receive ratably dividends, if any, as may be declared by the Board of Directors out of funds legally available for dividend payments. If we liquidate, dissolve, or wind up, the holders of common stock are entitled to share ratably in all assets remaining after payment of liabilities and liquidation preferences of any outstanding shares of preferred stock. Holders of common stock have no pre-emptive rights or rights to convert their common stock into any other securities. There are no redemption or sinking fund provisions applicable to the common stock. The rights, preferences and privileges of the holders of common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of preferred stock that we may designate in the future. Our board of directors has the authority to (i) issue the undesignated preferred stock in one or more series, (ii) determine the powers, preferences and rights and the qualifications, limitations or restrictions granted to or imposed upon any wholly un-issued series of undesignated preferred stock and (iii) fix the number of shares constituting any series and the designation of the series, without any further vote or action by our stockholders. 2. Stock Options 1997 Stock Option Plan In 1997, we adopted a Stock Option Plan (the “1997 Plan”). The 1997 Plan provided for the grant to key employees of both nonqualified stock options and incentive stock options and to members of the Board of Directors and consultants of nonqualified stock options. A total of 1,497,674 shares of our common stock were available to be issued under the 1997 Plan pursuant to the exercise of options. All stock options were to have an exercise price of not less than the fair market value of the shares on the date of grant. Options are exercisable over a period of time to be designated by the administrators of the 1997 Plan (but not more than 10 years from the date of grant) and are subject to such other terms and conditions as the administrators may determine. The vesting schedule is subject to the discretion of our Board of Directors. Options are exercisable immediately upon vesting. In addition, all options, whether vested or not, become exercisable in full immediately upon a change of control, as defined under the 1997 Plan. The 1997 Plan terminated in March 2007 and as such, no further options will be granted under this plan. 2004 Stock and Incentive Award Plan The 2004 Stock and Incentive Award Plan (the “2004 Plan”) provides for the grant of incentive options to our employees and for the grant of non-statutory stock options, restricted stock, stock appreciation rights, performance units, performance shares and other incentive awards to our employees, directors and other service providers. A total of 6,750,000 shares of our common stock have been reserved for issuance under the 2004 Plan, of which up to 800,000 shares may be issued upon the exercise of incentive stock options. The compensation committee of the Board of Directors administers the 2004 Plan. The committee determines vesting terms and the exercise price of options granted under the 2004 Plan, but for all incentive stock options the exercise price must at least be equal to the fair market value of our common stock on the date of grant. The term of an incentive stock option may not exceed ten years . On October 5, 2011, we amended the 2004 Stock and Incentive Award Plan to increase the maximum number of shares of our common stock with respect to which stock options may be granted during any calendar year to one employee from 200,000 shares to 500,000 shares. The following table summarizes information about stock options activity for the fiscal year ended May 31, 2016 . 2016 Shares Weighted- average exercise price Weighted average remaining contractual life Aggregate intrinsic value (in thousands) Outstanding at beginning of year 2,299,313 $ 14.86 Granted 564,380 $ 14.22 Exercised (145,260 ) $ 13.73 Forfeited (304,563 ) $ 13.85 Expired (132,252 ) $ 22.75 Outstanding at end of year 2,281,618 $ 14.45 3.79 $ 164 Options exercisable at year-end 1,313,698 $ 14.25 2.34 $ 130 Options expected to vest in future periods 854,189 $ 14.72 5.76 $ 30 As of May 31, 2016, there remained approximately 2.2 million shares available for granting of options under the 2004 Plan. Options are exercisable into common stock. The following table summarizes information about stock options outstanding at May 31, 2016. Range of exercise prices Number Weighted- Weighted- Number Weighted- $10.25 - $14.24 1,398,385 3.46 $ 12.93 957,571 $ 13.14 $14.25 - $18.24 684,427 4.75 16.04 228,571 15.84 $18.25 - $22.24 183,695 3.01 19.30 112,445 19.23 $22.25 - $26.24 14,250 0.48 23.62 14,251 23.62 $26.25 - $30.24 861 0.60 26.94 860 26.94 2,281,618 3.79 $ 14.45 1,313,698 $ 14.25 Stock options are granted at exercise prices equal to the quoted market price of our common stock at the date of the grant. Options vest 25% per year over four years for employees and 100% after one year for consultants. Grants to directors vest 33.33% per year over three years . Stock options granted prior to May 1, 2007 expire on the tenth anniversary of the grant date. Stock options granted on or after May 1, 2007, expire on the seventh anniversary of the grant date. We measure the fair value of each stock option grant at the date of grant using a Black-Scholes option pricing model. The weighted average grant-date fair value of options granted during the years ended May 31, 2016, 2015 and 2014 was $4.16 , $4.74 , and $4.10 , respectively. The following assumptions were used in arriving at the fair value of options granted during 2016, 2015 and 2014, respectively: risk-free interest rates of 1.48% , 1.54% and 1.44% ; expected volatility of 31% , 31% , and 34% ; and expected lives of 4.81 years , 4.76 years , and 4.74 years . We do not declare dividends therefore a dividend yield of zero was used for the years ended 2016, 2015 and 2014. Risk-free interest rates reflect the yield on zero-coupon U.S. Treasury bonds whose maturity period equals the expected term of the option. Expected volatilities are based on the historical volatility of our stock. The expected option lives are based on our historical experience of employee exercise behavior. The total intrinsic value of options exercised during the years ended 2016, 2015 and 2014 amounted to $0.1 million , $1.6 million , and $1.0 million , respectively. As of May 31, 2016, there was $3.3 million of total unrecognized compensation cost related to non-vested options. The cost is expected to be recognized over a weighted average period of 3 years . Cash received from option exercises during 2016, 2015 and 2014 was $1.3 million , $4.3 million and $1.3 million , respectively. The tax benefit realized from stock options exercised during the years ended 2016, 2015 and 2014 were $0.1 million , $0.5 million and $0.1 million , respectively. 3. Performance Share and Restricted Stock Unit Awards We grant restricted stock units to certain employees under the 2004 Plan which give the recipients the right to receive shares of our stock upon vesting. The restricted stock unit awards vest in equal annual installments over the term of the grants. Unvested restricted stock unit awards will be forfeited if the recipient ceases to be employed by us, competes with our business or otherwise engages in activities detrimental to our business before such date. The following table summarizes information about restricted stock unit activity for the year ended May 31, 2016. Non-Vested Stock Award Units Weighted Average Grant-Date Fair Value Non-vested at beginning of year 563,101 $ 13.73 Granted 259,917 $ 15.21 Vested (160,845 ) $ 15.39 Canceled (112,396 ) $ 13.81 Non-vested at end of year 549,777 $ 14.62 Awards expected to vest in future periods 482,594 $ 14.62 The fair value of each restricted stock unit is the market price of our stock on the date of grant. The weighted average grant date fair value of restricted stock units granted during the years ended May 31, 2016 , 2015 and 2014 was $15.21 , $14.75 and $13.23 , respectively. The total intrinsic value of restricted stock units vesting during the years ended 2016, 2015 and 2014 was $2.5 million , $2.4 million , and $1.8 million , respectively. As of May 31, 2016, there was $5.4 million of total unrecognized compensation cost related to non-vested restricted stock awards. The cost is expected to be recognized over a weighted average period of 2 years . We grant performance share awards to certain employees under the 2004 Plan which gives the recipients the right to receive shares of our stock if certain criteria is met. The performance criteria is established by the compensation committee for vesting of the performance share awards and may include factors such as the achievement of relative total shareholder return ("TSR"), certain sales, operating income and earnings per share (“EPS”) goals. Performance share awards are subject to additional conditions, including the recipient’s continued employment with us. Performance share units are valued using a Monte Carlo simulation model on the date of grant. As of May 31, 2016, 2015 and 2014, the weighted average grant date fair market value for new grants was $18.07 , $19.83 and $25.56 , respectively. Compensation cost is recognized over the performance period which is typically three years. As of May 31, 2016, 0.4 million performance share units with a weighted average remaining contractual term of 3 years and $4.6 million of unrecognized compensation cost were outstanding. As of May 31, 2015, 0.2 million performance share units with a weighted average remaining contractual term of 3 years and $2.2 million of unrecognized compensation cost were outstanding. 4. Employee Stock Purchase Plan The Employee Stock Purchase Plan (the “Stock Purchase Plan”) provides a means by which our employees (the “participants”) are given an opportunity to purchase our common stock through payroll deductions. A total of 2,000,000 shares of our common stock have been reserved for issuance under the Stock Purchase Plan. Shares are offered through two purchase periods, each with duration of approximately 6 months , commencing on the first business day of the first and third fiscal quarters. An employee is eligible to participate in an offering period if, on the first day of an offering period, he or she has been employed in a full-time capacity for at least six months , with a customary working schedule of 20 or more hours per week and more than five months in a calendar year . Employees who own stock possessing 5% or more of the total combined voting power or value of all classes of our stock are not eligible to participate in the Stock Purchase Plan. The purchase price of the shares of common stock acquired on each purchase date will be the lower of (i) 85% of the fair market value of a share of common stock on the first day of the offering period or (ii) 85% of the fair market value of a share of common stock on the last day of the purchase period, subject to adjustments made by the Board of Directors. The Stock Purchase Plan is intended to qualify as an “employee stock purchase plan” within the meaning of Section 423 of the Internal Revenue Code. During the year ended May 31, 2015, an additional 800,000 shares of our common stock have been reserved for issuance under the Stock Purchase Plan. We use the Black-Scholes option-pricing model to calculate the purchase date fair value of the shares issued under the Stock Purchase Plan and recognize expense related to shares purchased ratably over the offering period. During the years ended 2016, 2015 and 2014, 137,957 , 119,001 and 146,275 shares, respectively, were issued at an average price of $10.67 , $11.89 and $9.30 , respectively, under the Stock Purchase Plan. As of May 31, 2016, 1.0 million shares remained available for future purchases under the Stock Purchase Plan. 5. Other items Share-based compensation expense recognized in the consolidated statement of operations during the years ended 2016, 2015 and 2014 amounted to $3.2 million , $6.0 million and $5.5 million , respectively. The income tax benefit recognized in earnings on the compensation expense recognized for all share-based compensation arrangements amounted to $1.0 million , $2.0 million and $1.8 million , respectively. Income tax expense of $0.8 million , $1.3 million and $0.5 million was recorded in continuing operations for the excess of cumulative book deductions over actual tax deductions for the years ended 2016, 2015 and 2014, respectively. The income tax benefit on all share based compensation expense in 2016 as well as the income tax expense on the excess book deductions over actual tax deductions in 2016 are negated by the full valuation allowance established at May 31, 2016. Additional income tax expense of $0.1 million for 2014 was recorded in shareholder’s equity for the excess book deductions to the extent prior tax deductions exceeded prior book deductions. As part of his employment agreement, the Company awarded James C. Clemmer, the Company’s President and CEO, 250,000 performance shares, 200,000 options and 50,000 restricted stock units. The award was unanimously approved by the Company's independent compensation committee. The performance shares have a three years term with payouts to be made in shares of the Company's common stock at the end of the term ranging between 0 and 200 percent of the grant amount depending on the Company's total shareholder return relative to a peer group of companies. The options will vest in four equal installments beginning on the first anniversary of the grant date, have a strike price equal to the closing price of the company's common stock as of April 4, 2016 and expire, if not exercised, on April 4, 2023. The restricted stock units will vest in four equal installments beginning on the first anniversary of the grant date.

Earnings Per Share

Earnings Per Share	12 Months Ended
	May 31, 2016
Earnings Per Share [Abstract]
Earnings Per Share	EARNINGS PER SHARE Basic earnings per share are based on the weighted average number of common shares outstanding without consideration of potential common stock. In addition, diluted earnings per share include the dilutive effect of potential common stock consisting of stock options, restricted stock units and performance stock units, provided that the inclusion of such securities is not anti-dilutive. In periods with a net loss, stock options and restricted stock units are not included in the computation of basic loss per share as the impact would be anti-dilutive. The following table reconciles basic to diluted weighted average shares outstanding for the years ended May 31, 2016 , 2015 and 2014 : 2016 2015 2014 Basic 36,161,383 35,683,139 35,135,689 Effect of dilutive securities — — 304,161 Diluted 36,161,383 35,683,139 35,439,850 Securities excluded as their inclusion would be anti-dilutive 3,277,037 2,862,414 2,347,426

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	May 31, 2016
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Leases We are committed under non-cancelable operating leases for facilities and equipment. During fiscal 2016 , 2015 and 2014 , aggregate rental costs under all operating leases were approximately $2.5 million , $3.4 million and $2.0 million , respectively. Future annual payments under non-cancelable operating leases in the aggregate, of which one includes an escalation clause, with initial remaining terms of more than one year at May 31, 2016 , are summarized as follows (in thousands): 2017 $ 2,183 2018 2,013 2019 1,981 2020 1,772 2021 935 $ 8,884 Litigation Matters AngioDynamics v. biolitec On January 2, 2008, we commenced an action in the United States District Court for the Northern District of New York entitled AngioDynamics, Inc. v. biolitec, Inc. In this action, we sought judgment against biolitec for defense and indemnification in two lawsuits which we previously settled. Our claims arise out of a Supply and Distribution Agreement (“SDA”) entered into with biolitec on April 1, 2002. On September 27, 2011, the U.S. District Court granted key portions of our motion for summary judgment in our legal case against biolitec. The Court also dismissed biolitec’s counterclaims against us. The court denied one portion of our summary judgment motion, which sought to recover additional costs from biolitec, leaving this for adjudication at trial. On November 8, 2012, the Court granted partial judgment to us in the amount of $23.2 million. Biolitec appealed this judgment. On August 23, 2013, the U.S. Court of Appeals for the Second Circuit dismissed biolitec’s appeal. In October 2009, we commenced an action in the United States District Court for the District of Massachusetts entitled AngioDynamics, Inc. v. biolitec AG and Wolfgang Neuberger. The Complaint in this action was amended in March 2010. This action seeks to recover against biolitec, Inc.’s parent entities and CEO for tortiously interfering with biolitec, Inc.’s contractual obligation to defend and indemnify us, and also seeks to pierce the corporate veil of biolitec, Inc. and to invalidate certain alleged fraudulent transfers in order to hold biolitec, Inc.’s parent entities jointly and severally liable for the alleged breach of the SDA. On September 13, 2012, the Massachusetts Court granted our request for a preliminary injunction prohibiting the downstream merger of biolitec AG with its Austrian subsidiary. On April 1, 2013, the U.S. Court of Appeals for the First Circuit affirmed the preliminary injunction. On January 14, 2014, the District Court entered judgment in our favor as to liability. On March 18, 2014, the District Court entered judgment in our favor against Biolitec AG, Biomed Technology Holdings, Ltd., and Wolfgang Neuberger, jointly and severally, in the amount of $74.9 million. On March 11, 2015, the U.S. Court of Appeals for the First Circuit affirmed the judgment. The defendants petitioned to the U.S. Supreme Court for a writ of certiorari. The Supreme Court denied the petition on November 30, 2015. The defendants have also filed an appeal with the U.S. Court of Appeals for the First Circuit regarding civil contempt sanctions imposed by the Massachusetts District Court as a result of defendants’ completion of the downstream merger in violation of the Court’s injunction. On May 6, 2016, the First Circuit issued an opinion rejecting this latest appeal. On February 18, 2016, the Massachusetts District Court issued an order compelling the Massachusetts defendants to provide post-judgment discovery intended to aid us in potentially collecting our judgment. On March 21, 2016, the Massachusetts defendants noticed an appeal from this order. On June 27, 2016, we filed a motion asking the Massachusetts District Court to impose sanctions on the Massachusetts defendants for their failure to comply with the post-judgment discovery order. On November 13, 2014, the U.S. District Court for the District of Massachusetts issued summonses to four Biolitec entities - Biolitec U.S., Inc., Biolitec Holding U.S., Inc., Biolitec Medical Devices, Inc., and CeramOptec Industries, Inc. - pursuant to Massachusetts trustee process. We sought to use this process to attach the assets of these entities in order to satisfy our judgment. The trustee process was automatically stayed when the four Biolitec entities filed Chapter 7 petitions in the U.S. Bankruptcy Court for the District of Delaware. However, on November 3, 2015, the Delaware Bankruptcy Court granted our request to modify the automatic stay to allow us to seek a default against the four Biolitec entities pursuant to trustee process. On January 21, 2016, the four Chapter 7 cases were transferred at our request to the U.S. Bankruptcy Court for the District of New Jersey. On August 29, 2013, we became co-plaintiffs in an adversary proceeding in the United States Bankruptcy Court for the District of New Jersey entitled Cyganowski, Trustee, et al. v. Biolitec U.S., Inc., et al. In this action, we assert claims of conversion, unjust enrichment, tortious interference, and unfair competition against various biolitec entities for alleged violation of Bankruptcy Court settlement and sale orders under which we acquired certain assets of Biolitec, Inc. On September 3, 2013, we, along with our co-plaintiff, obtained a temporary restraining order against the defendants in this action. On January 22, 2015, the Bankruptcy Court entered a permanent injunction on our behalf for an additional two years. C.R. Bard, Inc. v. AngioDynamics, Inc. On January 11, 2012, C.R. Bard, Inc. (“Bard”) filed a suit in the United States District Court of Utah claiming certain of our implantable port products infringe on three U.S. patents held by Bard (the "Utah Action"). Bard is seeking unspecified damages and other relief. The Court denied Bard’s motion for pre-trial consolidation with separate actions it filed on the same day against Medical Components, Inc. and Smiths Medical ASD, Inc., but had asked for supplemental briefing on the issue of whether to conduct a common Markman hearing. Meanwhile, we filed petitions for reexamination in the US Patent and Trademark Office ("PTO") which seek to invalidate all 3 patents asserted by Bard in the litigation. Our petitions were granted and 40 of 41 patent claims were rejected and, following further proceedings, the Patent Office issued a Final Rejection of all 40 claims subject to reexamination. Thereafter, Bard filed appeals to the PTO Board of Appeals and Interferences for all three reexams. The parties completed briefing on the appeals and oral argument was held on June 18, 2015. The Patent Office has issued decisions in the three appeals. In one (issued on March 11, 2016 for US Patent No. 7,785,302), the rejections of six of the ten claims under reexamination were affirmed, but were reversed on four of the ten claims. In the second (issued on March 24, 2016 for U.S. Patent No. 7,959,615), the rejections of eight of the ten claims under reexamination were affirmed but the rejections of the other two of the ten claims were reversed. In the third (issued on March 29 for U.S. Patent No. 7,947.022) the rejections of all twenty claims under reexamination were affirmed. Bard has since filed Requests for Rehearing in all three reexamination appeals and the Company filed Requests for Rehearing in two of the reexamination appeals (the ‘302 and ‘615 patent reexaminations). Each party has filed comments in Opposition to the other party’s Rehearing Requests, and we are awaiting the PTO determinations in all three reexaminations. The Utah Action has been stayed pending final resolution of the PTO process. We believe these claims are without merit and intend to defend them vigorously. We have not recorded an expense related to the outcome of this litigation because it is not yet possible to determine if a potential loss is probable nor reasonably estimable. On March 10, 2015, C.R. Bard, Inc. and Bard Peripheral Vascular, Inc. (“Bard”) filed suit in the United States District Court for the District of Delaware claiming certain of our implantable port products infringe on three U.S. patents held by Bard (the “Delaware Action). Bard is seeking unspecified damages and other relief. The patents asserted in the Delaware Action are different than those asserted in the Utah Action. On June 1, 2015, we filed two motions in response to Bard’s Complaint - one sought transfer to the District of Utah where the Utah Action is currently pending, and the other sought dismissal of the entire complaint on grounds that none of the claims in the asserted patents is directed to patent eligible subject matter under Section 101 of the Patent Statute and in light of recent authority from the U. S. Supreme Court. On January 12, 2016, the court issued a decision denying both motions. We have since served an Answer and Counterclaim to which Bard has served a Reply. On March 10, 2016, the Court held a case management conference, and, on March 14, 2016, the court entered a Scheduling Order which set, inter alia, a Markman hearing for March 10, 2017, a summary judgment hearing for December 8, 2017 and trial for March 12, 2018. The parties have since served various discovery requests on each other; on May 27, 2016 Bard served its Infringement Contentions which identified all the port products accused of infringement; and, on June 24, 2016, we served Invalidity Contentions which detail various grounds for invalidating the three asserted patents. We believe these claims are without merit and intend to defend them vigorously. We have not recorded an expense related to the outcome of this litigation because it is not yet possible to determine if a potential loss is probable nor reasonably estimable. Governmental Investigations LC Beads In June 2014 we received a subpoena from the U.S. Department of Justice (the “DOJ”) requesting documents in relation to a criminal and civil investigation the DOJ is conducting regarding BTG International, Inc.’s LC Bead® product beginning in 2003. RITA Medical Systems and AngioDynamics, Inc., after its acquisition of RITA, was the exclusive distributor of LC Beads in the United States from 2006 through December 31, 2011. We are cooperating fully with this investigation and at this time are unable to predict its scope, duration or outcome. We are unable at this time to reasonably estimate the amount or range of any loss, although it is possible that the amount of such loss could be material. In accordance with ASC 450, "Contingencies," or "ASC 450," no amount in respect of any potential liability in this matter, including for penalties, fines or other sanctions, has been accrued in the consolidated financial statements. EVLT In April 2015 we received a subpoena from the DOJ requesting documents in relation to a criminal and civil investigation the DOJ is conducting regarding purported promotion of certain of AngioDynamics’ VenaCure EVLT products for un-cleared indications. We are cooperating fully with this investigation and at this time are unable to predict its scope, duration or outcome. We are unable at this time to reasonably estimate the amount or range of any loss, although it is possible that the amount of such loss could be material. In accordance with ASC 450, "Contingencies," or "ASC 450," no amount in respect of any potential liability in this matter, including for penalties, fines or other sanctions, has been accrued in the consolidated financial statements. Future Purchase Obligations We have entered into commitments for future minimum inventory purchases related to several core products. Total future non-cancelable purchase obligations through fiscal 2021 amount to $8.9 million . There are no such obligations thereafter.

Segments and Geographic Informa

Segments and Geographic Information	12 Months Ended
	May 31, 2016
Segment Reporting [Abstract]
SEGMENTS AND GEOGRAPHIC INFORMATION	SEGMENTS AND GEOGRAPHIC INFORMATION Segment information We consider our business to be a single segment entity related to the development, manufacture and sale on a global basis of medical devices for vascular access, surgery, peripheral vascular disease and oncology. Our chief operating decision maker (CEO) evaluates the various global product portfolios on a net sales basis. Executives reporting in to the CEO include those responsible for operations and supply chain management, research and development, sales, franchise marketing and certain corporate functions. The CEO evaluates profitability, investment and cash flow metrics on a consolidated worldwide basis due to shared infrastructure and resources. Total sales by product category are summarized below (in thousands): Year Ended May 31, May 31, May 31, Net sales by Product Category Peripheral Vascular $ 202,780 $ 192,713 $ 192,626 Vascular Access 99,375 107,754 106,394 Oncology/Surgery 48,895 51,890 49,360 Supply Agreement 2,840 4,177 6,045 Total $ 353,890 $ 356,534 $ 354,425 Geographic information Total sales for geographic areas are summarized below (in thousands): Year Ended May 31, May 31, May 31, Net sales by Geography United States $ 283,519 $ 280,611 $ 280,161 International 67,531 71,746 68,219 Supply Agreement 2,840 4,177 6,045 Total $ 353,890 $ 356,534 $ 354,425 For fiscal years 2016, 2015 and 2014, International sales as a percentage of total net sales were 19% , 20% and 19% , respectively. Sales to any one country outside the U.S., as determined by shipment destination, did not comprise a material portion of our net sales in any of the last three fiscal years. 99% of our total assets are located within the United States.

Restructuring

Restructuring	12 Months Ended
	May 31, 2016
Restructuring and Related Activities [Abstract]
RESTRUCTURING	RESTRUCTURING On December 5, 2013, we announced a company-wide operational excellence program designed to save between $15 and $18 million during the course of the next three years. The initiative is expected to create greater efficiencies and drive business performance improvements by focusing on several key elements, including product rationalization, lean manufacturing initiatives, supply chain optimization and enterprise resource planning (ERP) implementation. The plan also incorporates the consolidation of our New York plants to establish a single manufacturing center in Glens Falls and a distribution center in Queensbury. During the course of the three years program, we reduced our New York employee base by approximately 80-100 positions as a result of this plant consolidation and reorganization. We have invested $5.4 million in facility improvements to date. In addition, total restructuring charges are estimated to be $4.9 million . During the year ended May 31, 2016 , the cost incurred was $1.5 million , consisting of $1.0 million of accelerated depreciation and $0.5 million of other related costs. During the year ended May 31, 2015 , the cost incurred was $2.0 million , consisting of $0.5 million of severance and related costs and $1.5 million of accelerated depreciation. These costs are included in “Acquisition, restructuring and other items, net” in the statements of income. During the year ended May 31, 2015 , we initiated a restructuring of finance, R&D and S&M organizations to improve our profitability. As part of the restructuring, we recorded $1.9 million and $0.8 million , for the years ended May 31, 2016 and 2015 , respectively, in severance expense which is included in "Acquisition, restructuring and other items, net" in the statement of operations. In addition, we recorded a gain of $0.7 million related to the modification of the stock based compensation for the former CEO.

Immaterial Error Corrections

Immaterial Error Corrections	12 Months Ended
	May 31, 2016
Accounting Changes and Error Corrections [Abstract]
Immaterial Error Corrections	IMMATERIAL ERROR CORRECTIONS During the financial closing process for the fourth quarter of fiscal year 2016, the Company determined that certain consolidated financial statement amounts were not accounted for correctly in prior periods. The Company has evaluated these errors together with errors identified in prior periods and concluded that they were not material individually or in the aggregate to any of its previously issued annual and interim financial statements. However, the financial statements included herein have been revised to correct for the impact of these items. The Company has corrected the relevant financial information from previous reporting periods contained in these financial statements. The immaterial error corrections identified were primarily related to a misclassification of credit card fees from Other Expense to Sales and Marketing (refer to the tables below for the impact in each period), intercompany foreign exchange losses (cumulative impact of approximately $0.7 million ), research and development expenses (cumulative impact of approximately $0.4 million ), lease expense (cumulative impact of approximately $0.3 million ) and other individually immaterial items. The impacts of these revisions are shown in the tables below: Year ended May 31, 2015 As previously reported Adjustments As revised Net sales $ 356,974 $ (440 ) $ 356,534 Cost of sales 180,085 653 180,738 Gross profit 176,889 (1,093 ) 175,796 Research and development 26,931 (337 ) 26,594 Sales and marketing 80,623 2,597 83,220 General and administrative 29,871 (709 ) 29,162 Amortization of intangibles 17,912 54 17,966 Change in fair value of contingent consideration (8,196 ) 100 (8,096 ) Acquisition, restructuring and other items, net 26,600 (343 ) 26,257 Total operating expenses 177,883 1,362 179,245 Operating income (994 ) (2,455 ) (3,449 ) Other expense (3,812 ) 2,323 (1,489 ) Total other income (expense) (7,005 ) 2,323 (4,682 ) Income (loss) before taxes (7,999 ) (132 ) (8,131 ) Income tax (benefit) expense (4,731 ) (12 ) (4,743 ) Net income (loss) (3,268 ) (120 ) (3,388 ) Year ended May 31, 2015 As previously reported Adjustments As revised Net income (loss) $ (3,268 ) $ (120 ) $ (3,388 ) Foreign currency translation (411 ) 147 (264 ) Other comprehensive income (loss), before tax (235 ) 147 (88 ) Other comprehensive income (loss), net of tax (299 ) 147 (152 ) Total comprehensive income (loss), net of tax (3,567 ) 27 (3,540 ) As of May 31, 2015 As previously reported Adjustments As revised Prepaid expenses and other $ 4,783 $ (651 ) $ 4,132 Total current assets 151,449 (651 ) 150,798 Property, Plant and Equipment, net 54,560 (110 ) 54,450 Other Assets 5,288 110 5,398 Intangible Assets, net 181,806 (154 ) 181,652 Deferred Income Taxes, long term 19,268 240 19,508 Total Assets 773,623 (565 ) 773,058 Accounts payable 23,668 (620 ) 23,048 Accrued liabilities 18,331 (222 ) 18,109 Other current liabilities — 200 200 Total current liabilities 61,157 (642 ) 60,515 Total Liabilities 228,601 (642 ) 227,959 Retained earnings 28,233 (658 ) 27,575 Accumulated other comprehensive loss (1,568 ) 735 (833 ) Total Stockholders' Equity 545,022 77 545,099 Total Liabilities and Stockholders' Equity 773,623 (565 ) 773,058 Year ended May 31, 2015 As previously reported Adjustments As revised Net cash provided by (used in) operating activities $ 26,242 $ (557 ) $ 25,685 Net cash provided by (used in) investing activities (13,293 ) 557 (12,736 ) Net cash provided by (used in) financing activities (10,465 ) — (10,465 ) Year ended May 31, 2014 As previously reported Adjustments As revised Cost of sales $ 174,757 $ (506 ) $ 174,251 Gross profit 179,668 506 180,174 Research and development 27,486 638 28,124 Sales and marketing 83,200 2,105 85,305 General and administrative 26,639 263 26,902 Amortization of intangibles 16,622 (60 ) 16,562 Change in fair value of contingent consideration (1,808 ) (100 ) (1,908 ) Acquisition, restructuring and other items, net 10,760 113 10,873 Total operating expenses 166,728 2,959 169,687 Operating income 12,940 (2,453 ) 10,487 Other expense (3,544 ) 1,899 (1,645 ) Total other income (expense) (7,200 ) 1,899 (5,301 ) Income (loss) before taxes 5,740 (554 ) 5,186 Income tax (benefit) expense 3,074 (235 ) 2,839 Net income (loss) 2,666 (319 ) 2,347 Year ended May 31, 2014 As previously reported Adjustments As revised Net income (loss) $ 2,666 $ (319 ) $ 2,347 Foreign currency translation 295 147 442 Other comprehensive income (loss), before tax 247 147 394 Other comprehensive income (loss), net of tax 265 147 412 Total comprehensive income (loss), net of tax 2,931 (172 ) 2,759 As of May 31, 2014 As previously reported Adjustments As revised Inventories $ 61,234 $ 506 $ 61,740 Prepaid expenses and other 5,471 (591 ) 4,880 Total current assets 147,097 (85 ) 147,012 Property, Plant and Equipment, net 66,590 (135 ) 66,455 Other Assets 3,926 (120 ) 3,806 Intangible Assets, net 205,256 (203 ) 205,053 Deferred Income Taxes, long term 15,028 228 15,256 Total Assets 798,891 (315 ) 798,576 Accrued liabilities 16,652 (712 ) 15,940 Current portion of contingent consideration 10,918 (100 ) 10,818 Other current liabilities 599 — 599 Total current liabilities 66,753 (812 ) 65,941 Other Long Term Liabilities 84 447 531 Total Liabilities 262,056 (365 ) 261,691 Retained earnings 31,501 (538 ) 30,963 Accumulated other comprehensive loss (1,269 ) 588 (681 ) Total Stockholders' Equity 536,835 50 536,885 Total Liabilities and Stockholders' Equity 798,891 (315 ) 798,576 Year ended May 31, 2014 As previously reported Adjustments As revised Net cash provided by (used in) operating activities $ 24,681 $ — $ 24,681 Net cash provided by (used in) investing activities (16,448 ) — (16,448 ) Net cash provided by (used in) financing activities (14,016 ) — (14,016 ) Year ended May 31, 2013 As previously reported Adjustments As revised Research and development $ 26,319 $ (228 ) $ 26,091 Sales and marketing 76,121 1,443 77,564 General and administrative 26,186 (151 ) 26,035 Amortization of intangibles 16,617 (18 ) 16,599 Total operating expenses 162,226 1,046 163,272 Operating income 6,288 (1,046 ) 5,242 Other expense (2,707 ) 1,296 (1,411 ) Total other income (expense) (7,875 ) 1,296 (6,579 ) Income (loss) before taxes (1,587 ) 250 (1,337 ) Income tax (benefit) expense (376 ) 90 (286 ) Net income (loss) (1,211 ) 160 (1,051 ) As of May 31, 2013 As previously reported Adjustments As revised Property, Plant and Equipment, net $ 62,391 $ (16 ) $ 62,375 Intangible Assets, net 214,673 (150 ) 214,523 Deferred Income Taxes, long term 18,016 (7 ) 18,009 Total Assets 790,734 (173 ) 790,561 Accrued liabilities 16,356 (395 ) 15,961 Total current liabilities 63,315 (395 ) 62,920 Total Liabilities 264,632 (395 ) 264,237 Retained earnings 28,835 (219 ) 28,616 Accumulated other comprehensive loss (1,534 ) 441 (1,093 ) Total Stockholders' Equity 526,102 222 526,324 Total Liabilities and Stockholders' Equity 790,734 (173 ) 790,561 Year ended May 31, 2012 As previously reported Adjustments As revised Sales and marketing $ 64,505 $ 1,252 $ 65,757 Amortization of intangibles 9,309 84 9,393 Total operating expenses 129,217 1,336 130,553 Operating income (3,908 ) (1,336 ) (5,244 ) Other expense (2,096 ) 1,105 (991 ) Total other income (expense) (1,514 ) 1,105 (409 ) Income (loss) before taxes (5,422 ) (231 ) (5,653 ) Income tax (benefit) expense (239 ) (83 ) (322 ) Net income (loss) (5,183 ) (148 ) (5,331 ) As of May 31, 2012 As previously reported Adjustments As revised Intangible Assets, net $ 147,363 $ (168 ) $ 147,195 Deferred Income Taxes, long term 44,194 83 44,277 Total Assets 719,988 (85 ) 719,903 Retained earnings 30,046 (379 ) 29,667 Accumulated other comprehensive loss (1,274 ) 294 (980 ) Total Stockholders' Equity 523,391 (85 ) 523,306 Total Liabilities and Stockholders' Equity 719,988 (85 ) 719,903

Quarterly Information (unaudite

Quarterly Information (unaudited)	12 Months Ended
	May 31, 2016
Quarterly Financial Information Disclosure [Abstract]
QUARTERLY INFORMATION (unaudited)	QUARTERLY INFORMATION (unaudited) Quarterly results of operations during the fiscal years ended May 31, 2016 and 2015 are as follows: 2016 First quarter Second quarter Third quarter Fourth quarter (in thousands, except per share data) Net sales $ 83,753 $ 89,284 $ 87,434 $ 93,419 Gross profit 43,371 45,884 43,534 41,527 Net income (loss) (775 ) (334 ) 594 (43,075 ) Earnings (loss) per common share Basic (0.02 ) (0.01 ) 0.02 (1.19 ) Diluted (0.02 ) (0.01 ) 0.02 (1.19 ) 2015 First quarter Second quarter Third quarter Fourth quarter (in thousands, except per share data) Net sales $ 87,091 $ 92,149 $ 86,597 $ 90,697 Gross profit 45,964 46,828 37,673 45,331 Net income (loss) 284 1,069 (4,153 ) (588 ) Earnings (loss) per common share Basic 0.01 0.03 (0.12 ) (0.02 ) Diluted 0.01 0.03 (0.12 ) (0.02 ) The data in the schedules above has been intentionally rounded to the nearest thousand and therefore the quarterly amounts may not sum to the full year amounts. We made adjustments to correct immaterial errors within this selected financial data. For a detailed explanation of these adjustments, please refer to Note R, "Immaterial Error Corrections". Three months ended February 29, 2016 As previously reported Adjustments As revised Net sales $ 87,384 $ 50 $ 87,434 Gross profit 43,484 50 43,534 Sales and marketing 20,301 654 20,955 General and administrative 6,784 117 6,901 Total operating expenses 40,797 771 41,568 Operating income 2,687 (721 ) 1,966 Other expense (868 ) 654 (214 ) Total other income (expense) (1,675 ) 654 (1,021 ) Income (loss) before taxes 1,012 (67 ) 945 Income tax (benefit) expense 382 (31 ) 351 Net income (loss) 630 (36 ) 594 Nine months ended February 29, 2016 As previously reported Adjustments As revised Net sales $ 260,321 $ 150 $ 260,471 Cost of sales 127,829 (147 ) 127,682 Gross profit 132,492 297 132,789 Research and development 18,189 (73 ) 18,116 Sales and marketing 61,429 2,105 63,534 General and administrative 22,300 597 22,897 Total operating expenses 127,418 2,629 130,047 Other expense (2,861 ) 2,291 (570 ) Total other income (expense) (5,464 ) 2,291 (3,173 ) Income (loss) before taxes (390 ) (41 ) (431 ) Income tax (benefit) expense 99 (15 ) 84 Net income (loss) (489 ) (26 ) (515 ) As of February 29, 2016 As previously reported Adjustments As revised Intangible Assets, net $ 168,080 $ (154 ) $ 167,926 Deferred Income Taxes, long term 19,563 255 19,818 Total Assets 753,513 101 753,614 Other current liabilities — 50 50 Total current liabilities 61,579 50 61,629 Total Liabilities 202,768 50 202,818 Retained earnings 27,744 (684 ) 27,060 Accumulated other comprehensive loss (1,790 ) 735 (1,055 ) Total Stockholders' Equity 550,745 51 550,796 Total Liabilities and Stockholders' Equity 753,513 101 753,614 Nine months ended February 29, 2016 As previously reported Adjustments As revised Net cash provided by (used in) operating activities $ 26,672 $ — $ 26,672 Net cash provided by (used in) investing activities (3,888 ) — (3,888 ) Net cash provided by (used in) financing activities (19,167 ) — (19,167 ) Three months ended November 30, 2015 As previously reported Adjustments As revised Net sales $ 89,234 $ 50 $ 89,284 Gross profit 45,834 50 45,884 Sales and marketing 20,569 809 21,378 General and administrative 8,089 (7 ) 8,082 Total operating expenses 44,517 802 45,319 Operating income 1,317 (752 ) 565 Other expense (1,048 ) 809 (239 ) Total other income (expense) (2,045 ) 809 (1,236 ) Income (loss) before taxes (728 ) 57 (671 ) Income tax (benefit) expense (366 ) 29 (337 ) Net income (loss) (362 ) 28 (334 ) Six months ended November 30, 2015 As previously reported Adjustments As revised Net sales $ 172,937 $ 100 $ 173,037 Cost of sales 83,929 (147 ) 83,782 Gross profit 89,008 247 89,255 Research and development 12,381 (73 ) 12,308 Sales and marketing 41,128 1,450 42,578 General and administrative 15,516 480 15,996 Total operating expenses 86,621 1,857 88,478 Operating income 2,387 (1,610 ) 777 Other expense (1,993 ) 1,636 (357 ) Total other income (expense) (3,789 ) 1,636 (2,153 ) Income (loss) before taxes (1,402 ) 26 (1,376 ) Income tax (benefit) expense (283 ) 16 (267 ) Net income (loss) (1,119 ) 10 (1,109 ) As of November 30, 2015 As previously reported Adjustments As revised Intangible Assets, net $ 172,511 $ (154 ) $ 172,357 Deferred Income Taxes, long term 19,826 224 20,050 Total Assets 760,371 70 760,441 Accrued liabilities 16,975 (117 ) 16,858 Other current liabilities — 100 100 Total current liabilities 60,104 (17 ) 60,087 Total Liabilities 212,732 (17 ) 212,715 Retained earnings 27,114 (648 ) 26,466 Accumulated other comprehensive loss (1,922 ) 735 (1,187 ) Total Stockholders' Equity 547,639 87 547,726 Total Liabilities and Stockholders' Equity 760,371 70 760,441 Six months ended November 30, 2015 As previously reported Adjustments As revised Net cash provided by (used in) operating activities $ 14,278 $ — $ 14,278 Net cash provided by (used in) investing activities (1,143 ) — (1,143 ) Net cash provided by (used in) financing activities (12,370 ) — (12,370 ) Three months ended August 31, 2015 As previously reported Adjustments As revised Net sales $ 83,703 $ 50 $ 83,753 Cost of sales 40,529 (147 ) 40,382 Gross profit 43,174 197 43,371 Research and development 6,202 (73 ) 6,129 Sales and marketing 20,559 641 21,200 General and administrative 7,427 487 7,914 Total operating expenses 42,104 1,055 43,159 Operating income 1,070 (858 ) 212 Other expense (945 ) 827 (118 ) Total other income (expense) (1,744 ) 827 (917 ) Income (loss) before taxes (674 ) (31 ) (705 ) Income tax (benefit) expense 83 (13 ) 70 Net income (loss) (757 ) (18 ) (775 ) As of August 31, 2015 As previously reported Adjustments As revised Other Assets $ 4,818 $ 110 $ 4,928 Intangible Assets, net 177,399 (154 ) 177,245 Deferred Income Taxes, long term 19,436 253 19,689 Total Assets 771,789 209 771,998 Other current liabilities — 150 150 Total current liabilities 60,651 150 60,801 Total Liabilities 224,666 150 224,816 Retained earnings 27,476 (676 ) 26,800 Accumulated other comprehensive loss (1,615 ) 735 (880 ) Total Stockholders' Equity 547,123 59 547,182 Total Liabilities and Stockholders' Equity 771,789 209 771,998 Three months ended August 31, 2015 As previously reported Adjustments As revised Net cash provided by (used in) operating activities $ 4,699 $ — $ 4,699 Net cash provided by (used in) investing activities (743 ) — (743 ) Net cash provided by (used in) financing activities (2,071 ) — (2,071 ) Three months ended May 31, 2015 As previously reported Adjustments As revised Net sales $ 90,897 $ (200 ) $ 90,697 Cost of sales 45,340 26 45,366 Gross profit 45,557 (226 ) 45,331 Research and development 7,289 (738 ) 6,551 Sales and marketing 20,218 933 21,151 General and administrative 7,658 (210 ) 7,448 Total operating expenses 44,217 (15 ) 44,202 Operating income 1,340 (211 ) 1,129 Other expense (860 ) 630 (230 ) Total other income (expense) (1,607 ) 630 (977 ) Income (loss) before taxes (267 ) 419 152 Income tax (benefit) expense 547 193 740 Net income (loss) (814 ) 226 (588 ) Three months ended February 28, 2015 As previously reported Adjustments As revised Cost of sales $ 48,746 $ 178 $ 48,924 Gross profit 37,851 (178 ) 37,673 Research and development 6,855 (277 ) 6,578 Sales and marketing 19,355 444 19,799 General and administrative 6,917 (304 ) 6,613 Amortization of intangibles 5,106 82 5,188 Change in fair value of contingent consideration (10,044 ) 250 (9,794 ) Acquisition, restructuring and other items, net 18,779 (103 ) 18,676 Total operating expenses 48,002 92 48,094 Operating income (10,151 ) (270 ) (10,421 ) Other expense (971 ) 497 (474 ) Total other income (expense) (1,828 ) 497 (1,331 ) Income (loss) before taxes (11,979 ) 227 (11,752 ) Income tax (benefit) expense (7,717 ) 118 (7,599 ) Net income (loss) (4,262 ) 109 (4,153 ) Nine months ended February 28, 2015 As previously reported Adjustments As revised Net sales $ 266,077 $ (240 ) $ 265,837 Cost of sales 134,745 627 135,372 Gross profit 131,332 (867 ) 130,465 Research and development 19,642 401 20,043 Sales and marketing 60,405 1,664 62,069 General and administrative 22,213 (499 ) 21,714 Amortization of intangibles 13,182 54 13,236 Change in fair value of contingent consideration (8,626 ) 100 (8,526 ) Acquisition, restructuring and other items, net 23,745 (343 ) 23,402 Total operating expenses 133,666 1,377 135,043 Operating income (2,334 ) (2,244 ) (4,578 ) Other expense (2,950 ) 1,693 (1,257 ) Total other income (expense) (5,398 ) 1,693 (3,705 ) Income (loss) before taxes (7,732 ) (551 ) (8,283 ) Income tax (benefit) expense (5,278 ) (205 ) (5,483 ) Net income (loss) (2,454 ) (346 ) (2,800 ) Three months ended February 28, 2015 As previously reported Adjustments As revised Net income (loss) $ (4,262 ) $ 109 $ (4,153 ) Foreign currency translation (624 ) 37 (587 ) Other comprehensive income (loss), before tax (508 ) 37 (471 ) Other comprehensive income (loss), net of tax (551 ) 37 (514 ) Total comprehensive income (loss), net of tax (4,813 ) 146 (4,667 ) Nine months ended February 28, 2015 As previously reported Adjustments As revised Net income (loss) $ (2,454 ) $ (346 ) $ (2,800 ) Foreign currency translation (728 ) 110 (618 ) Other comprehensive income (loss), before tax (568 ) 110 (458 ) Other comprehensive income (loss), net of tax (627 ) 110 (517 ) Total comprehensive income (loss), net of tax (3,081 ) (236 ) (3,317 ) As of February 28, 2015 As previously reported Adjustments As revised Inventories $ 68,710 $ 57 $ 68,767 Prepaid expenses and other 4,859 (221 ) 4,638 Total current assets 154,654 (164 ) 154,490 Property, Plant and Equipment, net 58,295 (80 ) 58,215 Other Assets 4,060 224 4,284 Intangible Assets, net 186,547 (154 ) 186,393 Deferred Income Taxes, long term 19,107 433 19,540 Total Assets 783,136 259 783,395 Accounts payable 21,696 278 21,974 Accrued liabilities 19,946 (461 ) 19,485 Total current liabilities 59,687 (183 ) 59,504 Other Long Term Liabilities — 628 628 Total Liabilities 239,380 445 239,825 Retained earnings 29,047 (884 ) 28,163 Accumulated other comprehensive loss (1,896 ) 698 (1,198 ) Total Stockholders' Equity 543,756 (186 ) 543,570 Total Liabilities and Stockholders' Equity 783,136 259 783,395 Nine months ended February 28, 2015 As previously reported Adjustments As revised Net cash provided by (used in) operating activities $ 15,436 $ (557 ) $ 14,879 Net cash provided by (used in) investing activities (12,042 ) 557 (11,485 ) Net cash provided by (used in) financing activities 641 — 641 Three months ended November 30, 2014 As previously reported Adjustments As revised Cost of sales $ 44,493 $ 828 $ 45,321 Gross profit 47,656 (828 ) 46,828 Research and development 6,069 207 6,276 Sales and marketing 20,983 553 21,536 General and administrative 7,973 (187 ) 7,786 Amortization of intangibles 4,061 (50 ) 4,011 Change in fair value of contingent consideration 617 (75 ) 542 Acquisition, restructuring and other items, net 2,302 (240 ) 2,062 Total operating expenses 43,081 208 43,289 Operating income 4,575 (1,036 ) 3,539 Other expense (954 ) 580 (374 ) Total other income (expense) (1,746 ) 580 (1,166 ) Income (loss) before taxes 2,829 (456 ) 2,373 Income tax (benefit) expense 1,491 (187 ) 1,304 Net income (loss) 1,338 (269 ) 1,069 Six months ended November 30, 2014 As previously reported Adjustments As revised Net sales $ 179,480 $ (240 ) $ 179,240 Cost of sales 85,999 449 86,448 Gross profit 93,481 (689 ) 92,792 Research and development 12,787 678 13,465 Sales and marketing 41,050 1,221 42,271 General and administrative 15,296 (195 ) 15,101 Amortization of intangibles 8,076 (28 ) 8,048 Change in fair value of contingent consideration 1,418 (150 ) 1,268 Acquisition, restructuring and other items, net 4,966 (240 ) 4,726 Total operating expenses 85,664 1,285 86,949 Operating income 7,817 (1,974 ) 5,843 Other expense (1,979 ) 1,196 (783 ) Total other income (expense) (3,570 ) 1,196 (2,374 ) Income (loss) before taxes 4,247 (778 ) 3,469 Income tax (benefit) expense 2,439 (323 ) 2,116 Net income (loss) 1,808 (455 ) 1,353 Three months ended November 30, 2014 As previously reported Adjustments As revised Net income (loss) $ 1,338 $ (269 ) $ 1,069 Foreign currency translation (104 ) 37 (67 ) Other comprehensive income (loss), before tax (100 ) 37 (63 ) Other comprehensive income (loss), net of tax (101 ) 37 (64 ) Total comprehensive income (loss), net of tax 1,237 (232 ) 1,005 Six months ended November 30, 2014 As previously reported Adjustments As revised Net income (loss) $ 1,808 $ (455 ) $ 1,353 Foreign currency translation (104 ) 74 (30 ) Other comprehensive income (loss), before tax (60 ) 74 14 Other comprehensive income (loss), net of tax (76 ) 74 (2 ) Total comprehensive income (loss), net of tax 1,732 (381 ) 1,351 As of November 30, 2014 As previously reported Adjustments As revised Inventories $ 75,315 $ 57 $ 75,372 Prepaid expenses and other 6,753 (191 ) 6,562 Total current assets 159,355 (134 ) 159,221 Property, Plant and Equipment, net 67,552 (829 ) 66,723 Other Assets 2,741 (15 ) 2,726 Intangible Assets, net 197,362 (175 ) 197,187 Deferred Income Taxes, long term 11,327 551 11,878 Total Assets 799,331 (602 ) 798,729 Accrued liabilities 19,177 (588 ) 18,589 Current portion of contingent consideration 9,795 (250 ) 9,545 Total current liabilities 57,937 (838 ) 57,099 Other Long Term Liabilities 124 568 692 Total Liabilities 255,760 (270 ) 255,490 Retained earnings 33,309 (993 ) 32,316 Accumulated other comprehensive loss (1,345 ) 662 (683 ) Total Stockholders' Equity 543,571 (332 ) 543,239 Total Liabilities and Stockholders' Equity 799,331 (602 ) 798,729 Six months ended November 30, 2014 As previously reported Adjustments As revised Net cash provided by (used in) operating activities $ 3,205 $ (557 ) 2,648 Net cash provided by (used in) investing activities (7,773 ) 557 (7,216 ) Net cash provided by (used in) financing activities 3,381 — 3,381 Three months ended August 31, 2014 As previously reported Adjustments As revised Net sales $ 87,331 $ (240 ) $ 87,091 Cost of sales 41,506 (379 ) 41,127 Gross profit 45,825 139 45,964 Research and development 6,718 470 7,188 Sales and marketing 20,067 668 20,735 General and administrative 7,323 (8 ) 7,315 Amortization of intangibles 4,015 22 4,037 Change in fair value of contingent consideration 801 (75 ) 726 Total operating expenses 42,583 1,077 43,660 Operating income 3,242 (938 ) 2,304 Other expense (1,025 ) 616 (409 ) Total other income (expense) (1,824 ) 616 (1,208 ) Income (loss) before taxes 1,418 (322 ) 1,096 Income tax (benefit) expense 948 (136 ) 812 Net income (loss) 470 (186 ) 284 Three months ended August 31, 2014 As previously reported Adjustments As revised Net income (loss) $ 470 $ (186 ) $ 284 Foreign currency translation — 37 37 Other comprehensive income (loss), before tax 41 37 78 Other comprehensive income (loss), net of tax 26 37 63 Total comprehensive income (loss), net of tax 496 (149 ) 347 As of August 30, 2014 As previously reported Adjustments As revised Inventories $ 70,421 $ 885 $ 71,306 Prepaid expenses and other 6,777 (311 ) 6,466 Total current assets 150,638 574 151,212 Property, Plant and Equipment, net 66,794 (605 ) 66,189 Other Assets 3,345 (53 ) 3,292 Intangible Assets, net 201,440 (225 ) 201,215 Deferred Income Taxes, long term 12,903 364 13,267 Total Assets 796,114 55 796,169 Accrued liabilities 17,700 (178 ) 17,522 Current portion of contingent consideration 10,897 (175 ) 10,722 Total current liabilities 63,707 (353 ) 63,354 Other Long Term Liabilities 32 507 539 Total Liabilities 256,430 154 256,584 Retained earnings 31,971 (724 ) 31,247 Accumulated other comprehensive loss (1,243 ) 625 (618 ) Total Stockholders' Equity 539,684 (99 ) 539,585 Total Liabilities and Stockholders' Equity 796,114 55 796,169 Three months ended August 30, 2014 As previously reported Adjustments As revised Net cash provided by (used in) operating activities $ 5,352 $ (410 ) $ 4,942 Net cash provided by (used in) investing activities (5,258 ) 410 (4,848 ) Net cash provided by (used in) financing activities (2,391 ) — (2,391 )

Valuation and Qualifying Accoun

Valuation and Qualifying Accounts	12 Months Ended
	May 31, 2016
Valuation and Qualifying Accounts [Abstract]
VALUATION AND QUALIFYING ACCOUNTS	AngioDynamics, Inc. and Subsidiaries SCHEDULE II -VALUATION AND QUALIFYING ACCOUNTS (in thousands) Column A Column B Column C Column D Column E Description Balance at Beginning of Year Additions - Charged to costs and expenses Deductions Balance at End of Period Year Ended May 31, 2014 Allowance for deferred tax asset (a) 712 819 — 1,531 Allowance for sales returns and doubtful accounts (b) 1,272 7,342 (6,878 ) 1,736 Totals $ 1,984 $ 8,161 $ (6,878 ) $ 3,267 Year Ended May 31, 2015 Allowance for deferred tax asset (a) 1,531 467 (207 ) 1,791 Allowance for sales returns and doubtful accounts (b) 1,736 1,846 (539 ) 3,043 Totals $ 3,267 $ 2,313 $ (746 ) $ 4,834 Year Ended May 31, 2016 Allowance for deferred tax asset (a) 1,791 40,685 (267 ) 42,209 Allowance for sales returns and doubtful accounts (b) 3,043 3,748 (2,419 ) 4,372 Totals $ 4,834 $ 44,433 $ (2,686 ) $ 46,581 (a) Fully reserved deferred tax assets and expiration of fully reserved state net operating loss. We made adjustments to correct immaterial errors within this selected financial data. For a detailed explanation of these adjustments, please refer to Note R, "Immaterial Error Corrections". (b) Previously reserved sales returns and accounts written off as uncollectible.

Basis of Presentation, Busine28

Basis of Presentation, Business Description and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	May 31, 2016
Accounting Policies [Abstract]
Basis of Presentation and Description of Business	Basis of Presentation and Description of Business The consolidated financial statements include the accounts of AngioDynamics, Inc. and its wholly owned subsidiaries, (collectively, the “Company”). We design, manufacture and sell a wide range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and in oncology and surgical settings. Our devices are generally used in minimally invasive, image-guided procedures. Most of our products are intended to be used once and then discarded, or they may be temporarily implanted for short- or long-term use. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect reported amounts of sales and expenses during the reporting period. Actual results could differ from those estimates. Assets and liabilities of non-U.S. dollar functional currency entities are translated to U.S. dollars at period-end exchange rates, and the resulting gains and losses arising from the translation of those net assets are recorded as a cumulative translation adjustment, a component of accumulated other comprehensive loss on the consolidated balance sheets. All intercompany balances and transactions have been eliminated.
Cash and Cash Equivalents	Cash and Cash Equivalents We consider all unrestricted highly liquid investments purchased with an initial maturity of less than three months to be cash equivalents. We maintain cash and cash equivalent balances with financial institutions in the United States in excess of amounts insured by the Federal Deposit Insurance Corporation.
Marketable Securities	Marketable Securities Marketable securities, which include auction rate investments, are classified as “available-for-sale securities” and are reported at fair value, with unrealized gains and losses excluded from operations and reported as a component of accumulated other comprehensive income (loss), net of the related tax effects, in stockholders’ equity. Cost is determined using the specific identification method. We hold investments in auction rate securities in order to generate higher than typical money market rate investment returns. Auction rate securities typically are high credit quality, generally achieved with municipal bond insurance. Credit risks are eased by the historical track record of bond insurers, which back a majority of this market. Sell orders for any security traded through an auction process could exceed bids and, in such cases, the auction fails and we may be unable to liquidate our position in the securities in the near term.
Accounts Receivable	Accounts Receivable Accounts receivable, principally trade, are generally due within 30 to 90 days and are stated at amounts due from customers, net of an allowance for sales returns and doubtful accounts. We perform ongoing credit evaluations of our customers and adjust credit limits based upon payment history and the customer’s current creditworthiness, as determined by a review of their current credit information. We continuously monitor aging reports, collections and payments from customers, and a provision for estimated credit losses is maintained based upon our historical experience and any specific customer collection issues that have been identified. While such credit losses have historically been within our expectations and the provisions established, we cannot guarantee that the same credit loss rates will be experienced in the future. We write off accounts receivable when they are determined to be uncollectible.
Inventories	Inventories Inventories are stated at the lower of cost (using the first-in, first-out method) or market. Appropriate consideration is given to deterioration, obsolescence, expiring and other factors in evaluating net realizable value.
Goodwill and Intangible Assets	Goodwill and Intangible Assets Intangible assets other than goodwill and acquired IP R&D are amortized over their estimated useful lives, which range between two and eighteen years, on either a straight-line basis over the expected period of benefit or as revenues are earned from the sales of the related products. We periodically review the estimated useful lives of our intangible assets and review such assets for impairment whenever events or changes in circumstances indicate that the carrying value of the assets is not recoverable. Our determination of impairment is based on estimates of future cash flows. If an intangible asset is considered to be impaired, the amount of the impairment will equal the excess of the carrying value over the fair value of the asset. Acquired IP R&D has an indefinite life and is not amortized until completion of the development of the project, at which time the IP R&D becomes an amortizable asset. If the related project is not completed in a timely manner or the project is terminated or abandoned, we may have an impairment related to the IP R&D, calculated as the excess of the asset’s carrying value over its fair value. Our policy defines IP R&D as the value assigned to those projects for which the related products have not received regulatory approval and have no alternative future use. Determining the portion of the purchase price allocated to IP R&D requires us to make significant estimates. The amount of the purchase price allocated to IP R&D is determined by estimating the future cash flows of each project or technology and discounting the net cash flows back to their present values. The discount rate used is determined at the time of measurement in accordance with accepted valuation methods. These methodologies include consideration of the risk of the project not achieving commercial feasibility. Goodwill and other intangible assets that have indefinite useful lives are not amortized, but rather, are tested for impairment annually or more frequently if impairment indicators arise. Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in each business combination. Goodwill and intangible assets have been recorded at either incurred or allocated cost. Allocated costs were based on respective fair market values at the date of acquisition. For goodwill, the impairment test requires a comparison of the estimated fair value of the reporting unit to which the goodwill is assigned to the sum of the carrying value of the assets and liabilities of that unit. If the sum of the carrying value of the assets and liabilities of a reporting unit exceeds the fair value of the reporting unit, the carrying value of the reporting unit’s goodwill is reduced to its implied fair value through an adjustment to the goodwill balance, resulting in an impairment charge. Our determination of impairment is based on estimates of future cash flows.
Contingent Consideration	Contingent Consideration The fair value of the liability for contingent consideration recorded on the acquisition date for a business combination is based on probability weighted estimated cash flow streams, discounted back to present value using a discount rate determined in accordance with accepted valuation methods. The liability for contingent consideration is remeasured to fair value at each reporting period with changes recorded in earnings until the contingency is resolved.
Revenue Recognition	Revenue Recognition We recognize revenue when the following four criteria has been met: (i) persuasive evidence that an arrangement exists; (ii) the price is fixed or determinable; (iii) collectability is reasonably assured; and (iv) product delivery has occurred or services have been rendered. We recognize revenue, net of sales taxes assessed by any governmental authority, as products are shipped, based on shipping terms, and when title and risk of loss passes to customers. We negotiate shipping and credit terms on a customer-by-customer basis and products are shipped at an agreed upon price. All product returns must be pre-approved by us and customers may be subject to a 20% restocking charge. To be accepted, a returned product must be unadulterated, undamaged and have at least twelve months remaining prior to its expiration date. Charges for discounts, returns, rebates and other allowances are recognized as a deduction from revenue on an accrual basis in the period in which the revenue is recorded. The accrual for product returns, discounts and other allowances is based on the company’s history. Shipping and handling costs, associated with the distribution of finished products to customers, are recorded in costs of goods sold and are recognized when the related finished product is shipped to the customer. Amounts charged to customers for shipping are recorded in net sales.
Research and Development	Research and Development Research and development costs, including salaries, consulting fees, building costs, utilities and administrative expenses that are related to developing new products, enhancing existing products, validating new and enhanced products, managing clinical, regulatory and medical affairs are expensed as incurred.
Income Taxes	Income Taxes In preparing our financial statements, we calculate income tax expense for each jurisdiction in which we operate. This involves estimating actual current taxes due plus assessing temporary differences arising from differing treatment for tax and accounting purposes that are recorded as deferred tax assets and liabilities. We periodically evaluate deferred tax assets, capital loss carryforwards and tax credit carryforwards to determine their recoverability based primarily on our ability to generate future taxable income and capital gains. Where it is more-likely-than-not these will not be recovered, we estimate a valuation allowance and record a corresponding additional tax expense in our statement of operations. We file income tax returns in the U.S. federal jurisdiction and various state and foreign jurisdictions. In the normal course of business we are subject to examination by taxing authorities throughout the world. Fiscal years 2012 through 2016 remain open to examination by the various tax authorities. New York State is currently auditing AngioDynamic’s franchise tax filings for 2011 through 2013, and we do not anticipate any material adjustments will result. We analyzed filing positions in all of the Federal and state jurisdictions where we are required to file income taxes, as well as all open tax years in these jurisdictions and believe that our income tax filing positions and deductions will be sustained on audit and we do not anticipate any adjustments will result in a material adverse effect on our financial condition, results of operations or cash flows.
Derivative Financial Instruments	Derivative Financial Instruments We are exposed to market risks, including changes in interest rates. We periodically enter into certain derivative financial instruments to hedge the underlying economic exposure. The derivative instruments used are floating-to-fixed rate interest rate swaps, which are subject to hedge accounting treatment. Derivative instruments are presented in the consolidated financial statements at their fair value. Changes in the fair value of derivative financial instruments are either recognized periodically in income or in stockholders’ equity as a component of accumulated other comprehensive income (loss) depending on whether the derivative financial instrument qualifies for hedge accounting and, if so, whether it qualifies as a fair value or cash flow hedge. Generally, the changes in the fair value of derivatives accounted for as fair value hedges are recorded in income along with the portions of the changes in the fair value of hedged items that relate to the hedged risks. Changes in the fair value of derivatives accounted for as cash flow hedges, to the extent they are effective as hedges, are recorded in accumulated other comprehensive income (loss).
Supplier Concentrations	Supplier Concentrations We are dependent upon the ability of our suppliers to provide products on a timely basis and on favorable pricing terms. The loss of our principal suppliers or a significant reduction in product availability from these suppliers could have a material adverse effect on us. We believe that our relationships with these suppliers are satisfactory.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In May 2014, the Financial Accounting Standards Board ("FASB") issued ASU No. 2014-09, "Revenue from Contracts with Customers" ("ASU 2014-09"). ASU 2014-09 provides a single, comprehensive accounting model for revenues arising from contracts with customers that supersedes most of the existing revenue recognition guidance, including industry-specific guidance. Under this model, revenue is recognized at an amount that an entity expects to be entitled to upon transferring control of goods or services to a customer, as opposed to when risks and rewards transfer to a customer under existing revenue recognition guidance. ASU 2014-09 is effective for the Company beginning in its fiscal year 2018, and may be applied retrospectively to all prior periods presented or through a cumulative adjustment to the opening retained earnings balance in the year of adoption. The Company is currently in the process of evaluating the impact of ASU 2014-09 on its consolidated financial statements. In June 2014, the FASB issued ASU 2014-12, Accounting for Share-Based Payments When the Terms of the Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period, that clarified that entities should treat performance targets that can be met after the requisite service period of a share-based payment award as performance conditions that affect vesting. Therefore, an entity would not record compensation expense related to an award for which transfer to the employee is contingent on the entity’s satisfaction of a performance target until it becomes probable that the performance target is met. This ASU is effective for the Company in its first quarter beginning after January 1, 2016 and did not have a material impact on the Company’s consolidated financial statements. In April 2015, the FASB issued ASC Update No. 2015-03, Interest-Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. Update No. 2015-03 requires debt issuance costs related to a recognized debt liability to be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. Update No. 2015-03 is effective for annual reporting periods beginning after December 15, 2015 and interim periods within those reporting periods. Early adoption is permitted for financial statements that have not been previously issued. This update is not expected to impact the results of our operations. In July 2015, the FASB issued ASC Update No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. Update No. 2015-11 more closely aligns the measurement of inventory in U.S. GAAP with the measurement of inventory in International Financial Reporting Standards by requiring companies using the first-in, first-out and average costs methods to measure inventory using the lower of cost and net realizable value, where net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Update No. 2015-11 is effective for annual reporting periods beginning after December 15, 2016 and interim periods within those fiscal years. Update No. 2015-11 should be applied prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. The adoption of Update No. 2015-11 is not expected to have a material impact on our financial position or results of operations. In November 2015, the FASB issued ASC Update No. 2015-17, “Balance Sheet Classification of Deferred Taxes” as part of its simplification initiatives. This update requires deferred tax liabilities and assets to be classified as non-current on the consolidated condensed balance sheet for fiscal years beginning after December 15, 2016, and interim periods within those annual periods. Early application is permitted. An entity can elect to adopt prospectively or retrospectively to all periods presented. This update was applied retrospectively as of November 30, 2015. The current deferred tax asset balance of $4.4 million was classified as a non-current deferred tax asset for the period ended May 31, 2015 in the consolidated condensed balance sheet. In January 2016, the FASB issued ASU 2016-01, Financial Instruments - Overall (Subtopic 825-10). Update No. 2016-01 addresses certain aspects of recognition, measurement, presentation and disclosure of financial instruments. Update No. 2016-01 is effective for annual reporting periods beginning after December 15, 2017 and interim periods within those fiscal years and early application is permitted. The adoption of Update No. 2016-01 is not expected to have a material impact on our financial position or results of operations. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). ASU 2016-02 increases transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information about leasing arrangements. For leases with a term or twelve months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and liabilities. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018 and early application is permitted. The Company is currently in the process of evaluating the impact of ASU 2016-02 on its consolidated financial statements. In March 2016, the FASB issued ASU 2016-09, Compensation - Stock Based Compensation (Topic 718: Improvements to Employee Share-Based Payment Accounting. ASU 2016-09 simplifies and improves various aspects of ASC 718 for share-based payments, including income tax items and the classification of these items on the statement of cash flows. ASU 2016-09 is effective for annual periods beginning after December 31, 2016 and early application is permitted. The Company is currently in the process of evaluating the impact of ASU 2016-09 on its consolidated financial statements.
Fair Value of Financial Instruments	FAIR VALUE OF FINANCIAL INSTRUMENTS Our financial instruments include cash and cash equivalents, accounts receivable, marketable securities, accounts payable, interest rate swap agreement and contingent earn outs. The carrying amount of cash and cash equivalents, accounts receivable, and accounts payable approximates fair value due to the immediate or short-term maturities. The marketable securities and interest rate swap agreement has been recorded at its fair value based on a valuation received from an independent third party. The contingent earn out has been recorded at fair value using the income approach. Fair value is the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. This policy establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The policy describes three levels of inputs that may be used to measure fair value which are provided in the table below. Level 1 Quoted prices in active markets for identical assets or liabilities. Level 1 assets include money market funds that are traded in an active exchange market. Level 2 Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. When quoted market prices are unobservable, we obtain pricing information from an independent pricing vendor. The pricing vendor uses various pricing models for each asset class that are consistent with what other market participants would use. The inputs and assumptions to the model of the pricing vendor are derived from market observable sources including: benchmark yields, reported trades, broker/dealer quotes, issuer spreads, benchmark securities, bids, offers, and other market-related data. The pricing vendor considers all available market observable inputs in determining the evaluation for a security. Thus, certain securities may not be priced using quoted prices, but rather determined from market observable information. Included in Level 2 assets is our interest rate swap agreement which is valued using a mid-market valuation model. Level 3 Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation. This category includes the auction rate securities where independent pricing information was not able to be obtained and the contingent consideration related to the acquisitions of Vortex, Microsulis and Clinical Devices. Our investments in auction-rate securities were classified as Level 3 as quoted prices were unavailable since these auction rate securities issued by New York state and local government authorities failed auction. Due to limited market information, we utilized a discounted cash flow (“DCF”) model to derive an estimate of fair value for contingent considerations for all periods presented. The assumptions used in preparing the DCF model included estimates with respect to the discount rate, amount and timing of future interest and principal payments and forward projections. Assumptions associated with the auction rate securities include the interest rate benchmarks, the probability of full repayment of the principal considering the credit quality and guarantees in place, and the rate of return required by investors to own such securities given the current liquidity risk.

Basis of Presentation, Busine29

Basis of Presentation, Business Description and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	May 31, 2016
Accounting Policies [Abstract]
Property, plant and equipment	Property, Plant and Equipment Property, plant and equipment are stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Refer below for useful lives by category: Estimated useful lives Building and building improvements 39 years Machinery and equipment 3 to 8 years Computer software and equipment 3 to 10 years We evaluate these assets for impairment periodically or as changes in circumstances or the occurrence of events suggest the remaining value is not recoverable. Expenditures for repairs and maintenance are charged to expense as incurred. Renewals and betterments are capitalized. roperty, plant and equipment are summarized as follows: May 31, 2016 May 31, 2015 (in thousands) Building and building improvements $ 39,585 $ 33,853 Machinery and equipment 24,078 23,626 Computer software and equipment 24,691 24,431 Construction in progress 1,743 7,033 90,097 88,943 Less accumulated depreciation and amortization (43,536 ) (36,197 ) 46,561 52,746 Land and land improvements 1,723 1,704 $ 48,284 $ 54,450

Fair Value of Financial Instr30

Fair Value of Financial Instruments Fair Value of Financial Instruments (Tables)	12 Months Ended
	May 31, 2016
Fair Value Disclosures [Abstract]
Fair value of assets and liabilities measured on recurring basis	The following tables provide information by level for assets and liabilities that are measured at fair value (in thousands): Fair Value Measurements using inputs considered as: Level 1 Level 2 Level 3 Fair Value at May 31, 2016 Financial Assets Marketable securities New York State government agency obligations $ — $ — $ 1,653 $ 1,653 Total — — 1,653 1,653 Total Financial Assets $ — $ — $ 1,653 $ 1,653 Financial Liabilities Contingent liability for acquisition earn out — — 38,275 38,275 Total Financial Liabilities $ — $ — $ 38,275 $ 38,275 Fair Value Measurements using inputs considered as: Level 1 Level 2 Level 3 Fair Value at May 31, 2015 Financial Assets Marketable securities New York State government agency obligations $ — $ — $ 1,689 $ 1,689 Total — — 1,689 1,689 Total Financial Assets $ — $ — $ 1,689 $ 1,689 Financial Liabilities Interest rate swap agreements $ — $ 257 $ — $ 257 Contingent liability for acquisition earn out — — 47,384 47,384 Total Financial Liabilities $ — $ 257 $ 47,384 $ 47,641
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation	The components of Level 3 fair value instruments as of May 31, 2016 are shown below (in thousands): Financial Assets Financial Liabilities Fair Value Measurements Fair Value Measurements Balance at May 31, 2015 $ 1,689 $ 47,384 Change in fair value of contingent consideration (1) — 948 Currency (gain) loss from remeasurement — 43 Fair market value adjustments (36 ) — Contingent consideration payments — (10,100 ) Balance at May 31, 2016 $ 1,653 $ 38,275 The components of Level 3 fair value instruments as of May 31, 2015 are shown below (in thousands): Financial Assets Financial Liabilities Fair Value Measurements Fair Value Measurements Balance at May 31, 2014 $ 1,809 $ 67,331 Change in fair value of contingent consideration (1) — (8,196 ) Currency (gain) loss from remeasurement — (529 ) Included in other comprehensive income (loss) (120 ) — Contingent consideration payments — (11,222 ) Balance at May 31, 2015 $ 1,689 $ 47,384 (1) Change in the fair value of contingent consideration is included in earnings and comprised of changes in estimated earn out payments based on projections of company performance and amortization of the present value discount.
Fair Value, Liabilities Measured on Recurring Basis	The recurring Level 3 fair value measurements of the contingent consideration liabilities include the following significant unobservable inputs as of May 31, 2016 (in thousands of dollars): Fair value at May 31, 2016 Valuation Technique Unobservable Input Range Revenue based payments $ 35,325 Discounted cash flow Discount rate 4% Milestone based payments 2,950 Discounted cash flow Discount rate 16% $ 38,275

Marketable Securities and Inv31

Marketable Securities and Investments (Tables)	12 Months Ended
	May 31, 2016
Investments, Debt and Equity Securities [Abstract]
Marketable securities	As of May 31, 2016 , marketable securities consisted of the following: Amortized cost Gross Unrealized Gains Gross Unrealized Losses Fair Value (in thousands) Available-for-sales securities New York State government agency obligations $ 1,800 $ — $ (147 ) $ 1,653 $ 1,800 $ — $ (147 ) $ 1,653 As of May 31, 2015 , marketable securities consisted of the following: Amortized cost Gross Unrealized Gains Gross Unrealized Losses Fair Value (in thousands) Available-for-sales securities New York State government agency obligations $ 1,825 $ — $ (136 ) $ 1,689 $ 1,825 $ — $ (136 ) $ 1,689
Amortized cost and fair value of marketable securities by contractual maturity	The amortized cost and fair value of marketable securities as of May 31, 2016 , by contractual maturity, are shown below. Expected maturities may differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without call or prepayment penalties. Amortized cost Fair Value (in thousands) As of May 31, 2016: Due in one year or less $ — $ — Due after one through five years — — Due after five through twenty years 1,800 1,653 $ 1,800 $ 1,653

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	May 31, 2016
Inventory Disclosure [Abstract]
Inventories	As of May 31, 2016 and 2015 , inventories consisted of the following: May 31, 2016 May 31, 2015 (in thousands) Raw materials $ 21,669 $ 28,040 Work in process 10,700 11,910 Finished goods 23,001 27,438 Total $ 55,370 $ 67,388

Prepaid Expenses and Other (Tab

Prepaid Expenses and Other (Tables)	12 Months Ended
	May 31, 2016
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid expenses and other	As of May 31, 2016 and 2015 , prepaid expenses and other consisted of the following: May 31, 2016 May 31, 2015 (in thousands) Deposits $ 190 $ 2,011 Other prepaid taxes 160 165 License fees 108 121 Software licenses 282 667 Trade shows 278 279 Rent 127 77 Other 2,098 812 Total $ 3,243 $ 4,132

Property, Plant and Equipment34

Property, Plant and Equipment, at Cost (Tables)	12 Months Ended
	May 31, 2016
Property, Plant and Equipment [Abstract]
Property, plant and equipment	Property, Plant and Equipment Property, plant and equipment are stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Refer below for useful lives by category: Estimated useful lives Building and building improvements 39 years Machinery and equipment 3 to 8 years Computer software and equipment 3 to 10 years We evaluate these assets for impairment periodically or as changes in circumstances or the occurrence of events suggest the remaining value is not recoverable. Expenditures for repairs and maintenance are charged to expense as incurred. Renewals and betterments are capitalized. roperty, plant and equipment are summarized as follows: May 31, 2016 May 31, 2015 (in thousands) Building and building improvements $ 39,585 $ 33,853 Machinery and equipment 24,078 23,626 Computer software and equipment 24,691 24,431 Construction in progress 1,743 7,033 90,097 88,943 Less accumulated depreciation and amortization (43,536 ) (36,197 ) 46,561 52,746 Land and land improvements 1,723 1,704 $ 48,284 $ 54,450

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	12 Months Ended
	May 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible assets	As of May 31, 2016 and 2015 , intangible assets consisted of the following: May 31, 2016 Gross carrying value Accumulated amortization Net carrying value Weighted average useful life (in thousands) (years) Product technologies $ 148,387 $ (51,313 ) $ 97,074 10.2 Customer relationships 88,389 (47,133 ) 41,256 11.9 Trademarks 28,470 (6,242 ) 22,228 10.7 In process R&D 3,600 — 3,600 Indefinite Licenses 7,931 (6,716 ) 1,215 7.6 Distributor relationships 2,150 (946 ) 1,204 5.2 $ 278,927 $ (112,350 ) $ 166,577 May 31, 2015 Gross carrying value Accumulated amortization Net carrying value Weighted avg useful life (in thousands) (years) Product technologies $ 148,776 $ (41,447 ) $ 107,329 10.2 Customer relationships 86,371 (42,813 ) 43,558 12.0 Trademarks 28,545 (3,383 ) 25,162 10.7 In process R&D 3,600 — 3,600 Indefinite Licenses 7,913 (5,910 ) 2,003 8.3 Distributor relationships 900 (900 ) — 3.0 $ 276,105 $ (94,453 ) $ 181,652
Expected amortization expense	Annual amortization of these intangible assets is expected to approximate the following amounts for each of the next five fiscal years (in thousands): 2017 $ 19,049 2018 $ 19,903 2019 $ 22,062 2020 $ 23,329 2021 $ 24,370
Adjustments to goodwill	Adjustments to goodwill for the fiscal year ended May 31, 2016 and May 31, 2015 are as follows (in thousands): Total Balance, May 31, 2014 $ 360,473 Tax basis adjustment 779 Balance, May 31, 2015 $ 361,252 — Balance, May 31, 2016 $ 361,252

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	May 31, 2016
Income Tax Disclosure [Abstract]
Components of income (loss) before income tax provision	The components of income (loss) before income tax provision for the years ended May 31 are as follows: 2016 2015 2014 (in thousands) (Loss) income before tax provision: US $ (4,444 ) $ (8,965 ) $ 4,645 Non-US 1,191 834 541 $ (3,253 ) $ (8,131 ) $ 5,186
Summary of Income tax (benefit) provision analyzed by category	Income tax (benefit) provision analyzed by category and by statement of operations classification for the years ended May 31 is summarized as follows: 2016 2015 2014 (in thousands) Current Federal $ 34 $ (242 ) $ (133 ) State and local 103 205 99 Non U.S. 217 417 157 354 380 123 Deferred 39,983 (5,123 ) 2,716 Income tax (benefit) provision $ 40,337 $ (4,743 ) $ 2,839
Summary of significant components of deferred income tax (benefit) expense from operations	The significant components of deferred income tax (benefit) expense from operations for the years ended May 31 consist of the following: 2016 2015 2014 (in thousands) Net effect of temporary differences $ 133 $ (1,916 ) $ 1,543 Adjustments for beginning-of-the-year valuation allowance balance for changes in circumstances 40,418 — — Impact of NYS tax reform legislation — — 1,173 Net operating loss carryforward (568 ) (3,207 ) — $ 39,983 $ (5,123 ) $ 2,716
Summary of deferred tax asset and liabilities	Temporary differences that give rise to deferred tax assets and liabilities are summarized as follows: May 31, 2016 May 31, 2015 (in thousands) Deferred tax assets Net operating loss carryforward $ 52,593 $ 52,025 Stock-based compensation 4,135 4,468 Federal and state R&D tax credit carryforward 2,145 1,646 Inventories 4,535 2,808 Expenses incurred not currently deductible 3,018 2,107 Accrued liabilities 339 114 Gross deferred tax asset 66,765 63,168 Deferred tax liabilities Excess tax over book depreciation and amortization 46,240 42,988 46,240 42,988 Valuation Allowance (42,209 ) (1,791 ) Net deferred tax asset (liability) $ (21,684 ) $ 18,389
Summary of Income tax rate reconciliation	Our consolidated income tax provision has differed from the amount that would be provided by applying the U.S. Federal statutory income tax rate to our income before income taxes for the following reasons: 2016 2015 2014 (in thousands) Income tax (benefit) provision at statutory tax rate of 35% $ (1,139 ) $ (2,845 ) $ 1,814 Effect of graduated tax rates 33 81 (51 ) State income taxes, net of Federal tax benefit (215 ) (21 ) 111 Impact of Non US operations (162 ) 133 (27 ) Research and development tax credit (499 ) (604 ) (236 ) Meals and entertainment 329 — — Nondeductible interest on contingent payments 262 265 540 Nontaxable gain on revaluation of contingent consideration liability (170 ) (3,102 ) (1,734 ) Tax law changes — (454 ) 1,173 Adjustment to beginning of year valuation allowance 40,685 — — Effect of elimination of stock compensation APIC pool 739 1,253 440 Nondeductible stock-based compensation — — 176 Other nondeductible expenses 207 498 384 Over (under) accrual of prior year Federal and state taxes 356 38 249 Other (89 ) 15 — Income tax (benefit) expense $ 40,337 $ (4,743 ) $ 2,839

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	12 Months Ended
	May 31, 2016
Payables and Accruals [Abstract]
Accrued liabilities	As of May 31, 2016 and 2015 , accrued liabilities consist of the following: May 31, 2016 May 31, 2015 (in thousands) Payroll and related expenses $ 9,414 $ 10,297 Royalties 2,489 2,237 Accrued severance 1,524 158 Sales and franchise taxes 565 489 Interest rate swap liability — 257 Outside services 2,063 1,522 Deferred Rent 35 808 Other 5,806 2,341 Total $ 21,896 $ 18,109

Long-Term Debt (Tables)

Long-Term Debt (Tables)	12 Months Ended
	May 31, 2016
Debt Disclosure [Abstract]
Future minimum principal payments on long-term debt	As of May 31, 2016 , future minimum principal payments on long-term debt were as follows (in thousands): 2017 $ 16,250 2018 26,250 2019 78,910 $ 121,410

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	May 31, 2016
Equity [Abstract]
Schedule summarizes stock option activity	The following table summarizes information about stock options activity for the fiscal year ended May 31, 2016 . 2016 Shares Weighted- average exercise price Weighted average remaining contractual life Aggregate intrinsic value (in thousands) Outstanding at beginning of year 2,299,313 $ 14.86 Granted 564,380 $ 14.22 Exercised (145,260 ) $ 13.73 Forfeited (304,563 ) $ 13.85 Expired (132,252 ) $ 22.75 Outstanding at end of year 2,281,618 $ 14.45 3.79 $ 164 Options exercisable at year-end 1,313,698 $ 14.25 2.34 $ 130 Options expected to vest in future periods 854,189 $ 14.72 5.76 $ 30
Share based compensation arrangement by share based payment award nonvested shares and weighted average grant date fair value	The following table summarizes information about restricted stock unit activity for the year ended May 31, 2016. Non-Vested Stock Award Units Weighted Average Grant-Date Fair Value Non-vested at beginning of year 563,101 $ 13.73 Granted 259,917 $ 15.21 Vested (160,845 ) $ 15.39 Canceled (112,396 ) $ 13.81 Non-vested at end of year 549,777 $ 14.62 Awards expected to vest in future periods 482,594 $ 14.62

Earnings Per Share (Tables)

Earnings Per Share (Tables)	12 Months Ended
	May 31, 2016
Earnings Per Share [Abstract]
Schedule of Weighted Average Number of Shares	The following table reconciles basic to diluted weighted average shares outstanding for the years ended May 31, 2016 , 2015 and 2014 : 2016 2015 2014 Basic 36,161,383 35,683,139 35,135,689 Effect of dilutive securities — — 304,161 Diluted 36,161,383 35,683,139 35,439,850 Securities excluded as their inclusion would be anti-dilutive 3,277,037 2,862,414 2,347,426

Commitments And Contingencies (

Commitments And Contingencies (Tables)	12 Months Ended
	May 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Aggregate of future annual payments under non cancelable operating leases for facilities and equipment	Future annual payments under non-cancelable operating leases in the aggregate, of which one includes an escalation clause, with initial remaining terms of more than one year at May 31, 2016 , are summarized as follows (in thousands): 2017 $ 2,183 2018 2,013 2019 1,981 2020 1,772 2021 935 $ 8,884

Segments and Geographic Infor42

Segments and Geographic Information (Tables)	12 Months Ended
	May 31, 2016
Segment Reporting [Abstract]
Summary of total net sales by product category	Total sales by product category are summarized below (in thousands): Year Ended May 31, May 31, May 31, Net sales by Product Category Peripheral Vascular $ 202,780 $ 192,713 $ 192,626 Vascular Access 99,375 107,754 106,394 Oncology/Surgery 48,895 51,890 49,360 Supply Agreement 2,840 4,177 6,045 Total $ 353,890 $ 356,534 $ 354,425
Summary of net sales for geographic areas	Total sales for geographic areas are summarized below (in thousands): Year Ended May 31, May 31, May 31, Net sales by Geography United States $ 283,519 $ 280,611 $ 280,161 International 67,531 71,746 68,219 Supply Agreement 2,840 4,177 6,045 Total $ 353,890 $ 356,534 $ 354,425

Immaterial Error Corrections (T

Immaterial Error Corrections (Tables)	12 Months Ended
	May 31, 2016
Accounting Changes and Error Corrections [Abstract]
Schedule of Error Corrections and Prior Period Adjustments	The impacts of these revisions are shown in the tables below: Year ended May 31, 2015 As previously reported Adjustments As revised Net sales $ 356,974 $ (440 ) $ 356,534 Cost of sales 180,085 653 180,738 Gross profit 176,889 (1,093 ) 175,796 Research and development 26,931 (337 ) 26,594 Sales and marketing 80,623 2,597 83,220 General and administrative 29,871 (709 ) 29,162 Amortization of intangibles 17,912 54 17,966 Change in fair value of contingent consideration (8,196 ) 100 (8,096 ) Acquisition, restructuring and other items, net 26,600 (343 ) 26,257 Total operating expenses 177,883 1,362 179,245 Operating income (994 ) (2,455 ) (3,449 ) Other expense (3,812 ) 2,323 (1,489 ) Total other income (expense) (7,005 ) 2,323 (4,682 ) Income (loss) before taxes (7,999 ) (132 ) (8,131 ) Income tax (benefit) expense (4,731 ) (12 ) (4,743 ) Net income (loss) (3,268 ) (120 ) (3,388 ) Year ended May 31, 2015 As previously reported Adjustments As revised Net income (loss) $ (3,268 ) $ (120 ) $ (3,388 ) Foreign currency translation (411 ) 147 (264 ) Other comprehensive income (loss), before tax (235 ) 147 (88 ) Other comprehensive income (loss), net of tax (299 ) 147 (152 ) Total comprehensive income (loss), net of tax (3,567 ) 27 (3,540 ) As of May 31, 2015 As previously reported Adjustments As revised Prepaid expenses and other $ 4,783 $ (651 ) $ 4,132 Total current assets 151,449 (651 ) 150,798 Property, Plant and Equipment, net 54,560 (110 ) 54,450 Other Assets 5,288 110 5,398 Intangible Assets, net 181,806 (154 ) 181,652 Deferred Income Taxes, long term 19,268 240 19,508 Total Assets 773,623 (565 ) 773,058 Accounts payable 23,668 (620 ) 23,048 Accrued liabilities 18,331 (222 ) 18,109 Other current liabilities — 200 200 Total current liabilities 61,157 (642 ) 60,515 Total Liabilities 228,601 (642 ) 227,959 Retained earnings 28,233 (658 ) 27,575 Accumulated other comprehensive loss (1,568 ) 735 (833 ) Total Stockholders' Equity 545,022 77 545,099 Total Liabilities and Stockholders' Equity 773,623 (565 ) 773,058 Year ended May 31, 2015 As previously reported Adjustments As revised Net cash provided by (used in) operating activities $ 26,242 $ (557 ) $ 25,685 Net cash provided by (used in) investing activities (13,293 ) 557 (12,736 ) Net cash provided by (used in) financing activities (10,465 ) — (10,465 ) Year ended May 31, 2014 As previously reported Adjustments As revised Cost of sales $ 174,757 $ (506 ) $ 174,251 Gross profit 179,668 506 180,174 Research and development 27,486 638 28,124 Sales and marketing 83,200 2,105 85,305 General and administrative 26,639 263 26,902 Amortization of intangibles 16,622 (60 ) 16,562 Change in fair value of contingent consideration (1,808 ) (100 ) (1,908 ) Acquisition, restructuring and other items, net 10,760 113 10,873 Total operating expenses 166,728 2,959 169,687 Operating income 12,940 (2,453 ) 10,487 Other expense (3,544 ) 1,899 (1,645 ) Total other income (expense) (7,200 ) 1,899 (5,301 ) Income (loss) before taxes 5,740 (554 ) 5,186 Income tax (benefit) expense 3,074 (235 ) 2,839 Net income (loss) 2,666 (319 ) 2,347 Year ended May 31, 2014 As previously reported Adjustments As revised Net income (loss) $ 2,666 $ (319 ) $ 2,347 Foreign currency translation 295 147 442 Other comprehensive income (loss), before tax 247 147 394 Other comprehensive income (loss), net of tax 265 147 412 Total comprehensive income (loss), net of tax 2,931 (172 ) 2,759 As of May 31, 2014 As previously reported Adjustments As revised Inventories $ 61,234 $ 506 $ 61,740 Prepaid expenses and other 5,471 (591 ) 4,880 Total current assets 147,097 (85 ) 147,012 Property, Plant and Equipment, net 66,590 (135 ) 66,455 Other Assets 3,926 (120 ) 3,806 Intangible Assets, net 205,256 (203 ) 205,053 Deferred Income Taxes, long term 15,028 228 15,256 Total Assets 798,891 (315 ) 798,576 Accrued liabilities 16,652 (712 ) 15,940 Current portion of contingent consideration 10,918 (100 ) 10,818 Other current liabilities 599 — 599 Total current liabilities 66,753 (812 ) 65,941 Other Long Term Liabilities 84 447 531 Total Liabilities 262,056 (365 ) 261,691 Retained earnings 31,501 (538 ) 30,963 Accumulated other comprehensive loss (1,269 ) 588 (681 ) Total Stockholders' Equity 536,835 50 536,885 Total Liabilities and Stockholders' Equity 798,891 (315 ) 798,576 Year ended May 31, 2014 As previously reported Adjustments As revised Net cash provided by (used in) operating activities $ 24,681 $ — $ 24,681 Net cash provided by (used in) investing activities (16,448 ) — (16,448 ) Net cash provided by (used in) financing activities (14,016 ) — (14,016 ) Year ended May 31, 2013 As previously reported Adjustments As revised Research and development $ 26,319 $ (228 ) $ 26,091 Sales and marketing 76,121 1,443 77,564 General and administrative 26,186 (151 ) 26,035 Amortization of intangibles 16,617 (18 ) 16,599 Total operating expenses 162,226 1,046 163,272 Operating income 6,288 (1,046 ) 5,242 Other expense (2,707 ) 1,296 (1,411 ) Total other income (expense) (7,875 ) 1,296 (6,579 ) Income (loss) before taxes (1,587 ) 250 (1,337 ) Income tax (benefit) expense (376 ) 90 (286 ) Net income (loss) (1,211 ) 160 (1,051 ) As of May 31, 2013 As previously reported Adjustments As revised Property, Plant and Equipment, net $ 62,391 $ (16 ) $ 62,375 Intangible Assets, net 214,673 (150 ) 214,523 Deferred Income Taxes, long term 18,016 (7 ) 18,009 Total Assets 790,734 (173 ) 790,561 Accrued liabilities 16,356 (395 ) 15,961 Total current liabilities 63,315 (395 ) 62,920 Total Liabilities 264,632 (395 ) 264,237 Retained earnings 28,835 (219 ) 28,616 Accumulated other comprehensive loss (1,534 ) 441 (1,093 ) Total Stockholders' Equity 526,102 222 526,324 Total Liabilities and Stockholders' Equity 790,734 (173 ) 790,561 Year ended May 31, 2012 As previously reported Adjustments As revised Sales and marketing $ 64,505 $ 1,252 $ 65,757 Amortization of intangibles 9,309 84 9,393 Total operating expenses 129,217 1,336 130,553 Operating income (3,908 ) (1,336 ) (5,244 ) Other expense (2,096 ) 1,105 (991 ) Total other income (expense) (1,514 ) 1,105 (409 ) Income (loss) before taxes (5,422 ) (231 ) (5,653 ) Income tax (benefit) expense (239 ) (83 ) (322 ) Net income (loss) (5,183 ) (148 ) (5,331 ) As of May 31, 2012 As previously reported Adjustments As revised Intangible Assets, net $ 147,363 $ (168 ) $ 147,195 Deferred Income Taxes, long term 44,194 83 44,277 Total Assets 719,988 (85 ) 719,903 Retained earnings 30,046 (379 ) 29,667 Accumulated other comprehensive loss (1,274 ) 294 (980 ) Total Stockholders' Equity 523,391 (85 ) 523,306 Total Liabilities and Stockholders' Equity 719,988 (85 ) 719,903 The data in the schedules above has been intentionally rounded to the nearest thousand and therefore the quarterly amounts may not sum to the full year amounts. We made adjustments to correct immaterial errors within this selected financial data. For a detailed explanation of these adjustments, please refer to Note R, "Immaterial Error Corrections". Three months ended February 29, 2016 As previously reported Adjustments As revised Net sales $ 87,384 $ 50 $ 87,434 Gross profit 43,484 50 43,534 Sales and marketing 20,301 654 20,955 General and administrative 6,784 117 6,901 Total operating expenses 40,797 771 41,568 Operating income 2,687 (721 ) 1,966 Other expense (868 ) 654 (214 ) Total other income (expense) (1,675 ) 654 (1,021 ) Income (loss) before taxes 1,012 (67 ) 945 Income tax (benefit) expense 382 (31 ) 351 Net income (loss) 630 (36 ) 594 Nine months ended February 29, 2016 As previously reported Adjustments As revised Net sales $ 260,321 $ 150 $ 260,471 Cost of sales 127,829 (147 ) 127,682 Gross profit 132,492 297 132,789 Research and development 18,189 (73 ) 18,116 Sales and marketing 61,429 2,105 63,534 General and administrative 22,300 597 22,897 Total operating expenses 127,418 2,629 130,047 Other expense (2,861 ) 2,291 (570 ) Total other income (expense) (5,464 ) 2,291 (3,173 ) Income (loss) before taxes (390 ) (41 ) (431 ) Income tax (benefit) expense 99 (15 ) 84 Net income (loss) (489 ) (26 ) (515 ) As of February 29, 2016 As previously reported Adjustments As revised Intangible Assets, net $ 168,080 $ (154 ) $ 167,926 Deferred Income Taxes, long term 19,563 255 19,818 Total Assets 753,513 101 753,614 Other current liabilities — 50 50 Total current liabilities 61,579 50 61,629 Total Liabilities 202,768 50 202,818 Retained earnings 27,744 (684 ) 27,060 Accumulated other comprehensive loss (1,790 ) 735 (1,055 ) Total Stockholders' Equity 550,745 51 550,796 Total Liabilities and Stockholders' Equity 753,513 101 753,614 Nine months ended February 29, 2016 As previously reported Adjustments As revised Net cash provided by (used in) operating activities $ 26,672 $ — $ 26,672 Net cash provided by (used in) investing activities (3,888 ) — (3,888 ) Net cash provided by (used in) financing activities (19,167 ) — (19,167 ) Three months ended November 30, 2015 As previously reported Adjustments As revised Net sales $ 89,234 $ 50 $ 89,284 Gross profit 45,834 50 45,884 Sales and marketing 20,569 809 21,378 General and administrative 8,089 (7 ) 8,082 Total operating expenses 44,517 802 45,319 Operating income 1,317 (752 ) 565 Other expense (1,048 ) 809 (239 ) Total other income (expense) (2,045 ) 809 (1,236 ) Income (loss) before taxes (728 ) 57 (671 ) Income tax (benefit) expense (366 ) 29 (337 ) Net income (loss) (362 ) 28 (334 ) Six months ended November 30, 2015 As previously reported Adjustments As revised Net sales $ 172,937 $ 100 $ 173,037 Cost of sales 83,929 (147 ) 83,782 Gross profit 89,008 247 89,255 Research and development 12,381 (73 ) 12,308 Sales and marketing 41,128 1,450 42,578 General and administrative 15,516 480 15,996 Total operating expenses 86,621 1,857 88,478 Operating income 2,387 (1,610 ) 777 Other expense (1,993 ) 1,636 (357 ) Total other income (expense) (3,789 ) 1,636 (2,153 ) Income (loss) before taxes (1,402 ) 26 (1,376 ) Income tax (benefit) expense (283 ) 16 (267 ) Net income (loss) (1,119 ) 10 (1,109 ) As of November 30, 2015 As previously reported Adjustments As revised Intangible Assets, net $ 172,511 $ (154 ) $ 172,357 Deferred Income Taxes, long term 19,826 224 20,050 Total Assets 760,371 70 760,441 Accrued liabilities 16,975 (117 ) 16,858 Other current liabilities — 100 100 Total current liabilities 60,104 (17 ) 60,087 Total Liabilities 212,732 (17 ) 212,715 Retained earnings 27,114 (648 ) 26,466 Accumulated other comprehensive loss (1,922 ) 735 (1,187 ) Total Stockholders' Equity 547,639 87 547,726 Total Liabilities and Stockholders' Equity 760,371 70 760,441 Six months ended November 30, 2015 As previously reported Adjustments As revised Net cash provided by (used in) operating activities $ 14,278 $ — $ 14,278 Net cash provided by (used in) investing activities (1,143 ) — (1,143 ) Net cash provided by (used in) financing activities (12,370 ) — (12,370 ) Three months ended August 31, 2015 As previously reported Adjustments As revised Net sales $ 83,703 $ 50 $ 83,753 Cost of sales 40,529 (147 ) 40,382 Gross profit 43,174 197 43,371 Research and development 6,202 (73 ) 6,129 Sales and marketing 20,559 641 21,200 General and administrative 7,427 487 7,914 Total operating expenses 42,104 1,055 43,159 Operating income 1,070 (858 ) 212 Other expense (945 ) 827 (118 ) Total other income (expense) (1,744 ) 827 (917 ) Income (loss) before taxes (674 ) (31 ) (705 ) Income tax (benefit) expense 83 (13 ) 70 Net income (loss) (757 ) (18 ) (775 ) As of August 31, 2015 As previously reported Adjustments As revised Other Assets $ 4,818 $ 110 $ 4,928 Intangible Assets, net 177,399 (154 ) 177,245 Deferred Income Taxes, long term 19,436 253 19,689 Total Assets 771,789 209 771,998 Other current liabilities — 150 150 Total current liabilities 60,651 150 60,801 Total Liabilities 224,666 150 224,816 Retained earnings 27,476 (676 ) 26,800 Accumulated other comprehensive loss (1,615 ) 735 (880 ) Total Stockholders' Equity 547,123 59 547,182 Total Liabilities and Stockholders' Equity 771,789 209 771,998 Three months ended August 31, 2015 As previously reported Adjustments As revised Net cash provided by (used in) operating activities $ 4,699 $ — $ 4,699 Net cash provided by (used in) investing activities (743 ) — (743 ) Net cash provided by (used in) financing activities (2,071 ) — (2,071 ) Three months ended May 31, 2015 As previously reported Adjustments As revised Net sales $ 90,897 $ (200 ) $ 90,697 Cost of sales 45,340 26 45,366 Gross profit 45,557 (226 ) 45,331 Research and development 7,289 (738 ) 6,551 Sales and marketing 20,218 933 21,151 General and administrative 7,658 (210 ) 7,448 Total operating expenses 44,217 (15 ) 44,202 Operating income 1,340 (211 ) 1,129 Other expense (860 ) 630 (230 ) Total other income (expense) (1,607 ) 630 (977 ) Income (loss) before taxes (267 ) 419 152 Income tax (benefit) expense 547 193 740 Net income (loss) (814 ) 226 (588 ) Three months ended February 28, 2015 As previously reported Adjustments As revised Cost of sales $ 48,746 $ 178 $ 48,924 Gross profit 37,851 (178 ) 37,673 Research and development 6,855 (277 ) 6,578 Sales and marketing 19,355 444 19,799 General and administrative 6,917 (304 ) 6,613 Amortization of intangibles 5,106 82 5,188 Change in fair value of contingent consideration (10,044 ) 250 (9,794 ) Acquisition, restructuring and other items, net 18,779 (103 ) 18,676 Total operating expenses 48,002 92 48,094 Operating income (10,151 ) (270 ) (10,421 ) Other expense (971 ) 497 (474 ) Total other income (expense) (1,828 ) 497 (1,331 ) Income (loss) before taxes (11,979 ) 227 (11,752 ) Income tax (benefit) expense (7,717 ) 118 (7,599 ) Net income (loss) (4,262 ) 109 (4,153 ) Nine months ended February 28, 2015 As previously reported Adjustments As revised Net sales $ 266,077 $ (240 ) $ 265,837 Cost of sales 134,745 627 135,372 Gross profit 131,332 (867 ) 130,465 Research and development 19,642 401 20,043 Sales and marketing 60,405 1,664 62,069 General and administrative 22,213 (499 ) 21,714 Amortization of intangibles 13,182 54 13,236 Change in fair value of contingent consideration (8,626 ) 100 (8,526 ) Acquisition, restructuring and other items, net 23,745 (343 ) 23,402 Total operating expenses 133,666 1,377 135,043 Operating income (2,334 ) (2,244 ) (4,578 ) Other expense (2,950 ) 1,693 (1,257 ) Total other income (expense) (5,398 ) 1,693 (3,705 ) Income (loss) before taxes (7,732 ) (551 ) (8,283 ) Income tax (benefit) expense (5,278 ) (205 ) (5,483 ) Net income (loss) (2,454 ) (346 ) (2,800 ) Three months ended February 28, 2015 As previously reported Adjustments As revised Net income (loss) $ (4,262 ) $ 109 $ (4,153 ) Foreign currency translation (624 ) 37 (587 ) Other comprehensive income (loss), before tax (508 ) 37 (471 ) Other comprehensive income (loss), net of tax (551 ) 37 (514 ) Total comprehensive income (loss), net of tax (4,813 ) 146 (4,667 ) Nine months ended February 28, 2015 As previously reported Adjustments As revised Net income (loss) $ (2,454 ) $ (346 ) $ (2,800 ) Foreign currency translation (728 ) 110 (618 ) Other comprehensive income (loss), before tax (568 ) 110 (458 ) Other comprehensive income (loss), net of tax (627 ) 110 (517 ) Total comprehensive income (loss), net of tax (3,081 ) (236 ) (3,317 ) As of February 28, 2015 As previously reported Adjustments As revised Inventories $ 68,710 $ 57 $ 68,767 Prepaid expenses and other 4,859 (221 ) 4,638 Total current assets 154,654 (164 ) 154,490 Property, Plant and Equipment, net 58,295 (80 ) 58,215 Other Assets 4,060 224 4,284 Intangible Assets, net 186,547 (154 ) 186,393 Deferred Income Taxes, long term 19,107 433 19,540 Total Assets 783,136 259 783,395 Accounts payable 21,696 278 21,974 Accrued liabilities 19,946 (461 ) 19,485 Total current liabilities 59,687 (183 ) 59,504 Other Long Term Liabilities — 628 628 Total Liabilities 239,380 445 239,825 Retained earnings 29,047 (884 ) 28,163 Accumulated other comprehensive loss (1,896 ) 698 (1,198 ) Total Stockholders' Equity 543,756 (186 ) 543,570 Total Liabilities and Stockholders' Equity 783,136 259 783,395 Nine months ended February 28, 2015 As previously reported Adjustments As revised Net cash provided by (used in) operating activities $ 15,436 $ (557 ) $ 14,879 Net cash provided by (used in) investing activities (12,042 ) 557 (11,485 ) Net cash provided by (used in) financing activities 641 — 641 Three months ended November 30, 2014 As previously reported Adjustments As revised Cost of sales $ 44,493 $ 828 $ 45,321 Gross profit 47,656 (828 ) 46,828 Research and development 6,069 207 6,276 Sales and marketing 20,983 553 21,536 General and administrative 7,973 (187 ) 7,786 Amortization of intangibles 4,061 (50 ) 4,011 Change in fair value of contingent consideration 617 (75 ) 542 Acquisition, restructuring and other items, net 2,302 (240 ) 2,062 Total operating expenses 43,081 208 43,289 Operating income 4,575 (1,036 ) 3,539 Other expense (954 ) 580 (374 ) Total other income (expense) (1,746 ) 580 (1,166 ) Income (loss) before taxes 2,829 (456 ) 2,373 Income tax (benefit) expense 1,491 (187 ) 1,304 Net income (loss) 1,338 (269 ) 1,069 Six months ended November 30, 2014 As previously reported Adjustments As revised Net sales $ 179,480 $ (240 ) $ 179,240 Cost of sales 85,999 449 86,448 Gross profit 93,481 (689 ) 92,792 Research and development 12,787 678 13,465 Sales and marketing 41,050 1,221 42,271 General and administrative 15,296 (195 ) 15,101 Amortization of intangibles 8,076 (28 ) 8,048 Change in fair value of contingent consideration 1,418 (150 ) 1,268 Acquisition, restructuring and other items, net 4,966 (240 ) 4,726 Total operating expenses 85,664 1,285 86,949 Operating income 7,817 (1,974 ) 5,843 Other expense (1,979 ) 1,196 (783 ) Total other income (expense) (3,570 ) 1,196 (2,374 ) Income (loss) before taxes 4,247 (778 ) 3,469 Income tax (benefit) expense 2,439 (323 ) 2,116 Net income (loss) 1,808 (455 ) 1,353 Three months ended November 30, 2014 As previously reported Adjustments As revised Net income (loss) $ 1,338 $ (269 ) $ 1,069 Foreign currency translation (104 ) 37 (67 ) Other comprehensive income (loss), before tax (100 ) 37 (63 ) Other comprehensive income (loss), net of tax (101 ) 37 (64 ) Total comprehensive income (loss), net of tax 1,237 (232 ) 1,005 Six months ended November 30, 2014 As previously reported Adjustments As revised Net income (loss) $ 1,808 $ (455 ) $ 1,353 Foreign currency translation (104 ) 74 (30 ) Other comprehensive income (loss), before tax (60 ) 74 14 Other comprehensive income (loss), net of tax (76 ) 74 (2 ) Total comprehensive income (loss), net of tax 1,732 (381 ) 1,351 As of November 30, 2014 As previously reported Adjustments As revised Inventories $ 75,315 $ 57 $ 75,372 Prepaid expenses and other 6,753 (191 ) 6,562 Total current assets 159,355 (134 ) 159,221 Property, Plant and Equipment, net 67,552 (829 ) 66,723 Other Assets 2,741 (15 ) 2,726 Intangible Assets, net 197,362 (175 ) 197,187 Deferred Income Taxes, long term 11,327 551 11,878 Total Assets 799,331 (602 ) 798,729 Accrued liabilities 19,177 (588 ) 18,589 Current portion of contingent consideration 9,795 (250 ) 9,545 Total current liabilities 57,937 (838 ) 57,099 Other Long Term Liabilities 124 568 692 Total Liabilities 255,760 (270 ) 255,490 Retained earnings 33,309 (993 ) 32,316 Accumulated other comprehensive loss (1,345 ) 662 (683 ) Total Stockholders' Equity 543,571 (332 ) 543,239 Total Liabilities and Stockholders' Equity 799,331 (602 ) 798,729 Six months ended November 30, 2014 As previously reported Adjustments As revised Net cash provided by (used in) operating activities $ 3,205 $ (557 ) 2,648 Net cash provided by (used in) investing activities (7,773 ) 557 (7,216 ) Net cash provided by (used in) financing activities 3,381 — 3,381 Three months ended August 31, 2014 As previously reported Adjustments As revised Net sales $ 87,331 $ (240 ) $ 87,091 Cost of sales 41,506 (379 ) 41,127 Gross profit 45,825 139 45,964 Research and development 6,718 470 7,188 Sales and marketing 20,067 668 20,735 General and administrative 7,323 (8 ) 7,315 Amortization of intangibles 4,015 22 4,037 Change in fair value of contingent consideration 801 (75 ) 726 Total operating expenses 42,583 1,077 43,660 Operating income 3,242 (938 ) 2,304 Other expense (1,025 ) 616 (409 ) Total other income (expense) (1,824 ) 616 (1,208 ) Income (loss) before taxes 1,418 (322 ) 1,096 Income tax (benefit) expense 948 (136 ) 812 Net income (loss) 470 (186 ) 284 Three months ended August 31, 2014 As previously reported Adjustments As revised Net income (loss) $ 470 $ (186 ) $ 284 Foreign currency translation — 37 37 Other comprehensive income (loss), before tax 41 37 78 Other comprehensive income (loss), net of tax 26 37 63 Total comprehensive income (loss), net of tax 496 (149 ) 347 As of August 30, 2014 As previously reported Adjustments As revised Inventories $ 70,421 $ 885 $ 71,306 Prepaid expenses and other 6,777 (311 ) 6,466 Total current assets 150,638 574 151,212 Property, Plant and Equipment, net 66,794 (605 ) 66,189 Other Assets 3,345 (53 ) 3,292 Intangible Assets, net 201,440 (225 ) 201,215 Deferred Income Taxes, long term 12,903 364 13,267 Total Assets 796,114 55 796,169 Accrued liabilities 17,700 (178 ) 17,522 Current portion of contingent consideration 10,897 (175 ) 10,722 Total current liabilities 63,707 (353 ) 63,354 Other Long Term Liabilities 32 507 539 Total Liabilities 256,430 154 256,584 Retained earnings 31,971 (724 ) 31,247 Accumulated other comprehensive loss (1,243 ) 625 (618 ) Total Stockholders' Equity 539,684 (99 ) 539,585 Total Liabilities and Stockholders' Equity 796,114 55 796,169 Three months ended August 30, 2014 As previously reported Adjustments As revised Net cash provided by (used in) operating activities $ 5,352 $ (410 ) $ 4,942 Net cash provided by (used in) investing activities (5,258 ) 410 (4,848 ) Net cash provided by (used in) financing activities (2,391 ) — (2,391 )

Quarterly Information (unaudi44

Quarterly Information (unaudited) (Tables)	12 Months Ended
	May 31, 2016
Quarterly Financial Information Disclosure [Abstract]
Summary of Quarterly Financial Information	Quarterly results of operations during the fiscal years ended May 31, 2016 and 2015 are as follows: 2016 First quarter Second quarter Third quarter Fourth quarter (in thousands, except per share data) Net sales $ 83,753 $ 89,284 $ 87,434 $ 93,419 Gross profit 43,371 45,884 43,534 41,527 Net income (loss) (775 ) (334 ) 594 (43,075 ) Earnings (loss) per common share Basic (0.02 ) (0.01 ) 0.02 (1.19 ) Diluted (0.02 ) (0.01 ) 0.02 (1.19 ) 2015 First quarter Second quarter Third quarter Fourth quarter (in thousands, except per share data) Net sales $ 87,091 $ 92,149 $ 86,597 $ 90,697 Gross profit 45,964 46,828 37,673 45,331 Net income (loss) 284 1,069 (4,153 ) (588 ) Earnings (loss) per common share Basic 0.01 0.03 (0.12 ) (0.02 ) Diluted 0.01 0.03 (0.12 ) (0.02 )
Schedule of Error Corrections and Prior Period Adjustments	The impacts of these revisions are shown in the tables below: Year ended May 31, 2015 As previously reported Adjustments As revised Net sales $ 356,974 $ (440 ) $ 356,534 Cost of sales 180,085 653 180,738 Gross profit 176,889 (1,093 ) 175,796 Research and development 26,931 (337 ) 26,594 Sales and marketing 80,623 2,597 83,220 General and administrative 29,871 (709 ) 29,162 Amortization of intangibles 17,912 54 17,966 Change in fair value of contingent consideration (8,196 ) 100 (8,096 ) Acquisition, restructuring and other items, net 26,600 (343 ) 26,257 Total operating expenses 177,883 1,362 179,245 Operating income (994 ) (2,455 ) (3,449 ) Other expense (3,812 ) 2,323 (1,489 ) Total other income (expense) (7,005 ) 2,323 (4,682 ) Income (loss) before taxes (7,999 ) (132 ) (8,131 ) Income tax (benefit) expense (4,731 ) (12 ) (4,743 ) Net income (loss) (3,268 ) (120 ) (3,388 ) Year ended May 31, 2015 As previously reported Adjustments As revised Net income (loss) $ (3,268 ) $ (120 ) $ (3,388 ) Foreign currency translation (411 ) 147 (264 ) Other comprehensive income (loss), before tax (235 ) 147 (88 ) Other comprehensive income (loss), net of tax (299 ) 147 (152 ) Total comprehensive income (loss), net of tax (3,567 ) 27 (3,540 ) As of May 31, 2015 As previously reported Adjustments As revised Prepaid expenses and other $ 4,783 $ (651 ) $ 4,132 Total current assets 151,449 (651 ) 150,798 Property, Plant and Equipment, net 54,560 (110 ) 54,450 Other Assets 5,288 110 5,398 Intangible Assets, net 181,806 (154 ) 181,652 Deferred Income Taxes, long term 19,268 240 19,508 Total Assets 773,623 (565 ) 773,058 Accounts payable 23,668 (620 ) 23,048 Accrued liabilities 18,331 (222 ) 18,109 Other current liabilities — 200 200 Total current liabilities 61,157 (642 ) 60,515 Total Liabilities 228,601 (642 ) 227,959 Retained earnings 28,233 (658 ) 27,575 Accumulated other comprehensive loss (1,568 ) 735 (833 ) Total Stockholders' Equity 545,022 77 545,099 Total Liabilities and Stockholders' Equity 773,623 (565 ) 773,058 Year ended May 31, 2015 As previously reported Adjustments As revised Net cash provided by (used in) operating activities $ 26,242 $ (557 ) $ 25,685 Net cash provided by (used in) investing activities (13,293 ) 557 (12,736 ) Net cash provided by (used in) financing activities (10,465 ) — (10,465 ) Year ended May 31, 2014 As previously reported Adjustments As revised Cost of sales $ 174,757 $ (506 ) $ 174,251 Gross profit 179,668 506 180,174 Research and development 27,486 638 28,124 Sales and marketing 83,200 2,105 85,305 General and administrative 26,639 263 26,902 Amortization of intangibles 16,622 (60 ) 16,562 Change in fair value of contingent consideration (1,808 ) (100 ) (1,908 ) Acquisition, restructuring and other items, net 10,760 113 10,873 Total operating expenses 166,728 2,959 169,687 Operating income 12,940 (2,453 ) 10,487 Other expense (3,544 ) 1,899 (1,645 ) Total other income (expense) (7,200 ) 1,899 (5,301 ) Income (loss) before taxes 5,740 (554 ) 5,186 Income tax (benefit) expense 3,074 (235 ) 2,839 Net income (loss) 2,666 (319 ) 2,347 Year ended May 31, 2014 As previously reported Adjustments As revised Net income (loss) $ 2,666 $ (319 ) $ 2,347 Foreign currency translation 295 147 442 Other comprehensive income (loss), before tax 247 147 394 Other comprehensive income (loss), net of tax 265 147 412 Total comprehensive income (loss), net of tax 2,931 (172 ) 2,759 As of May 31, 2014 As previously reported Adjustments As revised Inventories $ 61,234 $ 506 $ 61,740 Prepaid expenses and other 5,471 (591 ) 4,880 Total current assets 147,097 (85 ) 147,012 Property, Plant and Equipment, net 66,590 (135 ) 66,455 Other Assets 3,926 (120 ) 3,806 Intangible Assets, net 205,256 (203 ) 205,053 Deferred Income Taxes, long term 15,028 228 15,256 Total Assets 798,891 (315 ) 798,576 Accrued liabilities 16,652 (712 ) 15,940 Current portion of contingent consideration 10,918 (100 ) 10,818 Other current liabilities 599 — 599 Total current liabilities 66,753 (812 ) 65,941 Other Long Term Liabilities 84 447 531 Total Liabilities 262,056 (365 ) 261,691 Retained earnings 31,501 (538 ) 30,963 Accumulated other comprehensive loss (1,269 ) 588 (681 ) Total Stockholders' Equity 536,835 50 536,885 Total Liabilities and Stockholders' Equity 798,891 (315 ) 798,576 Year ended May 31, 2014 As previously reported Adjustments As revised Net cash provided by (used in) operating activities $ 24,681 $ — $ 24,681 Net cash provided by (used in) investing activities (16,448 ) — (16,448 ) Net cash provided by (used in) financing activities (14,016 ) — (14,016 ) Year ended May 31, 2013 As previously reported Adjustments As revised Research and development $ 26,319 $ (228 ) $ 26,091 Sales and marketing 76,121 1,443 77,564 General and administrative 26,186 (151 ) 26,035 Amortization of intangibles 16,617 (18 ) 16,599 Total operating expenses 162,226 1,046 163,272 Operating income 6,288 (1,046 ) 5,242 Other expense (2,707 ) 1,296 (1,411 ) Total other income (expense) (7,875 ) 1,296 (6,579 ) Income (loss) before taxes (1,587 ) 250 (1,337 ) Income tax (benefit) expense (376 ) 90 (286 ) Net income (loss) (1,211 ) 160 (1,051 ) As of May 31, 2013 As previously reported Adjustments As revised Property, Plant and Equipment, net $ 62,391 $ (16 ) $ 62,375 Intangible Assets, net 214,673 (150 ) 214,523 Deferred Income Taxes, long term 18,016 (7 ) 18,009 Total Assets 790,734 (173 ) 790,561 Accrued liabilities 16,356 (395 ) 15,961 Total current liabilities 63,315 (395 ) 62,920 Total Liabilities 264,632 (395 ) 264,237 Retained earnings 28,835 (219 ) 28,616 Accumulated other comprehensive loss (1,534 ) 441 (1,093 ) Total Stockholders' Equity 526,102 222 526,324 Total Liabilities and Stockholders' Equity 790,734 (173 ) 790,561 Year ended May 31, 2012 As previously reported Adjustments As revised Sales and marketing $ 64,505 $ 1,252 $ 65,757 Amortization of intangibles 9,309 84 9,393 Total operating expenses 129,217 1,336 130,553 Operating income (3,908 ) (1,336 ) (5,244 ) Other expense (2,096 ) 1,105 (991 ) Total other income (expense) (1,514 ) 1,105 (409 ) Income (loss) before taxes (5,422 ) (231 ) (5,653 ) Income tax (benefit) expense (239 ) (83 ) (322 ) Net income (loss) (5,183 ) (148 ) (5,331 ) As of May 31, 2012 As previously reported Adjustments As revised Intangible Assets, net $ 147,363 $ (168 ) $ 147,195 Deferred Income Taxes, long term 44,194 83 44,277 Total Assets 719,988 (85 ) 719,903 Retained earnings 30,046 (379 ) 29,667 Accumulated other comprehensive loss (1,274 ) 294 (980 ) Total Stockholders' Equity 523,391 (85 ) 523,306 Total Liabilities and Stockholders' Equity 719,988 (85 ) 719,903 The data in the schedules above has been intentionally rounded to the nearest thousand and therefore the quarterly amounts may not sum to the full year amounts. We made adjustments to correct immaterial errors within this selected financial data. For a detailed explanation of these adjustments, please refer to Note R, "Immaterial Error Corrections". Three months ended February 29, 2016 As previously reported Adjustments As revised Net sales $ 87,384 $ 50 $ 87,434 Gross profit 43,484 50 43,534 Sales and marketing 20,301 654 20,955 General and administrative 6,784 117 6,901 Total operating expenses 40,797 771 41,568 Operating income 2,687 (721 ) 1,966 Other expense (868 ) 654 (214 ) Total other income (expense) (1,675 ) 654 (1,021 ) Income (loss) before taxes 1,012 (67 ) 945 Income tax (benefit) expense 382 (31 ) 351 Net income (loss) 630 (36 ) 594 Nine months ended February 29, 2016 As previously reported Adjustments As revised Net sales $ 260,321 $ 150 $ 260,471 Cost of sales 127,829 (147 ) 127,682 Gross profit 132,492 297 132,789 Research and development 18,189 (73 ) 18,116 Sales and marketing 61,429 2,105 63,534 General and administrative 22,300 597 22,897 Total operating expenses 127,418 2,629 130,047 Other expense (2,861 ) 2,291 (570 ) Total other income (expense) (5,464 ) 2,291 (3,173 ) Income (loss) before taxes (390 ) (41 ) (431 ) Income tax (benefit) expense 99 (15 ) 84 Net income (loss) (489 ) (26 ) (515 ) As of February 29, 2016 As previously reported Adjustments As revised Intangible Assets, net $ 168,080 $ (154 ) $ 167,926 Deferred Income Taxes, long term 19,563 255 19,818 Total Assets 753,513 101 753,614 Other current liabilities — 50 50 Total current liabilities 61,579 50 61,629 Total Liabilities 202,768 50 202,818 Retained earnings 27,744 (684 ) 27,060 Accumulated other comprehensive loss (1,790 ) 735 (1,055 ) Total Stockholders' Equity 550,745 51 550,796 Total Liabilities and Stockholders' Equity 753,513 101 753,614 Nine months ended February 29, 2016 As previously reported Adjustments As revised Net cash provided by (used in) operating activities $ 26,672 $ — $ 26,672 Net cash provided by (used in) investing activities (3,888 ) — (3,888 ) Net cash provided by (used in) financing activities (19,167 ) — (19,167 ) Three months ended November 30, 2015 As previously reported Adjustments As revised Net sales $ 89,234 $ 50 $ 89,284 Gross profit 45,834 50 45,884 Sales and marketing 20,569 809 21,378 General and administrative 8,089 (7 ) 8,082 Total operating expenses 44,517 802 45,319 Operating income 1,317 (752 ) 565 Other expense (1,048 ) 809 (239 ) Total other income (expense) (2,045 ) 809 (1,236 ) Income (loss) before taxes (728 ) 57 (671 ) Income tax (benefit) expense (366 ) 29 (337 ) Net income (loss) (362 ) 28 (334 ) Six months ended November 30, 2015 As previously reported Adjustments As revised Net sales $ 172,937 $ 100 $ 173,037 Cost of sales 83,929 (147 ) 83,782 Gross profit 89,008 247 89,255 Research and development 12,381 (73 ) 12,308 Sales and marketing 41,128 1,450 42,578 General and administrative 15,516 480 15,996 Total operating expenses 86,621 1,857 88,478 Operating income 2,387 (1,610 ) 777 Other expense (1,993 ) 1,636 (357 ) Total other income (expense) (3,789 ) 1,636 (2,153 ) Income (loss) before taxes (1,402 ) 26 (1,376 ) Income tax (benefit) expense (283 ) 16 (267 ) Net income (loss) (1,119 ) 10 (1,109 ) As of November 30, 2015 As previously reported Adjustments As revised Intangible Assets, net $ 172,511 $ (154 ) $ 172,357 Deferred Income Taxes, long term 19,826 224 20,050 Total Assets 760,371 70 760,441 Accrued liabilities 16,975 (117 ) 16,858 Other current liabilities — 100 100 Total current liabilities 60,104 (17 ) 60,087 Total Liabilities 212,732 (17 ) 212,715 Retained earnings 27,114 (648 ) 26,466 Accumulated other comprehensive loss (1,922 ) 735 (1,187 ) Total Stockholders' Equity 547,639 87 547,726 Total Liabilities and Stockholders' Equity 760,371 70 760,441 Six months ended November 30, 2015 As previously reported Adjustments As revised Net cash provided by (used in) operating activities $ 14,278 $ — $ 14,278 Net cash provided by (used in) investing activities (1,143 ) — (1,143 ) Net cash provided by (used in) financing activities (12,370 ) — (12,370 ) Three months ended August 31, 2015 As previously reported Adjustments As revised Net sales $ 83,703 $ 50 $ 83,753 Cost of sales 40,529 (147 ) 40,382 Gross profit 43,174 197 43,371 Research and development 6,202 (73 ) 6,129 Sales and marketing 20,559 641 21,200 General and administrative 7,427 487 7,914 Total operating expenses 42,104 1,055 43,159 Operating income 1,070 (858 ) 212 Other expense (945 ) 827 (118 ) Total other income (expense) (1,744 ) 827 (917 ) Income (loss) before taxes (674 ) (31 ) (705 ) Income tax (benefit) expense 83 (13 ) 70 Net income (loss) (757 ) (18 ) (775 ) As of August 31, 2015 As previously reported Adjustments As revised Other Assets $ 4,818 $ 110 $ 4,928 Intangible Assets, net 177,399 (154 ) 177,245 Deferred Income Taxes, long term 19,436 253 19,689 Total Assets 771,789 209 771,998 Other current liabilities — 150 150 Total current liabilities 60,651 150 60,801 Total Liabilities 224,666 150 224,816 Retained earnings 27,476 (676 ) 26,800 Accumulated other comprehensive loss (1,615 ) 735 (880 ) Total Stockholders' Equity 547,123 59 547,182 Total Liabilities and Stockholders' Equity 771,789 209 771,998 Three months ended August 31, 2015 As previously reported Adjustments As revised Net cash provided by (used in) operating activities $ 4,699 $ — $ 4,699 Net cash provided by (used in) investing activities (743 ) — (743 ) Net cash provided by (used in) financing activities (2,071 ) — (2,071 ) Three months ended May 31, 2015 As previously reported Adjustments As revised Net sales $ 90,897 $ (200 ) $ 90,697 Cost of sales 45,340 26 45,366 Gross profit 45,557 (226 ) 45,331 Research and development 7,289 (738 ) 6,551 Sales and marketing 20,218 933 21,151 General and administrative 7,658 (210 ) 7,448 Total operating expenses 44,217 (15 ) 44,202 Operating income 1,340 (211 ) 1,129 Other expense (860 ) 630 (230 ) Total other income (expense) (1,607 ) 630 (977 ) Income (loss) before taxes (267 ) 419 152 Income tax (benefit) expense 547 193 740 Net income (loss) (814 ) 226 (588 ) Three months ended February 28, 2015 As previously reported Adjustments As revised Cost of sales $ 48,746 $ 178 $ 48,924 Gross profit 37,851 (178 ) 37,673 Research and development 6,855 (277 ) 6,578 Sales and marketing 19,355 444 19,799 General and administrative 6,917 (304 ) 6,613 Amortization of intangibles 5,106 82 5,188 Change in fair value of contingent consideration (10,044 ) 250 (9,794 ) Acquisition, restructuring and other items, net 18,779 (103 ) 18,676 Total operating expenses 48,002 92 48,094 Operating income (10,151 ) (270 ) (10,421 ) Other expense (971 ) 497 (474 ) Total other income (expense) (1,828 ) 497 (1,331 ) Income (loss) before taxes (11,979 ) 227 (11,752 ) Income tax (benefit) expense (7,717 ) 118 (7,599 ) Net income (loss) (4,262 ) 109 (4,153 ) Nine months ended February 28, 2015 As previously reported Adjustments As revised Net sales $ 266,077 $ (240 ) $ 265,837 Cost of sales 134,745 627 135,372 Gross profit 131,332 (867 ) 130,465 Research and development 19,642 401 20,043 Sales and marketing 60,405 1,664 62,069 General and administrative 22,213 (499 ) 21,714 Amortization of intangibles 13,182 54 13,236 Change in fair value of contingent consideration (8,626 ) 100 (8,526 ) Acquisition, restructuring and other items, net 23,745 (343 ) 23,402 Total operating expenses 133,666 1,377 135,043 Operating income (2,334 ) (2,244 ) (4,578 ) Other expense (2,950 ) 1,693 (1,257 ) Total other income (expense) (5,398 ) 1,693 (3,705 ) Income (loss) before taxes (7,732 ) (551 ) (8,283 ) Income tax (benefit) expense (5,278 ) (205 ) (5,483 ) Net income (loss) (2,454 ) (346 ) (2,800 ) Three months ended February 28, 2015 As previously reported Adjustments As revised Net income (loss) $ (4,262 ) $ 109 $ (4,153 ) Foreign currency translation (624 ) 37 (587 ) Other comprehensive income (loss), before tax (508 ) 37 (471 ) Other comprehensive income (loss), net of tax (551 ) 37 (514 ) Total comprehensive income (loss), net of tax (4,813 ) 146 (4,667 ) Nine months ended February 28, 2015 As previously reported Adjustments As revised Net income (loss) $ (2,454 ) $ (346 ) $ (2,800 ) Foreign currency translation (728 ) 110 (618 ) Other comprehensive income (loss), before tax (568 ) 110 (458 ) Other comprehensive income (loss), net of tax (627 ) 110 (517 ) Total comprehensive income (loss), net of tax (3,081 ) (236 ) (3,317 ) As of February 28, 2015 As previously reported Adjustments As revised Inventories $ 68,710 $ 57 $ 68,767 Prepaid expenses and other 4,859 (221 ) 4,638 Total current assets 154,654 (164 ) 154,490 Property, Plant and Equipment, net 58,295 (80 ) 58,215 Other Assets 4,060 224 4,284 Intangible Assets, net 186,547 (154 ) 186,393 Deferred Income Taxes, long term 19,107 433 19,540 Total Assets 783,136 259 783,395 Accounts payable 21,696 278 21,974 Accrued liabilities 19,946 (461 ) 19,485 Total current liabilities 59,687 (183 ) 59,504 Other Long Term Liabilities — 628 628 Total Liabilities 239,380 445 239,825 Retained earnings 29,047 (884 ) 28,163 Accumulated other comprehensive loss (1,896 ) 698 (1,198 ) Total Stockholders' Equity 543,756 (186 ) 543,570 Total Liabilities and Stockholders' Equity 783,136 259 783,395 Nine months ended February 28, 2015 As previously reported Adjustments As revised Net cash provided by (used in) operating activities $ 15,436 $ (557 ) $ 14,879 Net cash provided by (used in) investing activities (12,042 ) 557 (11,485 ) Net cash provided by (used in) financing activities 641 — 641 Three months ended November 30, 2014 As previously reported Adjustments As revised Cost of sales $ 44,493 $ 828 $ 45,321 Gross profit 47,656 (828 ) 46,828 Research and development 6,069 207 6,276 Sales and marketing 20,983 553 21,536 General and administrative 7,973 (187 ) 7,786 Amortization of intangibles 4,061 (50 ) 4,011 Change in fair value of contingent consideration 617 (75 ) 542 Acquisition, restructuring and other items, net 2,302 (240 ) 2,062 Total operating expenses 43,081 208 43,289 Operating income 4,575 (1,036 ) 3,539 Other expense (954 ) 580 (374 ) Total other income (expense) (1,746 ) 580 (1,166 ) Income (loss) before taxes 2,829 (456 ) 2,373 Income tax (benefit) expense 1,491 (187 ) 1,304 Net income (loss) 1,338 (269 ) 1,069 Six months ended November 30, 2014 As previously reported Adjustments As revised Net sales $ 179,480 $ (240 ) $ 179,240 Cost of sales 85,999 449 86,448 Gross profit 93,481 (689 ) 92,792 Research and development 12,787 678 13,465 Sales and marketing 41,050 1,221 42,271 General and administrative 15,296 (195 ) 15,101 Amortization of intangibles 8,076 (28 ) 8,048 Change in fair value of contingent consideration 1,418 (150 ) 1,268 Acquisition, restructuring and other items, net 4,966 (240 ) 4,726 Total operating expenses 85,664 1,285 86,949 Operating income 7,817 (1,974 ) 5,843 Other expense (1,979 ) 1,196 (783 ) Total other income (expense) (3,570 ) 1,196 (2,374 ) Income (loss) before taxes 4,247 (778 ) 3,469 Income tax (benefit) expense 2,439 (323 ) 2,116 Net income (loss) 1,808 (455 ) 1,353 Three months ended November 30, 2014 As previously reported Adjustments As revised Net income (loss) $ 1,338 $ (269 ) $ 1,069 Foreign currency translation (104 ) 37 (67 ) Other comprehensive income (loss), before tax (100 ) 37 (63 ) Other comprehensive income (loss), net of tax (101 ) 37 (64 ) Total comprehensive income (loss), net of tax 1,237 (232 ) 1,005 Six months ended November 30, 2014 As previously reported Adjustments As revised Net income (loss) $ 1,808 $ (455 ) $ 1,353 Foreign currency translation (104 ) 74 (30 ) Other comprehensive income (loss), before tax (60 ) 74 14 Other comprehensive income (loss), net of tax (76 ) 74 (2 ) Total comprehensive income (loss), net of tax 1,732 (381 ) 1,351 As of November 30, 2014 As previously reported Adjustments As revised Inventories $ 75,315 $ 57 $ 75,372 Prepaid expenses and other 6,753 (191 ) 6,562 Total current assets 159,355 (134 ) 159,221 Property, Plant and Equipment, net 67,552 (829 ) 66,723 Other Assets 2,741 (15 ) 2,726 Intangible Assets, net 197,362 (175 ) 197,187 Deferred Income Taxes, long term 11,327 551 11,878 Total Assets 799,331 (602 ) 798,729 Accrued liabilities 19,177 (588 ) 18,589 Current portion of contingent consideration 9,795 (250 ) 9,545 Total current liabilities 57,937 (838 ) 57,099 Other Long Term Liabilities 124 568 692 Total Liabilities 255,760 (270 ) 255,490 Retained earnings 33,309 (993 ) 32,316 Accumulated other comprehensive loss (1,345 ) 662 (683 ) Total Stockholders' Equity 543,571 (332 ) 543,239 Total Liabilities and Stockholders' Equity 799,331 (602 ) 798,729 Six months ended November 30, 2014 As previously reported Adjustments As revised Net cash provided by (used in) operating activities $ 3,205 $ (557 ) 2,648 Net cash provided by (used in) investing activities (7,773 ) 557 (7,216 ) Net cash provided by (used in) financing activities 3,381 — 3,381 Three months ended August 31, 2014 As previously reported Adjustments As revised Net sales $ 87,331 $ (240 ) $ 87,091 Cost of sales 41,506 (379 ) 41,127 Gross profit 45,825 139 45,964 Research and development 6,718 470 7,188 Sales and marketing 20,067 668 20,735 General and administrative 7,323 (8 ) 7,315 Amortization of intangibles 4,015 22 4,037 Change in fair value of contingent consideration 801 (75 ) 726 Total operating expenses 42,583 1,077 43,660 Operating income 3,242 (938 ) 2,304 Other expense (1,025 ) 616 (409 ) Total other income (expense) (1,824 ) 616 (1,208 ) Income (loss) before taxes 1,418 (322 ) 1,096 Income tax (benefit) expense 948 (136 ) 812 Net income (loss) 470 (186 ) 284 Three months ended August 31, 2014 As previously reported Adjustments As revised Net income (loss) $ 470 $ (186 ) $ 284 Foreign currency translation — 37 37 Other comprehensive income (loss), before tax 41 37 78 Other comprehensive income (loss), net of tax 26 37 63 Total comprehensive income (loss), net of tax 496 (149 ) 347 As of August 30, 2014 As previously reported Adjustments As revised Inventories $ 70,421 $ 885 $ 71,306 Prepaid expenses and other 6,777 (311 ) 6,466 Total current assets 150,638 574 151,212 Property, Plant and Equipment, net 66,794 (605 ) 66,189 Other Assets 3,345 (53 ) 3,292 Intangible Assets, net 201,440 (225 ) 201,215 Deferred Income Taxes, long term 12,903 364 13,267 Total Assets 796,114 55 796,169 Accrued liabilities 17,700 (178 ) 17,522 Current portion of contingent consideration 10,897 (175 ) 10,722 Total current liabilities 63,707 (353 ) 63,354 Other Long Term Liabilities 32 507 539 Total Liabilities 256,430 154 256,584 Retained earnings 31,971 (724 ) 31,247 Accumulated other comprehensive loss (1,243 ) 625 (618 ) Total Stockholders' Equity 539,684 (99 ) 539,585 Total Liabilities and Stockholders' Equity 796,114 55 796,169 Three months ended August 30, 2014 As previously reported Adjustments As revised Net cash provided by (used in) operating activities $ 5,352 $ (410 ) $ 4,942 Net cash provided by (used in) investing activities (5,258 ) 410 (4,848 ) Net cash provided by (used in) financing activities (2,391 ) — (2,391 )

Basis of Presentation, Busine45

Basis of Presentation, Business Description and Summary of Significant Accounting Policies (Details Textual) $ in Thousands

Mar. 31, 2016

Mar. 31, 2014Observation

Feb. 04, 2014Observation

Feb. 13, 2012Observation

Feb. 10, 2012Observation

Apr. 21, 2014

Feb. 25, 2014

Sep. 24, 2012Observation

Mar. 05, 2012

May 31, 2016USD ($)Investment

Feb. 28, 2014

May 31, 2016USD ($)Investment

May 31, 2015USD ($)

May 31, 2014USD ($)

May 31, 2016USD ($)Investment

Nov. 30, 2015USD ($)

Business Acquisition [Line Items]

Medical device excise tax

$ 2,416

$ 4,142

$ 3,829

$ 12,000

Inventory write-off

5,800

Write-off of hardware assets

$ 100

Costs for quality call to action program

3,200

Number of observations | Observation

3

1

6

12

5

Number of business days to provide response to FDA

15 days

15 days

15 days

15 days

Short Term Investments Maturity Period

less than three months

Investments in auction rate securities that failed auctions

$ 1,700

$ 1,700

$ 1,700

Number of investments | Investment

2

2

2

Restocking charge percentage

20.00%

Deferred Tax Assets, Net

18,389

Distribution Rights and Customer Lists

Business Acquisition [Line Items]

Acquired finite lived intangible assets

$ 3,300

Federal

Business Acquisition [Line Items]

Deferred Tax Assets, Net

$ 4,400

$ 3,500

Former President and Chief Executive Officer | Employee Stock Option

Business Acquisition [Line Items]

Term of award

1 year

Former President and Chief Executive Officer | Restricted Stock Units

Business Acquisition [Line Items]

Term of award

1 year

Former President and Chief Executive Officer | Performance Shares

Business Acquisition [Line Items]

Term of award

1 year

Maximum

Business Acquisition [Line Items]

Accounts receivables period due

90 days

Weighted average useful life

18 years

Minimum

Business Acquisition [Line Items]

Accounts receivables period due

30 days

Weighted average useful life

2 years

Undamaged product expiration date

12 months

Machinery and equipment | Maximum

Business Acquisition [Line Items]

Useful life

8 years

Machinery and equipment | Minimum

Business Acquisition [Line Items]

Useful life

3 years

Building and building improvements

Business Acquisition [Line Items]

Useful life

39 years

Computer software and equipment | Maximum

Business Acquisition [Line Items]

Useful life

10 years

Computer software and equipment | Minimum

Business Acquisition [Line Items]

Useful life

3 years

Other Assets (Details)

Other Assets (Details) - USD ($) $ in Millions	Dec. 07, 2015	May 31, 2016
Investments in and Advances to Affiliates [Line Items]
Purchase of non-transferable warrants	$ 2
Contingent consideration		$ 4
Warrant
Investments in and Advances to Affiliates [Line Items]
Contingent consideration		$ 5

Fair Value of Financial Instr47

Fair Value of Financial Instruments Fair Value of Financial Instruments (Details) - Recurring - USD ($) $ in Thousands	May 31, 2016	May 31, 2015
Financial Assets
Marketable securities	$ 1,653	$ 1,689
Total Financial Assets	1,653	1,689
Financial Liabilities
Total Financial Liabilities	38,275	47,641
Interest rate swap agreements
Financial Liabilities
Total Financial Liabilities		257
Contingent liability for acquisition earn out
Financial Liabilities
Total Financial Liabilities	38,275	47,384
New York State government agency obligations
Financial Assets
Marketable securities	1,653	1,689
Level 1
Financial Assets
Marketable securities	0	0
Total Financial Assets	0	0
Financial Liabilities
Total Financial Liabilities	0	0
Level 1 | Interest rate swap agreements
Financial Liabilities
Total Financial Liabilities		0
Level 1 | Contingent liability for acquisition earn out
Financial Liabilities
Total Financial Liabilities	0	0
Level 1 | New York State government agency obligations
Financial Assets
Marketable securities	0	0
Level 2
Financial Assets
Marketable securities	0	0
Total Financial Assets	0	0
Financial Liabilities
Total Financial Liabilities	0	257
Level 2 | Interest rate swap agreements
Financial Liabilities
Total Financial Liabilities		257
Level 2 | Contingent liability for acquisition earn out
Financial Liabilities
Total Financial Liabilities	0	0
Level 2 | New York State government agency obligations
Financial Assets
Marketable securities	0	0
Level 3
Financial Assets
Marketable securities	1,653	1,689
Total Financial Assets	1,653	1,689
Financial Liabilities
Total Financial Liabilities	38,275	47,384
Level 3 | Interest rate swap agreements
Financial Liabilities
Total Financial Liabilities		0
Level 3 | Contingent liability for acquisition earn out
Financial Liabilities
Total Financial Liabilities	38,275	47,384
Level 3 | New York State government agency obligations
Financial Assets
Marketable securities	$ 1,653	$ 1,689

Fair Value of Financial Instr48

Fair Value of Financial Instruments Fair Value of Financial Instruments (Details 2) - USD ($) $ in Thousands	12 Months Ended
	May 31, 2016	May 31, 2015
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 1,689	$ 1,809
Change in fair value of contingent consideration and currency (gain) loss from remeasurement	0	0
Fair market value adjustments	(36)
Included in other comprehensive income (loss)		(120)
Contingent consideration payments	0	0
Ending balance	1,653	1,689
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	47,384	67,331
Change in fair value of contingent consideration	948	(8,196)
Currency (gain) loss from remeasurement	43	(529)
Fair market value adjustments	0
Included in other comprehensive income (loss)		0
Contingent consideration payments	(10,100)	(11,222)
Ending balance	$ 38,275	$ 47,384

Fair Value of Financial Instr49

Fair Value of Financial Instruments Fair Value of Financial Instruments (Details 3) - USD ($) $ in Thousands	12 Months Ended
	May 31, 2016	May 31, 2015	May 31, 2014
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Contingent consideration liability at fair value	$ 38,275	$ 47,384	$ 67,331
Potential amount of undiscounted future contingent consideration	$ 40,800
Summary showing the recurring fair value measurements of the contingent consideration liability
Discount rate used in fair value calculation	12.50%
Level 3 | Contingent liability for acquisition earn out | Recurring
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Contingent consideration liability at fair value	$ 38,275
Revenue based payments | Level 3 | Contingent liability for acquisition earn out | Recurring
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Contingent consideration liability at fair value	$ 35,325
Summary showing the recurring fair value measurements of the contingent consideration liability
Discount rate used in fair value calculation	4.00%
Revenue based payments | Level 3 | Minimum | Contingent liability for acquisition earn out | Recurring
Summary showing the recurring fair value measurements of the contingent consideration liability
Probability of payment	75.00%
Revenue based payments | Level 3 | Maximum | Contingent liability for acquisition earn out | Recurring
Summary showing the recurring fair value measurements of the contingent consideration liability
Probability of payment	100.00%
Milestone based payments | Level 3 | Contingent liability for acquisition earn out | Recurring
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Contingent consideration liability at fair value	$ 2,950
Summary showing the recurring fair value measurements of the contingent consideration liability
Discount rate used in fair value calculation	16.00%
Milestone based payments | Level 3 | Minimum | Contingent liability for acquisition earn out | Recurring
Summary showing the recurring fair value measurements of the contingent consideration liability
Probability of payment	75.00%
Milestone based payments | Level 3 | Maximum | Contingent liability for acquisition earn out | Recurring
Summary showing the recurring fair value measurements of the contingent consideration liability
Probability of payment	100.00%

Marketable Securities and Inv50

Marketable Securities and Investments (Details) - USD ($) $ in Thousands	May 31, 2016	May 31, 2015
Marketable securities
Amortized cost	$ 1,800	$ 1,825
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(147)	(136)
Fair Value	1,653	1,689
New York State government agency obligations
Marketable securities
Amortized cost	1,800	1,825
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(147)	(136)
Fair Value	$ 1,653	$ 1,689

Marketable Securities and Inv51

Marketable Securities and Investments (Details 1) - USD ($) $ in Thousands	May 31, 2016	May 31, 2015
Amortized cost and fair value of marketable securities by contractual maturity
Amortized cost, Due in one year or less	$ 0
Amortized cost, Due after one through five years	0
Amortized cost, Due after five through twenty years	1,800
Amortized cost	1,800	$ 1,825
Fair Value, Due in one year or less	0
Fair Value, Due after one through five years	0
Fair Value, Due after five through twenty years	1,653
Fair Value, Total	$ 1,653

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	12 Months Ended
	May 31, 2016	May 31, 2015	Feb. 28, 2015	Nov. 30, 2014	Aug. 31, 2014	May 31, 2014
Inventories
Raw materials	$ 21,669	$ 28,040
Work in process	10,700	11,910
Finished goods	23,001	27,438
Total	55,370	67,388	$ 68,767	$ 75,372	$ 71,306	$ 61,740
Inventory valuation reserve	12,600	$ 7,800
Inventory write-off	$ 5,800

Prepaid Expenses and Other (Det

Prepaid Expenses and Other (Details) - USD ($) $ in Thousands	May 31, 2016	May 31, 2015	Feb. 28, 2015	Nov. 30, 2014	Aug. 31, 2014	May 31, 2014
Prepaid expenses and other
Deposits	$ 190	$ 2,011
Other prepaid taxes	160	165
License fees	108	121
Software licenses	282	667
Trade shows	278	279
Rent	127	77
Other	2,098	812
Total	$ 3,243	$ 4,132	$ 4,638	$ 6,562	$ 6,466	$ 4,880

Property, Plant, and Equipment,

Property, Plant, and Equipment, at Cost (Details) - USD ($) $ in Thousands	12 Months Ended
	May 31, 2016	May 31, 2015	May 31, 2014	Feb. 28, 2015	Nov. 30, 2014	Aug. 31, 2014	May 31, 2013
Property, plant and equipment
Property, plant and equipment	$ 90,097	$ 88,943
Less accumulated depreciation and amortization	(43,536)	(36,197)
Property, plant and equipment excluding land and land improvements	46,561	52,746
Land and land improvements	1,723	1,704
Property, plant and equipment, Net	48,284	54,450	$ 66,455	$ 58,215	$ 66,723	$ 66,189	$ 62,375
Depreciation expense	8,200	9,800	8,400
Additional depreciation due to change in useful life	1,000	1,500	$ 800
Building and building improvements
Property, plant and equipment
Property, plant and equipment	39,585	33,853
Machinery and equipment
Property, plant and equipment
Property, plant and equipment	24,078	23,626
Computer software and equipment
Property, plant and equipment
Property, plant and equipment	24,691	24,431
Construction in progress
Property, plant and equipment
Property, plant and equipment	$ 1,743	$ 7,033

Goodwill and Intangible Asset55

Goodwill and Intangible Assets (Details Textual) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended	9 Months Ended	12 Months Ended
	Feb. 28, 2015	Nov. 30, 2014	Aug. 31, 2014	Nov. 30, 2014	Feb. 28, 2015	May 31, 2016	May 31, 2015	May 31, 2014	May 31, 2013	May 31, 2012	Dec. 31, 2015
Goodwill and Intangible Assets (Textual) [Abstract]
Discount rate used in fair value calculation						12.50%
Capitalization rate						8.50%
Percentage of fair value, carrying value											9.20%
Amortization expense	$ 5,188	$ 4,011	$ 4,037	$ 8,048	$ 13,236	$ 17,964	$ 17,966	$ 16,562	$ 16,599	$ 9,393
Adjustment of goodwill and deferred tax liabilities							$ 800
Maximum
Goodwill and Intangible Assets (Textual) [Abstract]
Estimates useful life of intangible assets other than goodwill						18 years
Minimum
Goodwill and Intangible Assets (Textual) [Abstract]
Estimates useful life of intangible assets other than goodwill						2 years
Income Approach Valuation Technique
Goodwill and Intangible Assets (Textual) [Abstract]
Weight assigned to valuation methods						75.00%
Market Approach Valuation Technique
Goodwill and Intangible Assets (Textual) [Abstract]
Weight assigned to valuation methods						25.00%

Goodwill and Intangible Asset56

Goodwill and Intangible Assets (Details 1) - USD ($) $ in Thousands	12 Months Ended
	May 31, 2016	May 31, 2015	Feb. 29, 2016	Nov. 30, 2015	Aug. 31, 2015	Feb. 28, 2015	Nov. 30, 2014	Aug. 31, 2014	May 31, 2014	May 31, 2013	May 31, 2012
Indefinite-lived Intangible Assets [Line Items]
Gross carrying value, finite and indefinite intangible assets total	$ 278,927	$ 276,105
Accumulated amortization	(112,350)	(94,453)
Net carrying value, finite and indefinite intangible assets total	166,577	181,652	$ 167,926	$ 172,357	$ 177,245	$ 186,393	$ 197,187	$ 201,215	$ 205,053	$ 214,523	$ 147,195
Product technologies
Indefinite-lived Intangible Assets [Line Items]
Gross carrying value, finite-lived intangible assets	148,387	148,776
Accumulated amortization	(51,313)	(41,447)
Net carrying value, finite-lived intangible assets	$ 97,074	$ 107,329
Weighted average useful life	10 years 2 months 12 days	10 years 2 months 12 days
Customer relationships
Indefinite-lived Intangible Assets [Line Items]
Gross carrying value, finite-lived intangible assets	$ 88,389	$ 86,371
Accumulated amortization	(47,133)	(42,813)
Net carrying value, finite-lived intangible assets	$ 41,256	$ 43,558
Weighted average useful life	11 years 10 months 24 days	12 years
Trademarks
Indefinite-lived Intangible Assets [Line Items]
Gross carrying value, finite-lived intangible assets		$ 28,545
Gross carrying value, indefinite-lived intangible assets	$ 28,470
Accumulated amortization	(6,242)	(3,383)
Net carrying value, finite-lived intangible assets		$ 25,162
Net carrying value, indefinite-lived intangible assets	$ 22,228
Weighted average useful life	10 years 8 months 12 days	10 years 8 months 12 days
Licenses
Indefinite-lived Intangible Assets [Line Items]
Gross carrying value, finite-lived intangible assets	$ 7,931	$ 7,913
Accumulated amortization	(6,716)	(5,910)
Net carrying value, finite-lived intangible assets	$ 1,215	$ 2,003
Weighted average useful life	7 years 7 months 6 days	8 years 3 months 18 days
Distributor relationships
Indefinite-lived Intangible Assets [Line Items]
Gross carrying value, finite-lived intangible assets	$ 2,150	$ 900
Accumulated amortization	(946)	(900)
Net carrying value, finite-lived intangible assets	$ 1,204	$ 0
Weighted average useful life	5 years 2 months 12 days	3 years
In process R&D
Indefinite-lived Intangible Assets [Line Items]
Gross carrying value, indefinite-lived intangible assets	$ 3,600	$ 3,600
Net carrying value, indefinite-lived intangible assets	$ 3,600	$ 3,600

Goodwill and Intangible Asset57

Goodwill and Intangible Assets (Details 2) $ in Thousands	May 31, 2016USD ($)
Expected amortization expense
2,017	$ 19,049
2,018	19,903
2,019	22,062
2,020	23,329
2,021	$ 24,370

Goodwill and Intangible Asset58

Goodwill and Intangible Assets Goodwill and Intangible Assets (Details 3) $ in Thousands	12 Months Ended
	May 31, 2015USD ($)
Goodwill [Roll Forward]
Goodwill, Beginning Balance	$ 360,473
Tax basis adjustment	779
Goodwill, Ending Balance	$ 361,252

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended							6 Months Ended		9 Months Ended		12 Months Ended
	Feb. 29, 2016	Nov. 30, 2015	Aug. 31, 2015	May 31, 2015	Feb. 28, 2015	Nov. 30, 2014	Aug. 31, 2014	Nov. 30, 2015	Nov. 30, 2014	Feb. 29, 2016	Feb. 28, 2015	May 31, 2016	May 31, 2015	May 31, 2014	May 31, 2013	May 31, 2012
Components of income (loss) before income tax provision
US												$ (4,444)	$ (8,965)	$ 4,645
Non-US												1,191	834	541
Total other (expenses) income, net	$ 945	$ (671)	$ (705)	$ 152	$ (11,752)	$ 2,373	$ 1,096	$ (1,376)	$ 3,469	$ (431)	$ (8,283)	$ (3,253)	$ (8,131)	$ 5,186	$ (1,337)	$ (5,653)

Income Taxes (Details 1)

Income Taxes (Details 1) - USD ($) $ in Thousands	3 Months Ended							6 Months Ended		9 Months Ended		12 Months Ended
	Feb. 29, 2016	Nov. 30, 2015	Aug. 31, 2015	May 31, 2015	Feb. 28, 2015	Nov. 30, 2014	Aug. 31, 2014	Nov. 30, 2015	Nov. 30, 2014	Feb. 29, 2016	Feb. 28, 2015	May 31, 2016	May 31, 2015	May 31, 2014	May 31, 2013	May 31, 2012
Current
Federal												$ 34	$ (242)	$ (133)
State and local												103	205	99
Non U.S.												217	417	157
Current, Total												354	380	123
Deferred												39,983	(5,123)	2,716
Income tax expense/(benefit), Total	$ 351	$ (337)	$ 70	$ 740	$ (7,599)	$ 1,304	$ 812	$ (267)	$ 2,116	$ 84	$ (5,483)	$ 40,337	$ (4,743)	$ 2,839	$ (286)	$ (322)

Income Taxes (Details 2)

Income Taxes (Details 2) - USD ($) $ in Thousands	12 Months Ended
	May 31, 2016	May 31, 2015	May 31, 2014
Summary of significant components of deferred income tax (benefit) expense from operations
Net effect of temporary differences	$ 133	$ (1,916)	$ 1,543
Adjustments for beginning-of-the-year valuation allowance balance for changes in circumstances	40,418	0	0
Impact of NYS tax reform legislation	0	0	1,173
Net operating loss carryforward	(568)	(3,207)	0
Deferred Income Tax Expense (Benefit)	$ 39,983	$ (5,123)	$ 2,716

Income Taxes (Details 3)

Income Taxes (Details 3) - USD ($) $ in Thousands	May 31, 2016	May 31, 2015
Deferred tax assets
Net operating loss carryforward	$ 52,593	$ 52,025
Stock-based compensation	4,135	4,468
Federal and state R&D tax credit carryforward	2,145	1,646
Inventories	4,535	2,808
Expenses incurred not currently deductible	3,018	2,107
Deferred revenue	339	114
Gross deferred tax asset	66,765	63,168
Deferred tax liabilities
Excess tax over book depreciation and amortization	46,240	42,988
Gross deferred Liability	46,240	42,988
Valuation Allowance	(42,209)	(1,791)
Net deferred tax liability	$ (21,684)
Net deferred tax asset (liability)		$ 18,389

Income Taxes (Details 4)

Income Taxes (Details 4) - USD ($) $ in Thousands	3 Months Ended							6 Months Ended		9 Months Ended		12 Months Ended
	Feb. 29, 2016	Nov. 30, 2015	Aug. 31, 2015	May 31, 2015	Feb. 28, 2015	Nov. 30, 2014	Aug. 31, 2014	Nov. 30, 2015	Nov. 30, 2014	Feb. 29, 2016	Feb. 28, 2015	May 31, 2016	May 31, 2015	May 31, 2014	May 31, 2013	May 31, 2012
Reasons for consolidated income tax provision
Effective income tax rate			35.00%				35.00%					35.00%
Income tax (benefit) provision at statutory tax rate of 35%												$ (1,139)	$ (2,845)	$ 1,814
Effect of Graduated tax rates												33	81	(51)
State income taxes, net of Federal tax benefit												(215)	(21)	111
Impact of Non US operations												(162)	133	(27)
Research and development tax credit												(499)	(604)	(236)
Meals and entertainment												329	0	0
Nondeductible interest on contingent payments												262	265	540
Nontaxable gain on revaluation of contingent consideration liability												(170)	(3,102)	(1,734)
Tax law change												0	(454)	1,173
Adjustment to beginning of year valuation allowance												40,685	0	0
Effect of elimination of ASC 718 APIC pool												739	1,253	440
Nondeductible stock-based compensation												0	0	176
Other nondeductible expenses												207	498	384
Overaccrual (underaccrual) of prior year Federal and state taxes												356	38	249
Other												(89)	15	0
Income tax expense/(benefit), Total	$ 351	$ (337)	$ 70	$ 740	$ (7,599)	$ 1,304	$ 812	$ (267)	$ 2,116	$ 84	$ (5,483)	$ 40,337	$ (4,743)	$ 2,839	$ (286)	$ (322)

Income Taxes (Details 5)

Income Taxes (Details 5) - USD ($) $ in Thousands	12 Months Ended
	May 31, 2016	May 31, 2015	May 31, 2014
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Unrecognized tax benefits, beginning balance	$ 0	$ 0	$ 0
Increase in gross amounts of tax positions related to prior years	899	0	0
Decrease in gross amounts of tax positions related to prior years	0	0	0
Increase in gross amounts of tax positions related to current year	0	0	0
Decrease due to settlements with tax authorities	0	0	0
Decrease due to lapse in statute of limitations	0	0	0
Unrecognized tax benefits, ending balance	$ 899	$ 0	$ 0

Income Taxes (Details Textual)

Income Taxes (Details Textual) - USD ($)	12 Months Ended
	May 31, 2016	May 31, 2015	May 31, 2014
Income Taxes (Textual) [Abstract]
Potential increase in equity if excess tax benefits are realized	$ 400,000
Net deferred income tax asset	21,700,000
Valuation allowance	(42,209,000)	$ (1,791,000)
Increase (decrease) valuation allowance	40,400,000
Net deferred tax asset before valuation allowance	19,900,000
Higher amount of valuation allowance	20,500,000
Accrued interest and penalties	0	$ 0	$ 0
Unrecognized tax benefits that would affect the effective tax rate	100,000
Additional unrecognized tax benefit	800,000
Foreign subsidiary undistributed earnings	4,600,000
Federal
Income Taxes (Textual) [Abstract]
Net operating loss carryforwards after considering limitations of use	151,700,000
Tax Year 2017 To 2016 | Federal
Income Taxes (Textual) [Abstract]
Federal and State net operating loss carryforwards	29,800,000
Tax Year 2027 To 2033 | Federal
Income Taxes (Textual) [Abstract]
Net operating loss carryforwards after considering limitations of use	121,900,000
Tax Year 2015 To 2033 | State
Income Taxes (Textual) [Abstract]
Federal and State net operating loss carryforwards	$ 30,800,000

Accrued Liabilities (Details)

Accrued Liabilities (Details) - USD ($) $ in Thousands	May 31, 2016	Nov. 30, 2015	May 31, 2015	Feb. 28, 2015	Nov. 30, 2014	Aug. 31, 2014	May 31, 2014	May 31, 2013
Accrued liabilities
Payroll and related expenses	$ 9,414		$ 10,297
Royalties	2,489		2,237
Accrued severance	1,524		158
Sales and franchise taxes	565		489
Interest rate swap liability	0		257
Outside services	2,063		1,522
Deferred Rent	35		808
Other	5,806		2,341
Total	$ 21,896	$ 16,858	$ 18,109	$ 19,485	$ 18,589	$ 17,522	$ 15,940	$ 15,961

Long-Term Debt (Details1)

Long-Term Debt (Details1) - Term Loan $ in Thousands	May 31, 2016USD ($)
Future minimum principal payments on long-term debt
2,017	$ 16,250
2,018	26,250
2,019	78,910
2,020	0
Bank Notes	$ 121,410

Long-Term Debt (Details Textual

Long-Term Debt (Details Textual)	Sep. 19, 2013USD ($)	May 31, 2016USD ($)	May 31, 2015USD ($)
Debt Instrument [Line Items]
Senior secured term loan facility	$ 100,000,000
Senior secured revolving credit facility	$ 100,000,000
Bank credit agreement maturity period	P5Y
Quarterly percentage repayment of term facility year one	5.00%
Quarterly percentage repayment of term facility year two	5.00%
Quarterly percentage repayment of term facility year three	10.00%
Quarterly percentage repayment of term facility year four	15.00%
Quarterly percentage repayment of term facility year five	65.00%
Percentage of increase in interest	2.00%
Notional amount of interest rate swap agreement		$ 100,000,000
Fixed interest rate payments		0.74%
Loans payable, noncurrent		$ 105,160,000	$ 128,910,000
Ratio for debt service coverage		1.35
Ratio of indebtedness to consolidated EBITDA		3.75
Revolving Credit Facility
Debt Instrument [Line Items]
Loans payable, noncurrent			$ 36,400,000
Term Loan
Debt Instrument [Line Items]
Loans payable		$ 85,000,000
Maximum
Debt Instrument [Line Items]
Commitment fee percentage	0.35%
Maximum | Line of Credit
Debt Instrument [Line Items]
State interest rate	2.25%
Maximum | Term Loan
Debt Instrument [Line Items]
State interest rate	1.25%
Minimum
Debt Instrument [Line Items]
Commitment fee percentage	0.20%
Minimum | Line of Credit
Debt Instrument [Line Items]
State interest rate	1.50%
Minimum | Term Loan
Debt Instrument [Line Items]
State interest rate	0.50%
Interest rate swap agreements
Debt Instrument [Line Items]
Fixed interest rate payments		3.26%
Letter of Credit
Debt Instrument [Line Items]
Credit facility borrowing capacity	$ 20,000,000
Swingline Loans
Debt Instrument [Line Items]
Credit facility borrowing capacity	5,000,000
Revolving Credit Facility
Debt Instrument [Line Items]
Borrowing under revolving facility	$ 41,400,000

Retirement Plans (Details)

Retirement Plans (Details) - USD ($) $ in Millions	12 Months Ended
	May 31, 2016	May 31, 2015	May 31, 2014
Retirement Plans (Textual) [Abstract]
Matching contributions	$ 3.7	$ 3.7	$ 2.8

Stockholders' Equity (Details)

Stockholders' Equity (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	May 31, 2016USD ($)$ / sharesshares
Schedule summarizes stock option activity
Shares Outstanding at beginning of year | shares	2,299,313
Shares Granted | shares	564,380
Shares Exercised | shares	(145,260)
Shares Forfeited | shares	(304,563)
Shares Expired | shares	(132,252)
Shares Outstanding at end of year | shares	2,281,618
Shares Options exercisable at year end | shares	1,313,698
Shares Option expected to vest in future periods | shares	854,189
Weighted Average exercise price, Outstanding at beginning of year | $ / shares	$ 14.86
Weighted Average exercise price Granted | $ / shares	14.22
Weighted Average exercise price Exercised | $ / shares	13.73
Weighted Average exercise price Forfeited | $ / shares	13.85
Weighted Average exercise price Expired | $ / shares	22.75
Weighted Average exercise price, Outstanding at end of year | $ / shares	14.45
Weighted Average exercise price, Options exercisable at year end | $ / shares	14.25
Weighted Average exercise price, Options expected to vest in future periods | $ / shares	$ 14.72
Weighted Average remaining contractual life	3 years 9 months 14 days
Weighted Average remaining contractual life, Option exercisable at year end	2 years 4 months 2 days
Weighted Average remaining contractual life, Option expected to vest in future periods	5 years 9 months 3 days
Aggregate intrinsic value, Outstanding at end of year | $	$ 164
Aggregate intrinsic value, Options exercisable at year end | $	130
Aggregate intrinsic value, Option expected to vest in future periods | $	$ 30

Stockholders' Equity (Details 2

Stockholders' Equity (Details 2)	12 Months Ended
	May 31, 2016$ / sharesshares
Options outstanding
Number outstanding | shares	2,281,618
Weighted- average remaining life in years	3 years 9 months 14 days
Weighted- average exercise price	$ 14.45
Number Exercisable | shares	1,313,698
Weighted- average exercise price	$ 14.25
$10.25 - $14.24
Options outstanding
Range of exercise prices, Lower limit	10.25
Range of exercise prices, Upper limit	$ 14.24
Number outstanding | shares	1,398,385
Weighted- average remaining life in years	3 years 5 months 15 days
Weighted- average exercise price	$ 12.93
Number Exercisable | shares	957,571
Weighted- average exercise price	$ 13.14
$14.25 - $18.24
Options outstanding
Range of exercise prices, Lower limit	14.25
Range of exercise prices, Upper limit	$ 18.24
Number outstanding | shares	684,427
Weighted- average remaining life in years	4 years 9 months
Weighted- average exercise price	$ 16.04
Number Exercisable | shares	228,571
Weighted- average exercise price	$ 15.84
$18.25 - $22.24
Options outstanding
Range of exercise prices, Lower limit	18.25
Range of exercise prices, Upper limit	$ 22.24
Number outstanding | shares	183,695
Weighted- average remaining life in years	3 years 3 days
Weighted- average exercise price	$ 19.30
Number Exercisable | shares	112,445
Weighted- average exercise price	$ 19.23
$22.25 - $26.24
Options outstanding
Range of exercise prices, Lower limit	22.25
Range of exercise prices, Upper limit	$ 26.24
Number outstanding | shares	14,250
Weighted- average remaining life in years	5 months 23 days
Weighted- average exercise price	$ 23.62
Number Exercisable | shares	14,251
Weighted- average exercise price	$ 23.62
$26.25 - $30.24
Options outstanding
Range of exercise prices, Lower limit	26.25
Range of exercise prices, Upper limit	$ 30.24
Number outstanding | shares	861
Weighted- average remaining life in years	7 months 6 days
Weighted- average exercise price	$ 26.94
Number Exercisable | shares	860
Weighted- average exercise price	$ 26.94

Stockholders' Equity (Details 3

Stockholders' Equity (Details 3) - $ / shares	12 Months Ended
	May 31, 2016	May 31, 2015	May 31, 2014
Share Based Compensation Arrangement by Share Based Payment Award Nonvested Shares and Weighted Average Grant Date Fair Value [Abstract]
Non-Vested Stock Award Units Beginning Balance	563,101
Non-Vested Stock Award Units, Granted	259,917
Non-Vested Stock Award Units, Cancelled	(160,845)
Non-Vested Stock Award Units, Vested	(112,396)
Non-Vested Stock Award Units Ending Balance	549,777	563,101
Non-Vested Stock Award Units, Awards expected to vest in future periods	482,594,000
Weighted Average Grant-Date Fair Value Beginning Balance	$ 13.73
Weighted Average Grant-Date Fair Value, Granted	15.21	$ 14.75	$ 13.23
Weighted Average Grant-Date Fair Value, Cancelled	15.39
Weighted Average Grant-Date Fair Value, Vested	13.81
Weighted Average Grant-Date Fair Value Ending Balance	14.62	$ 13.73
Weighted Average Grant-Date Fair Value, Awards expected to vest in future periods	$ 14,620

Stockholders' Equity (Details T

Stockholders' Equity (Details Textual) $ / shares in Units, $ in Thousands	May 31, 2016USD ($)$ / sharesshares	Oct. 29, 2014$ / sharesshares	Oct. 05, 2011shares	Feb. 29, 2016USD ($)	Nov. 30, 2015USD ($)	Aug. 31, 2015USD ($)	May 31, 2015USD ($)$ / sharesshares	Feb. 28, 2015USD ($)	Nov. 30, 2014USD ($)	Aug. 31, 2014USD ($)	Nov. 30, 2015USD ($)	Nov. 30, 2014USD ($)	Feb. 29, 2016USD ($)	Feb. 28, 2015USD ($)	May 31, 2016USD ($)installmentworking_hourEmployees$ / sharesshares	May 31, 2015USD ($)$ / sharesshares	May 31, 2014USD ($)$ / sharesshares	May 31, 2013USD ($)	May 31, 2012USD ($)
Other Ownership Interests [Line Items]
Authorized capital stock		80,000,000
Shares of common stock (shares)	75,000,000	75,000,000					75,000,000								75,000,000	75,000,000
Common stock, par value (usd per share) | $ / shares	$ 0.01	$ 0.01					$ 0.01								$ 0.01	$ 0.01
Preferred stock, shares authorized (shares)	5,000,000	5,000,000					5,000,000								5,000,000	5,000,000
Preferred stock, par value (usd per share) | $ / shares	$ 0.01	$ 0.01					$ 0.01								$ 0.01	$ 0.01
Common stock, votes per share		1
Percentage of grants to employees vesting															25.00%
Option grants to employees vesting period															4 years
Percentage of grants for consultants vesting															100.00%
Option grants to consultants vesting period															1 year
Subsequent grants for directors vesting															33.33%
Subsequent grants for directors vesting period															3 years
Option grants in the period, weighted average grant date fair value (usd per share) | $ / shares															$ 4.16	$ 4.74	$ 4.10
Risk free interest rate															1.48%	1.54%	1.44%
Expected volatility rate															31.00%	31.00%	34.00%
Expected term															4 years 9 months 21 days	4 years 9 months 3 days	4 years 8 months 25 days
The total intrinsic value of options exercised | $															$ 100	$ 1,600	$ 1,000
Compensation not yet recognized | $	$ 3,300														3,300
Proceeds from stock options exercised | $															1,300	4,300	1,300
Stock based compensation pre tax amount | $															$ 100	$ 500	$ 100
Grants in the period, weighted average grant date fair value (usd per share) | $ / shares															$ 15.21	$ 14.75	$ 13.23
Tax benefit from compensation expense | $															$ 1,000	$ 2,000	$ 1,800
Share-based Compensation | $															$ 3,240	$ 5,998	$ 5,502
Average price of share issued | $ / shares	$ 10.67						11.89								$ 10.67	$ 11.89	$ 9.30
Nonvested compensation, weighted average grant date fair valur (usd per share) | $ / shares	$ 14.62						$ 13.73								$ 14.62	$ 13.73
Nonvested compensation (shares)	549,777						563,101								549,777	563,101
Income tax expense (benefit) | $				$ 351	$ (337)	$ 70	$ 740	$ (7,599)	$ 1,304	$ 812	$ (267)	$ 2,116	$ 84	$ (5,483)	$ 40,337	$ (4,743)	$ 2,839	$ (286)	$ (322)
Options awarded (shares)															259,917
Shares awarded (shares)															564,380
Performance Share and Restricted Stock Unit Awards
Other Ownership Interests [Line Items]
Total fair value of restricted stock awards vesting | $															$ 2,500	2,400	$ 1,800
Restricted Stock
Other Ownership Interests [Line Items]
Period of recognition for costs not yet recognized	2 years
Employee service, compensation cost not yet recognized | $	$ 5,400														5,400
Performance Shares
Other Ownership Interests [Line Items]
Employee service, compensation cost not yet recognized | $	$ 4,600						$ 2,200								$ 4,600	$ 2,200
Nonvested compensation, weighted average grant date fair valur (usd per share) | $ / shares	$ 18.07						$ 19.83								$ 18.07	$ 19.83	$ 25.56
Performance period															3 years
Nonvested compensation (shares)	400,000						200,000								400,000	200,000
Weighted average remaining contractual term															3 years	3 years
Continuing Operations
Other Ownership Interests [Line Items]
Income tax expense (benefit) | $						$ 1,300				$ 500					$ 800
Shareholders' Equity
Other Ownership Interests [Line Items]
Income tax expense (benefit) | $																$ 100
Employee Stock Option
Other Ownership Interests [Line Items]
Period of recognition for costs not yet recognized															3 years
Chief Executive Officer | Performance Shares
Other Ownership Interests [Line Items]
Options awarded (shares)															250,000
Term of award															3 years
Chief Executive Officer | Restricted Stock Units
Other Ownership Interests [Line Items]
Options awarded (shares)															50,000
Award vesting installments (installment) | installment															4
Chief Executive Officer | Employee Stock Option
Other Ownership Interests [Line Items]
Shares awarded (shares)															200,000
Award vesting installments (installment) | installment															4
Chief Executive Officer | Minimum | Performance Shares
Other Ownership Interests [Line Items]
Payouts as a percent of grant amount															0.00%
Chief Executive Officer | Maximum | Performance Shares
Other Ownership Interests [Line Items]
Payouts as a percent of grant amount															20000.00%
1997 Stock Option Plan
Other Ownership Interests [Line Items]
Total number of common stock available to be issued	1,497,674														1,497,674
Options exercisable period															10 years
2004 Stock and Incentive Award Plan
Other Ownership Interests [Line Items]
Total number of common stock available to be issued	2,200,000														2,200,000
Options exercisable period															10 years
Total number of common stock reserved for issuance	6,750,000														6,750,000
Incentive award plan to increase the minimum number of shares			200,000
Incentive award plan to increase the maximum number of shares			500,000
2004 Stock and Incentive Award Plan | Maximum
Other Ownership Interests [Line Items]
Total number of common stock available to be issued	800,000														800,000
Stock Purchase Plan
Other Ownership Interests [Line Items]
Total number of common stock available to be issued	1,000,000														1,000,000
Share purchase periods | Employees															2
Duration of purchase of shares															6 months
Employee eligible in participating in offering period															6 months
Maximum number of shares to be offered	2,000,000														2,000,000
Working schedule of employee to participate in offering period															20 or more hours per week and more than five months in a calendar year
Number of working hours to be eligible (working hour) | working_hour															20
Number of working months to be eligible															5 months
Employees ownership threshold															5.00%
Percentage of fair market value of a share of common stock on the first day of the offering period															85.00%
Percentage of fair market value of a share of common stock on the last day of the offering period															85.00%
Number of additional shares reserved for issuance (shares)																800,000
Maximum number of shares to be offered under the Stock Purchase Plan															137,957	119,001	146,275

Earnings Per Share (Details)

Earnings Per Share (Details) - shares	12 Months Ended
	May 31, 2016	May 31, 2015	May 31, 2014
Earnings Per Share [Abstract]
Basic weighted average shares outstanding (in shares)	36,161,383	35,683,139	35,135,689
Effect of dilutive securities (shares)	0	0	304,161
Diluted weighted average shares outstanding (in shares)	36,161,383	35,683,139	35,439,850
Securities excluded as their inclusion would be anti-dilutive (shares)	3,277,037	2,862,414	2,347,426

Commitments and Contingencies75

Commitments and Contingencies (Details) $ in Thousands	May 31, 2016USD ($)
Aggregate of future annual payments under non cancelable operating leases for facilities and equipment [Abstract]
2,015	$ 2,183
2,016	2,013
2,017	1,981
2,018	1,772
2,019	935
Total	$ 8,884

Commitments and Contingencies76

Commitments and Contingencies (Details Textual)

Mar. 29, 2016claim

Mar. 24, 2016claim

Mar. 11, 2016claim

Jun. 05, 2015motion

Mar. 10, 2015patent

Mar. 18, 2014USD ($)

Nov. 08, 2012USD ($)

Jan. 11, 2012reexamination_appealclaim

Jan. 02, 2008Lawsuit

May 31, 2016USD ($)reexamination_appeal

May 31, 2016USD ($)Petition

May 31, 2015USD ($)

May 31, 2014USD ($)

Commitments and Contingencies (Textual) [Abstract]

Aggregate rental costs under operating leases

$ 2,500,000

$ 3,400,000

$ 2,000,000

Judgment entered in favor

$ 74,900,000

Total future purchase obligations due through 2021

$ 8,900,000

8,900,000

Purchase obligations thereafter

$ 0

$ 0

Biolitec

Commitments and Contingencies (Textual) [Abstract]

Number of lawsuits against biolitec previously settled for which seeking defense and indemnification | Lawsuit

2

Partial judgment granted

$ 23,200,000

The Utah Action

Commitments and Contingencies (Textual) [Abstract]

Number of petitions filed for reexamination of patents | Petition

3

Number of claims rejected (claim) | claim

20

8

6

40

Number of claims filed (claim) | claim

41

Number of reexaminations (reexamination appeal) | reexamination_appeal

3

Number of pending claims (claim) | claim

10

10

Number of claims reversed (claim) | claim

2

4

The Delaware Action

Commitments and Contingencies (Textual) [Abstract]

Number of patents allegedly infringed (patent)

2

3

Pending Litigation | The Utah Action

Commitments and Contingencies (Textual) [Abstract]

Number of reexaminations (reexamination appeal) | reexamination_appeal

2

C.R. Bard, Inc. | Pending Litigation | The Utah Action

Commitments and Contingencies (Textual) [Abstract]

Number of reexaminations (reexamination appeal) | reexamination_appeal

3

Segments and Geographic Infor77

Segments and Geographic Information (Details) - USD ($) $ in Thousands	3 Months Ended								6 Months Ended		9 Months Ended		12 Months Ended
	May 31, 2016	Feb. 29, 2016	Nov. 30, 2015	Aug. 31, 2015	May 31, 2015	Feb. 28, 2015	Nov. 30, 2014	Aug. 31, 2014	Nov. 30, 2015	Nov. 30, 2014	Feb. 29, 2016	Feb. 28, 2015	May 31, 2016	May 31, 2015	May 31, 2014
Summary of total net sales by product category
Net sales	$ 93,419	$ 87,434	$ 89,284	$ 83,753	$ 90,697	$ 86,597	$ 92,149	$ 87,091	$ 173,037	$ 179,240	$ 260,471	$ 265,837	$ 353,890	$ 356,534	$ 354,425
Peripheral Vascular
Summary of total net sales by product category
Net sales													202,780	192,713	192,626
Vascular Access
Summary of total net sales by product category
Net sales													99,375	107,754	106,394
Oncology/Surgery
Summary of total net sales by product category
Net sales													48,895	51,890	49,360
Supply Agreement
Summary of total net sales by product category
Net sales													$ 2,840	$ 4,177	$ 6,045

Segments and Geographic Infor78

Segments and Geographic Information (Details 1) - USD ($) $ in Thousands	3 Months Ended								6 Months Ended		9 Months Ended		12 Months Ended
	May 31, 2016	Feb. 29, 2016	Nov. 30, 2015	Aug. 31, 2015	May 31, 2015	Feb. 28, 2015	Nov. 30, 2014	Aug. 31, 2014	Nov. 30, 2015	Nov. 30, 2014	Feb. 29, 2016	Feb. 28, 2015	May 31, 2016	May 31, 2015	May 31, 2014
Net Sales by Geography
Net sales	$ 93,419	$ 87,434	$ 89,284	$ 83,753	$ 90,697	$ 86,597	$ 92,149	$ 87,091	$ 173,037	$ 179,240	$ 260,471	$ 265,837	$ 353,890	$ 356,534	$ 354,425
United States
Net Sales by Geography
Net sales													283,519	280,611	280,161
International
Net Sales by Geography
Net sales													67,531	71,746	68,219
Supply Agreement
Net Sales by Geography
Net sales													$ 2,840	$ 4,177	$ 6,045

Segments and Geographic Infor79

Segments and Geographic Information (Details Textual) - Segment	12 Months Ended
	May 31, 2016	May 31, 2015	May 31, 2014
Segment Reporting [Abstract]
International sales percentage of total net sales	19.00%	20.00%	19.00%
Number of segment (segment)	1
Total assets are located within the United States	99.00%

Restructuring (Details)

Restructuring (Details) $ in Millions	Dec. 05, 2013USD ($)Employees	May 31, 2016USD ($)	May 31, 2015USD ($)
Operational Excellence Program
Restructuring Cost and Reserve [Line Items]
Period of restructuring plan	3 years
Expected restructuring costs	$ 4.9
Restructuring costs incurred to date		$ 1.5	$ 2
Accelerated depreciation due to restructuring		1	1.5
Profitability Improvement Plan
Restructuring Cost and Reserve [Line Items]
Accelerated depreciation due to restructuring		1.9	0.8
Gain related to the modification of stock based compensation		0.7
Severance | Operational Excellence Program
Restructuring Cost and Reserve [Line Items]
Restructuring costs incurred to date		$ 0.5	$ 0.5
Minimum
Restructuring Cost and Reserve [Line Items]
Expected number of positions (employee) | Employees	80,000
Minimum | Operational Excellence Program
Restructuring Cost and Reserve [Line Items]
Expected future saving	$ 15
Maximum
Restructuring Cost and Reserve [Line Items]
Expected number of positions (employee) | Employees	100,000
Maximum | Operational Excellence Program
Restructuring Cost and Reserve [Line Items]
Expected future saving	$ 18
Facility Improvements | Operational Excellence Program
Restructuring Cost and Reserve [Line Items]
Expected restructuring costs	$ 5.4

Immaterial Error Corrections Na

Immaterial Error Corrections Narrative (Details) - USD ($) $ in Thousands	3 Months Ended					6 Months Ended		9 Months Ended		12 Months Ended
	Aug. 31, 2015	May 31, 2015	Feb. 28, 2015	Nov. 30, 2014	Aug. 31, 2014	Nov. 30, 2015	Nov. 30, 2014	Feb. 29, 2016	Feb. 28, 2015	May 31, 2016	May 31, 2015	May 31, 2014	May 31, 2013
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Research and development	$ 6,129	$ 6,551	$ 6,578	$ 6,276	$ 7,188	$ 12,308	$ 13,465	$ 18,116	$ 20,043	$ 25,053	$ 26,594	$ 28,124	$ 26,091
Lease expense										2,500	$ 3,400	$ 2,000
Restatement Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Intercompany foreign exchange loss										700
Research and development										400
Lease expense										$ 300

Immaterial Error Corrections (D

Immaterial Error Corrections (Details) - USD ($) $ in Thousands	3 Months Ended								6 Months Ended		9 Months Ended		12 Months Ended
	May 31, 2016	Feb. 29, 2016	Nov. 30, 2015	Aug. 31, 2015	May 31, 2015	Feb. 28, 2015	Nov. 30, 2014	Aug. 31, 2014	Nov. 30, 2015	Nov. 30, 2014	Feb. 29, 2016	Feb. 28, 2015	May 31, 2016	May 31, 2015	May 31, 2014	May 31, 2013	May 31, 2012
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net sales	$ 93,419	$ 87,434	$ 89,284	$ 83,753	$ 90,697	$ 86,597	$ 92,149	$ 87,091	$ 173,037	$ 179,240	$ 260,471	$ 265,837	$ 353,890	$ 356,534	$ 354,425
Cost of sales				40,382	45,366	48,924	45,321	41,127	83,782	86,448	127,682	135,372	179,574	180,738	174,251
Gross profit	41,527	43,534	45,884	43,371	45,331	37,673	46,828	45,964	89,255	92,792	132,789	130,465	174,316	175,796	180,174
Research and development				6,129	6,551	6,578	6,276	7,188	12,308	13,465	18,116	20,043	25,053	26,594	28,124	$ 26,091
Sales and marketing		20,955	21,378	21,200	21,151	19,799	21,536	20,735	42,578	42,271	63,534	62,069	84,723	83,220	85,305	77,564	$ 65,757
General and administrative		6,901	8,082	7,914	7,448	6,613	7,786	7,315	15,996	15,101	22,897	21,714	29,603	29,162	26,902	26,035
Amortization of intangibles						5,188	4,011	4,037		8,048		13,236	17,964	17,966	16,562	16,599	9,393
Change in fair value of contingent consideration						(9,794)	542	726		1,268		(8,526)	948	(8,096)	(1,908)
Acquisition, restructuring and other items, net						18,676	2,062			4,726		23,402	12,591	26,257	10,873
Total operating expenses		41,568	45,319	43,159	44,202	48,094	43,289	43,660	88,478	86,949	130,047	135,043	173,298	179,245	169,687	163,272	130,553
Operating income (loss)		1,966	565	212	1,129	(10,421)	3,539	2,304	777	5,843		(4,578)	1,018	(3,449)	10,487	5,242	(5,244)
Other expense		(214)	(239)	(118)	(230)	(474)	(374)	(409)	(357)	(783)	(570)	(1,257)	(886)	(1,489)	(1,645)	(1,411)	(991)
Total other expenses, net		(1,021)	(1,236)	(917)	(977)	(1,331)	(1,166)	(1,208)	(2,153)	(2,374)	(3,173)	(3,705)	(4,271)	(4,682)	(5,301)	(6,579)	(409)
Income (loss) before income tax expense (benefit)		945	(671)	(705)	152	(11,752)	2,373	1,096	(1,376)	3,469	(431)	(8,283)	(3,253)	(8,131)	5,186	(1,337)	(5,653)
Income tax expense (benefit)		351	(337)	70	740	(7,599)	1,304	812	(267)	2,116	84	(5,483)	40,337	(4,743)	2,839	(286)	(322)
Net income (loss)	(43,075)	594	(334)	(775)	(588)	(4,153)	1,069	284	(1,109)	1,353	(515)	(2,800)	(43,590)	(3,388)	2,347	(1,051)	(5,331)
Foreign currency translation						(587)	(67)	37		(30)		(618)	(112)	(264)	442
Other comprehensive income (loss), before tax						(471)	(63)	78		14		(458)	134	(88)	394
Other comprehensive income (loss), net of tax						(514)	(64)	63		(2)		(517)	42	(152)	412
Total comprehensive income (loss), net of tax						(4,667)	1,005	347		1,351		(3,317)	(43,548)	(3,540)	2,759
Net cash provided by (used in) operating activities				4,699				4,942	14,278	2,648	26,672	14,879	45,216	25,685	24,681
Net cash provided by (used in) investing activities				(743)				(4,848)	(1,143)	(7,216)	(3,888)	(11,485)	(7,569)	(12,736)	(16,448)
Net cash provided by (used in) financing activities				(2,071)				(2,391)	(12,370)	3,381	(19,167)	641	(23,663)	(10,465)	(14,016)
Inventories	55,370				67,388	68,767	75,372	71,306		75,372		68,767	55,370	67,388	61,740
Prepaid expenses and other	3,243				4,132	4,638	6,562	6,466		6,562		4,638	3,243	4,132	4,880
Total current assets	146,254				150,798	154,490	159,221	151,212		159,221		154,490	146,254	150,798	147,012
Property, Plant and Equipment, net	48,284				54,450	58,215	66,723	66,189		66,723		58,215	48,284	54,450	66,455	62,375
Other Assets	4,696			4,928	5,398	4,284	2,726	3,292		2,726		4,284	4,696	5,398	3,806
Intangible Assets, net	166,577	167,926	172,357	177,245	181,652	186,393	197,187	201,215	172,357	197,187	167,926	186,393	166,577	181,652	205,053	214,523	147,195
Deferred Income Taxes, long term	0	19,818	20,050	19,689	19,508	19,540	11,878	13,267	20,050	11,878	19,818	19,540	0	19,508	15,256	18,009	44,277
Total Assets	727,063	753,614	760,441	771,998	773,058	783,395	798,729	796,169	760,441	798,729	753,614	783,395	727,063	773,058	798,576	790,561	719,903
Accounts payable	15,616				23,048	21,974						21,974	15,616	23,048
Accrued liabilities	21,896		16,858		18,109	19,485	18,589	17,522	16,858	18,589		19,485	21,896	18,109	15,940	15,961
Current portion of contingent consideration	12,919				9,969		9,545	10,722		9,545			12,919	9,969	10,818
Other current liabilities	0	50	100	150	200				100		50		0	200	599
Total current liabilities	66,727	61,629	60,087	60,801	60,515	59,504	57,099	63,354	60,087	57,099	61,629	59,504	66,727	60,515	65,941	62,920
Other Long Term Liabilities	908				0	628	692	539		692		628	908	0	531
Total Liabilities	219,835	202,818	212,715	224,816	227,959	239,825	255,490	256,584	212,715	255,490	202,818	239,825	219,835	227,959	261,691	264,237
Retained earnings	(16,015)	27,060	26,466	26,800	27,575	28,163	32,316	31,247	26,466	32,316	27,060	28,163	(16,015)	27,575	30,963	28,616	29,667
Accumulated other comprehensive loss	(791)	(1,055)	(1,187)	(880)	(833)	(1,198)	(683)	(618)	(1,187)	(683)	(1,055)	(1,198)	(791)	(833)	(681)	(1,093)	(980)
Total Stockholders' Equity	507,228	550,796	547,726	547,182	545,099	543,570	543,239	539,585	547,726	543,239	550,796	543,570	507,228	545,099	536,885	526,324	523,306
Total Liabilities and Stockholders' Equity	$ 727,063	753,614	760,441	771,998	773,058	783,395	798,729	796,169	760,441	798,729	753,614	783,395	$ 727,063	773,058	798,576	790,561	719,903
As previously reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net sales		87,384	89,234	83,703	90,897			87,331	172,937	179,480	260,321	266,077		356,974
Cost of sales				40,529	45,340	48,746	44,493	41,506	83,929	85,999	127,829	134,745		180,085	174,757
Gross profit		43,484	45,834	43,174	45,557	37,851	47,656	45,825	89,008	93,481	132,492	131,332		176,889	179,668
Research and development				6,202	7,289	6,855	6,069	6,718	12,381	12,787	18,189	19,642		26,931	27,486	26,319
Sales and marketing		20,301	20,569	20,559	20,218	19,355	20,983	20,067	41,128	41,050	61,429	60,405		80,623	83,200	76,121	64,505
General and administrative		6,784	8,089	7,427	7,658	6,917	7,973	7,323	15,516	15,296	22,300	22,213		29,871	26,639	26,186
Amortization of intangibles						5,106	4,061	4,015		8,076		13,182		17,912	16,622	16,617	9,309
Change in fair value of contingent consideration						(10,044)	617	801		1,418		(8,626)		(8,196)	(1,808)
Acquisition, restructuring and other items, net						18,779	2,302			4,966		23,745		26,600	10,760
Total operating expenses		40,797	44,517	42,104	44,217	48,002	43,081	42,583	86,621	85,664	127,418	133,666		177,883	166,728	162,226	129,217
Operating income (loss)		2,687	1,317	1,070	1,340	(10,151)	4,575	3,242	2,387	7,817		(2,334)		(994)	12,940	6,288	(3,908)
Other expense		(868)	(1,048)	(945)	(860)	(971)	(954)	(1,025)	(1,993)	(1,979)	(2,861)	(2,950)		(3,812)	(3,544)	(2,707)	(2,096)
Total other expenses, net		(1,675)	(2,045)	(1,744)	(1,607)	(1,828)	(1,746)	(1,824)	(3,789)	(3,570)	(5,464)	(5,398)		(7,005)	(7,200)	(7,875)	(1,514)
Income (loss) before income tax expense (benefit)		1,012	(728)	(674)	(267)	(11,979)	2,829	1,418	(1,402)	4,247	(390)	(7,732)		(7,999)	5,740	(1,587)	(5,422)
Income tax expense (benefit)		382	(366)	83	547	(7,717)	1,491	948	(283)	2,439	99	(5,278)		(4,731)	3,074	(376)	(239)
Net income (loss)		630	(362)	(757)	(814)	(4,262)	1,338	470	(1,119)	1,808	(489)	(2,454)		(3,268)	2,666	(1,211)	(5,183)
Foreign currency translation						(624)	(104)	0		(104)		(728)		(411)	295
Other comprehensive income (loss), before tax						(508)	(100)	41		(60)		(568)		(235)	247
Other comprehensive income (loss), net of tax						(551)	(101)	26		(76)		(627)		(299)	265
Total comprehensive income (loss), net of tax						(4,813)	1,237	496		1,732		(3,081)		(3,567)	2,931
Net cash provided by (used in) operating activities				4,699				5,352	14,278	3,205	26,672	15,436		26,242	24,681
Net cash provided by (used in) investing activities				(743)				(5,258)	(1,143)	(7,773)	(3,888)	(12,042)		(13,293)	(16,448)
Net cash provided by (used in) financing activities				(2,071)				(2,391)	(12,370)	3,381	(19,167)	641		(10,465)	(14,016)
Inventories						68,710	75,315	70,421		75,315		68,710			61,234
Prepaid expenses and other					4,783	4,859	6,753	6,777		6,753		4,859		4,783	5,471
Total current assets					151,449	154,654	159,355	150,638		159,355		154,654		151,449	147,097
Property, Plant and Equipment, net					54,560	58,295	67,552	66,794		67,552		58,295		54,560	66,590	62,391
Other Assets				4,818	5,288	4,060	2,741	3,345		2,741		4,060		5,288	3,926
Intangible Assets, net		168,080	172,511	177,399	181,806	186,547	197,362	201,440	172,511	197,362	168,080	186,547		181,806	205,256	214,673	147,363
Deferred Income Taxes, long term		19,563	19,826	19,436	19,268	19,107	11,327	12,903	19,826	11,327	19,563	19,107		19,268	15,028	18,016	44,194
Total Assets		753,513	760,371	771,789	773,623	783,136	799,331	796,114	760,371	799,331	753,513	783,136		773,623	798,891	790,734	719,988
Accounts payable					23,668	21,696						21,696		23,668
Accrued liabilities			16,975		18,331	19,946	19,177	17,700	16,975	19,177		19,946		18,331	16,652	16,356
Current portion of contingent consideration							9,795	10,897		9,795					10,918
Other current liabilities		0	0	0	0				0		0			0	599
Total current liabilities		61,579	60,104	60,651	61,157	59,687	57,937	63,707	60,104	57,937	61,579	59,687		61,157	66,753	63,315
Other Long Term Liabilities						0	124	32		124		0			84
Total Liabilities		202,768	212,732	224,666	228,601	239,380	255,760	256,430	212,732	255,760	202,768	239,380		228,601	262,056	264,632
Retained earnings		27,744	27,114	27,476	28,233	29,047	33,309	31,971	27,114	33,309	27,744	29,047		28,233	31,501	28,835	30,046
Accumulated other comprehensive loss		(1,790)	(1,922)	(1,615)	(1,568)	(1,896)	(1,345)	(1,243)	(1,922)	(1,345)	(1,790)	(1,896)		(1,568)	(1,269)	(1,534)	(1,274)
Total Stockholders' Equity		550,745	547,639	547,123	545,022	543,756	543,571	539,684	547,639	543,571	550,745	543,756		545,022	536,835	526,102	523,391
Total Liabilities and Stockholders' Equity		753,513	760,371	771,789	773,623	783,136	799,331	796,114	760,371	799,331	753,513	783,136		773,623	798,891	790,734	719,988
Adjustments
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net sales		50	50	50	(200)			(240)	100	(240)	150	(240)		(440)
Cost of sales				(147)	26	178	828	(379)	(147)	449	(147)	627		653	(506)
Gross profit		50	50	197	(226)	(178)	(828)	139	247	(689)	297	(867)		(1,093)	506
Research and development				(73)	(738)	(277)	207	470	(73)	678	(73)	401		(337)	638	(228)
Sales and marketing		654	809	641	933	444	553	668	1,450	1,221	2,105	1,664		2,597	2,105	1,443	1,252
General and administrative		117	(7)	487	(210)	(304)	(187)	(8)	480	(195)	597	(499)		(709)	263	(151)
Amortization of intangibles						82	(50)	22		(28)		54		54	(60)	(18)	84
Change in fair value of contingent consideration						250	(75)	(75)		(150)		100		100	(100)
Acquisition, restructuring and other items, net						(103)	(240)			(240)		(343)		(343)	113
Total operating expenses		771	802	1,055	(15)	92	208	1,077	1,857	1,285	2,629	1,377		1,362	2,959	1,046	1,336
Operating income (loss)		(721)	(752)	(858)	(211)	(270)	(1,036)	(938)	(1,610)	(1,974)		(2,244)		(2,455)	(2,453)	(1,046)	(1,336)
Other expense		654	809	827	630	497	580	616	1,636	1,196	2,291	1,693		2,323	1,899	1,296	1,105
Total other expenses, net		654	809	827	630	497	580	616	1,636	1,196	2,291	1,693		2,323	1,899	1,296	1,105
Income (loss) before income tax expense (benefit)		(67)	57	(31)	419	227	(456)	(322)	26	(778)	(41)	(551)		(132)	(554)	250	(231)
Income tax expense (benefit)		(31)	29	(13)	193	118	(187)	(136)	16	(323)	(15)	(205)		(12)	(235)	90	(83)
Net income (loss)		(36)	28	(18)	226	109	(269)	(186)	10	(455)	(26)	(346)		(120)	(319)	160	(148)
Foreign currency translation						37	37	37		74		110		147	147
Other comprehensive income (loss), before tax						37	37	37		74		110		147	147
Other comprehensive income (loss), net of tax						37	37	37		74		110		147	147
Total comprehensive income (loss), net of tax						146	(232)	(149)		(381)		(236)		27	(172)
Net cash provided by (used in) operating activities				0				(410)	0	(557)	0	(557)		(557)	0
Net cash provided by (used in) investing activities				0				410	0	557	0	557		557	0
Net cash provided by (used in) financing activities				0				0	0	0	0	0		0	0
Inventories						57	57	885		57		57			506
Prepaid expenses and other					(651)	(221)	(191)	(311)		(191)		(221)		(651)	(591)
Total current assets					(651)	(164)	(134)	574		(134)		(164)		(651)	(85)
Property, Plant and Equipment, net					(110)	(80)	(829)	(605)		(829)		(80)		(110)	(135)	(16)
Other Assets				110	110	224	(15)	(53)		(15)		224		110	(120)
Intangible Assets, net		(154)	(154)	(154)	(154)	(154)	(175)	(225)	(154)	(175)	(154)	(154)		(154)	(203)	(150)	(168)
Deferred Income Taxes, long term		255	224	253	240	433	551	364	224	551	255	433		240	228	(7)	83
Total Assets		101	70	209	(565)	259	(602)	55	70	(602)	101	259		(565)	(315)	(173)	(85)
Accounts payable					(620)	278						278		(620)
Accrued liabilities			(117)		(222)	(461)	(588)	(178)	(117)	(588)		(461)		(222)	(712)	(395)
Current portion of contingent consideration							(250)	(175)		(250)					(100)
Other current liabilities		50	100	150	200				100		50			200	0
Total current liabilities		50	(17)	150	(642)	(183)	(838)	(353)	(17)	(838)	50	(183)		(642)	(812)	(395)
Other Long Term Liabilities						628	568	507		568		628			447
Total Liabilities		50	(17)	150	(642)	445	(270)	154	(17)	(270)	50	445		(642)	(365)	(395)
Retained earnings		(684)	(648)	(676)	(658)	(884)	(993)	(724)	(648)	(993)	(684)	(884)		(658)	(538)	(219)	(379)
Accumulated other comprehensive loss		735	735	735	735	698	662	625	735	662	735	698		735	588	441	294
Total Stockholders' Equity		51	87	59	77	(186)	(332)	(99)	87	(332)	51	(186)		77	50	222	(85)
Total Liabilities and Stockholders' Equity		$ 101	$ 70	$ 209	$ (565)	$ 259	$ (602)	$ 55	$ 70	$ (602)	$ 101	$ 259		$ (565)	$ (315)	$ (173)	$ (85)

Quarterly Information (unaudi83

Quarterly Information (unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								6 Months Ended		9 Months Ended		12 Months Ended
	May 31, 2016	Feb. 29, 2016	Nov. 30, 2015	Aug. 31, 2015	May 31, 2015	Feb. 28, 2015	Nov. 30, 2014	Aug. 31, 2014	Nov. 30, 2015	Nov. 30, 2014	Feb. 29, 2016	Feb. 28, 2015	May 31, 2016	May 31, 2015	May 31, 2014
Summary of Quarterly Financial Information
Net sales	$ 93,419	$ 87,434	$ 89,284	$ 83,753	$ 90,697	$ 86,597	$ 92,149	$ 87,091	$ 173,037	$ 179,240	$ 260,471	$ 265,837	$ 353,890	$ 356,534	$ 354,425
Earnings per common share
Basic (usd per share)	$ (1.19)	$ 0.02	$ (0.01)	$ (0.02)	$ (0.02)	$ (0.12)	$ 0.03	$ 0.01					$ (1.21)	$ (0.09)	$ 0.07
Diluted (usd per share)	$ (1.19)	$ 0.02	$ (0.01)	$ (0.02)	$ (0.02)	$ (0.12)	$ 0.03	$ 0.01					$ (1.21)	$ (0.09)	$ 0.07

Quarterly Information - Adjustm

Quarterly Information - Adjustments for Error Corrections (Details) - USD ($) $ in Thousands	3 Months Ended								6 Months Ended		9 Months Ended		12 Months Ended
	May 31, 2016	Feb. 29, 2016	Nov. 30, 2015	Aug. 31, 2015	May 31, 2015	Feb. 28, 2015	Nov. 30, 2014	Aug. 31, 2014	Nov. 30, 2015	Nov. 30, 2014	Feb. 29, 2016	Feb. 28, 2015	May 31, 2016	May 31, 2015	May 31, 2014	May 31, 2013	May 31, 2012
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net sales	$ 93,419	$ 87,434	$ 89,284	$ 83,753	$ 90,697	$ 86,597	$ 92,149	$ 87,091	$ 173,037	$ 179,240	$ 260,471	$ 265,837	$ 353,890	$ 356,534	$ 354,425
Cost of sales				40,382	45,366	48,924	45,321	41,127	83,782	86,448	127,682	135,372	179,574	180,738	174,251
Gross profit	41,527	43,534	45,884	43,371	45,331	37,673	46,828	45,964	89,255	92,792	132,789	130,465	174,316	175,796	180,174
Research and development				6,129	6,551	6,578	6,276	7,188	12,308	13,465	18,116	20,043	25,053	26,594	28,124	$ 26,091
Sales and marketing		20,955	21,378	21,200	21,151	19,799	21,536	20,735	42,578	42,271	63,534	62,069	84,723	83,220	85,305	77,564	$ 65,757
General and administrative		6,901	8,082	7,914	7,448	6,613	7,786	7,315	15,996	15,101	22,897	21,714	29,603	29,162	26,902	26,035
Amortization of intangibles						5,188	4,011	4,037		8,048		13,236	17,964	17,966	16,562	16,599	9,393
Change in fair value of contingent consideration						(9,794)	542	726		1,268		(8,526)	948	(8,096)	(1,908)
Acquisition, restructuring and other items, net						18,676	2,062			4,726		23,402	12,591	26,257	10,873
Total operating expenses		41,568	45,319	43,159	44,202	48,094	43,289	43,660	88,478	86,949	130,047	135,043	173,298	179,245	169,687	163,272	130,553
Operating income (loss)		1,966	565	212	1,129	(10,421)	3,539	2,304	777	5,843		(4,578)	1,018	(3,449)	10,487	5,242	(5,244)
Other expense		(214)	(239)	(118)	(230)	(474)	(374)	(409)	(357)	(783)	(570)	(1,257)	(886)	(1,489)	(1,645)	(1,411)	(991)
Total other expenses, net		(1,021)	(1,236)	(917)	(977)	(1,331)	(1,166)	(1,208)	(2,153)	(2,374)	(3,173)	(3,705)	(4,271)	(4,682)	(5,301)	(6,579)	(409)
Income (loss) before income tax expense (benefit)		945	(671)	(705)	152	(11,752)	2,373	1,096	(1,376)	3,469	(431)	(8,283)	(3,253)	(8,131)	5,186	(1,337)	(5,653)
Income tax expense (benefit)		351	(337)	70	740	(7,599)	1,304	812	(267)	2,116	84	(5,483)	40,337	(4,743)	2,839	(286)	(322)
Net income (loss)	(43,075)	594	(334)	(775)	(588)	(4,153)	1,069	284	(1,109)	1,353	(515)	(2,800)	(43,590)	(3,388)	2,347	(1,051)	(5,331)
Foreign currency translation						(587)	(67)	37		(30)		(618)	(112)	(264)	442
Other comprehensive income (loss), before tax						(471)	(63)	78		14		(458)	134	(88)	394
Other comprehensive income (loss), net of tax						(514)	(64)	63		(2)		(517)	42	(152)	412
Total comprehensive income (loss), net of tax						(4,667)	1,005	347		1,351		(3,317)	(43,548)	(3,540)	2,759
Inventories	55,370				67,388	68,767	75,372	71,306		75,372		68,767	55,370	67,388	61,740
Prepaid expenses and other	3,243				4,132	4,638	6,562	6,466		6,562		4,638	3,243	4,132	4,880
Total current assets	146,254				150,798	154,490	159,221	151,212		159,221		154,490	146,254	150,798	147,012
Property, Plant and Equipment, net	48,284				54,450	58,215	66,723	66,189		66,723		58,215	48,284	54,450	66,455	62,375
Other Assets	4,696			4,928	5,398	4,284	2,726	3,292		2,726		4,284	4,696	5,398	3,806
Intangible Assets, net	166,577	167,926	172,357	177,245	181,652	186,393	197,187	201,215	172,357	197,187	167,926	186,393	166,577	181,652	205,053	214,523	147,195
Deferred Income Taxes, long term	0	19,818	20,050	19,689	19,508	19,540	11,878	13,267	20,050	11,878	19,818	19,540	0	19,508	15,256	18,009	44,277
Total Assets	727,063	753,614	760,441	771,998	773,058	783,395	798,729	796,169	760,441	798,729	753,614	783,395	727,063	773,058	798,576	790,561	719,903
Accounts payable	15,616				23,048	21,974						21,974	15,616	23,048
Accrued liabilities	21,896		16,858		18,109	19,485	18,589	17,522	16,858	18,589		19,485	21,896	18,109	15,940	15,961
Current portion of contingent consideration	12,919				9,969		9,545	10,722		9,545			12,919	9,969	10,818
Other current liabilities	0	50	100	150	200				100		50		0	200	599
Total current liabilities	66,727	61,629	60,087	60,801	60,515	59,504	57,099	63,354	60,087	57,099	61,629	59,504	66,727	60,515	65,941	62,920
Deferred Income Taxes, long term	21,684				1,119								21,684	1,119
Other Long Term Liabilities	908				0	628	692	539		692		628	908	0	531
Total Liabilities	219,835	202,818	212,715	224,816	227,959	239,825	255,490	256,584	212,715	255,490	202,818	239,825	219,835	227,959	261,691	264,237
Retained earnings	(16,015)	27,060	26,466	26,800	27,575	28,163	32,316	31,247	26,466	32,316	27,060	28,163	(16,015)	27,575	30,963	28,616	29,667
Accumulated other comprehensive loss	(791)	(1,055)	(1,187)	(880)	(833)	(1,198)	(683)	(618)	(1,187)	(683)	(1,055)	(1,198)	(791)	(833)	(681)	(1,093)	(980)
Total Stockholders' Equity	507,228	550,796	547,726	547,182	545,099	543,570	543,239	539,585	547,726	543,239	550,796	543,570	507,228	545,099	536,885	526,324	523,306
Total Liabilities and Stockholders' Equity	$ 727,063	753,614	760,441	771,998	773,058	783,395	798,729	796,169	760,441	798,729	753,614	783,395	727,063	773,058	798,576	790,561	719,903
Net cash provided by (used in) operating activities				4,699				4,942	14,278	2,648	26,672	14,879	45,216	25,685	24,681
Net cash provided by (used in) investing activities				(743)				(4,848)	(1,143)	(7,216)	(3,888)	(11,485)	(7,569)	(12,736)	(16,448)
Net cash provided by (used in) financing activities				(2,071)				(2,391)	(12,370)	3,381	(19,167)	641	$ (23,663)	(10,465)	(14,016)
As previously reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net sales		87,384	89,234	83,703	90,897			87,331	172,937	179,480	260,321	266,077		356,974
Cost of sales				40,529	45,340	48,746	44,493	41,506	83,929	85,999	127,829	134,745		180,085	174,757
Gross profit		43,484	45,834	43,174	45,557	37,851	47,656	45,825	89,008	93,481	132,492	131,332		176,889	179,668
Research and development				6,202	7,289	6,855	6,069	6,718	12,381	12,787	18,189	19,642		26,931	27,486	26,319
Sales and marketing		20,301	20,569	20,559	20,218	19,355	20,983	20,067	41,128	41,050	61,429	60,405		80,623	83,200	76,121	64,505
General and administrative		6,784	8,089	7,427	7,658	6,917	7,973	7,323	15,516	15,296	22,300	22,213		29,871	26,639	26,186
Amortization of intangibles						5,106	4,061	4,015		8,076		13,182		17,912	16,622	16,617	9,309
Change in fair value of contingent consideration						(10,044)	617	801		1,418		(8,626)		(8,196)	(1,808)
Acquisition, restructuring and other items, net						18,779	2,302			4,966		23,745		26,600	10,760
Total operating expenses		40,797	44,517	42,104	44,217	48,002	43,081	42,583	86,621	85,664	127,418	133,666		177,883	166,728	162,226	129,217
Operating income (loss)		2,687	1,317	1,070	1,340	(10,151)	4,575	3,242	2,387	7,817		(2,334)		(994)	12,940	6,288	(3,908)
Other expense		(868)	(1,048)	(945)	(860)	(971)	(954)	(1,025)	(1,993)	(1,979)	(2,861)	(2,950)		(3,812)	(3,544)	(2,707)	(2,096)
Total other expenses, net		(1,675)	(2,045)	(1,744)	(1,607)	(1,828)	(1,746)	(1,824)	(3,789)	(3,570)	(5,464)	(5,398)		(7,005)	(7,200)	(7,875)	(1,514)
Income (loss) before income tax expense (benefit)		1,012	(728)	(674)	(267)	(11,979)	2,829	1,418	(1,402)	4,247	(390)	(7,732)		(7,999)	5,740	(1,587)	(5,422)
Income tax expense (benefit)		382	(366)	83	547	(7,717)	1,491	948	(283)	2,439	99	(5,278)		(4,731)	3,074	(376)	(239)
Net income (loss)		630	(362)	(757)	(814)	(4,262)	1,338	470	(1,119)	1,808	(489)	(2,454)		(3,268)	2,666	(1,211)	(5,183)
Foreign currency translation						(624)	(104)	0		(104)		(728)		(411)	295
Other comprehensive income (loss), before tax						(508)	(100)	41		(60)		(568)		(235)	247
Other comprehensive income (loss), net of tax						(551)	(101)	26		(76)		(627)		(299)	265
Total comprehensive income (loss), net of tax						(4,813)	1,237	496		1,732		(3,081)		(3,567)	2,931
Inventories						68,710	75,315	70,421		75,315		68,710			61,234
Prepaid expenses and other					4,783	4,859	6,753	6,777		6,753		4,859		4,783	5,471
Total current assets					151,449	154,654	159,355	150,638		159,355		154,654		151,449	147,097
Property, Plant and Equipment, net					54,560	58,295	67,552	66,794		67,552		58,295		54,560	66,590	62,391
Other Assets				4,818	5,288	4,060	2,741	3,345		2,741		4,060		5,288	3,926
Intangible Assets, net		168,080	172,511	177,399	181,806	186,547	197,362	201,440	172,511	197,362	168,080	186,547		181,806	205,256	214,673	147,363
Deferred Income Taxes, long term		19,563	19,826	19,436	19,268	19,107	11,327	12,903	19,826	11,327	19,563	19,107		19,268	15,028	18,016	44,194
Total Assets		753,513	760,371	771,789	773,623	783,136	799,331	796,114	760,371	799,331	753,513	783,136		773,623	798,891	790,734	719,988
Accounts payable					23,668	21,696						21,696		23,668
Accrued liabilities			16,975		18,331	19,946	19,177	17,700	16,975	19,177		19,946		18,331	16,652	16,356
Current portion of contingent consideration							9,795	10,897		9,795					10,918
Other current liabilities		0	0	0	0				0		0			0	599
Total current liabilities		61,579	60,104	60,651	61,157	59,687	57,937	63,707	60,104	57,937	61,579	59,687		61,157	66,753	63,315
Other Long Term Liabilities						0	124	32		124		0			84
Total Liabilities		202,768	212,732	224,666	228,601	239,380	255,760	256,430	212,732	255,760	202,768	239,380		228,601	262,056	264,632
Retained earnings		27,744	27,114	27,476	28,233	29,047	33,309	31,971	27,114	33,309	27,744	29,047		28,233	31,501	28,835	30,046
Accumulated other comprehensive loss		(1,790)	(1,922)	(1,615)	(1,568)	(1,896)	(1,345)	(1,243)	(1,922)	(1,345)	(1,790)	(1,896)		(1,568)	(1,269)	(1,534)	(1,274)
Total Stockholders' Equity		550,745	547,639	547,123	545,022	543,756	543,571	539,684	547,639	543,571	550,745	543,756		545,022	536,835	526,102	523,391
Total Liabilities and Stockholders' Equity		753,513	760,371	771,789	773,623	783,136	799,331	796,114	760,371	799,331	753,513	783,136		773,623	798,891	790,734	719,988
Net cash provided by (used in) operating activities				4,699				5,352	14,278	3,205	26,672	15,436		26,242	24,681
Net cash provided by (used in) investing activities				(743)				(5,258)	(1,143)	(7,773)	(3,888)	(12,042)		(13,293)	(16,448)
Net cash provided by (used in) financing activities				(2,071)				(2,391)	(12,370)	3,381	(19,167)	641		(10,465)	(14,016)
Adjustments
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net sales		50	50	50	(200)			(240)	100	(240)	150	(240)		(440)
Cost of sales				(147)	26	178	828	(379)	(147)	449	(147)	627		653	(506)
Gross profit		50	50	197	(226)	(178)	(828)	139	247	(689)	297	(867)		(1,093)	506
Research and development				(73)	(738)	(277)	207	470	(73)	678	(73)	401		(337)	638	(228)
Sales and marketing		654	809	641	933	444	553	668	1,450	1,221	2,105	1,664		2,597	2,105	1,443	1,252
General and administrative		117	(7)	487	(210)	(304)	(187)	(8)	480	(195)	597	(499)		(709)	263	(151)
Amortization of intangibles						82	(50)	22		(28)		54		54	(60)	(18)	84
Change in fair value of contingent consideration						250	(75)	(75)		(150)		100		100	(100)
Acquisition, restructuring and other items, net						(103)	(240)			(240)		(343)		(343)	113
Total operating expenses		771	802	1,055	(15)	92	208	1,077	1,857	1,285	2,629	1,377		1,362	2,959	1,046	1,336
Operating income (loss)		(721)	(752)	(858)	(211)	(270)	(1,036)	(938)	(1,610)	(1,974)		(2,244)		(2,455)	(2,453)	(1,046)	(1,336)
Other expense		654	809	827	630	497	580	616	1,636	1,196	2,291	1,693		2,323	1,899	1,296	1,105
Total other expenses, net		654	809	827	630	497	580	616	1,636	1,196	2,291	1,693		2,323	1,899	1,296	1,105
Income (loss) before income tax expense (benefit)		(67)	57	(31)	419	227	(456)	(322)	26	(778)	(41)	(551)		(132)	(554)	250	(231)
Income tax expense (benefit)		(31)	29	(13)	193	118	(187)	(136)	16	(323)	(15)	(205)		(12)	(235)	90	(83)
Net income (loss)		(36)	28	(18)	226	109	(269)	(186)	10	(455)	(26)	(346)		(120)	(319)	160	(148)
Foreign currency translation						37	37	37		74		110		147	147
Other comprehensive income (loss), before tax						37	37	37		74		110		147	147
Other comprehensive income (loss), net of tax						37	37	37		74		110		147	147
Total comprehensive income (loss), net of tax						146	(232)	(149)		(381)		(236)		27	(172)
Inventories						57	57	885		57		57			506
Prepaid expenses and other					(651)	(221)	(191)	(311)		(191)		(221)		(651)	(591)
Total current assets					(651)	(164)	(134)	574		(134)		(164)		(651)	(85)
Property, Plant and Equipment, net					(110)	(80)	(829)	(605)		(829)		(80)		(110)	(135)	(16)
Other Assets				110	110	224	(15)	(53)		(15)		224		110	(120)
Intangible Assets, net		(154)	(154)	(154)	(154)	(154)	(175)	(225)	(154)	(175)	(154)	(154)		(154)	(203)	(150)	(168)
Deferred Income Taxes, long term		255	224	253	240	433	551	364	224	551	255	433		240	228	(7)	83
Total Assets		101	70	209	(565)	259	(602)	55	70	(602)	101	259		(565)	(315)	(173)	(85)
Accounts payable					(620)	278						278		(620)
Accrued liabilities			(117)		(222)	(461)	(588)	(178)	(117)	(588)		(461)		(222)	(712)	(395)
Current portion of contingent consideration							(250)	(175)		(250)					(100)
Other current liabilities		50	100	150	200				100		50			200	0
Total current liabilities		50	(17)	150	(642)	(183)	(838)	(353)	(17)	(838)	50	(183)		(642)	(812)	(395)
Other Long Term Liabilities						628	568	507		568		628			447
Total Liabilities		50	(17)	150	(642)	445	(270)	154	(17)	(270)	50	445		(642)	(365)	(395)
Retained earnings		(684)	(648)	(676)	(658)	(884)	(993)	(724)	(648)	(993)	(684)	(884)		(658)	(538)	(219)	(379)
Accumulated other comprehensive loss		735	735	735	735	698	662	625	735	662	735	698		735	588	441	294
Total Stockholders' Equity		51	87	59	77	(186)	(332)	(99)	87	(332)	51	(186)		77	50	222	(85)
Total Liabilities and Stockholders' Equity		$ 101	$ 70	209	$ (565)	$ 259	$ (602)	55	70	(602)	101	259		(565)	(315)	$ (173)	$ (85)
Net cash provided by (used in) operating activities				0				(410)	0	(557)	0	(557)		(557)	0
Net cash provided by (used in) investing activities				0				410	0	557	0	557		557	0
Net cash provided by (used in) financing activities				$ 0				$ 0	$ 0	$ 0	$ 0	$ 0		$ 0	$ 0

Valuation and Qualifying Acco85

Valuation and Qualifying Accounts (Details) - USD ($) $ in Thousands	12 Months Ended
	May 31, 2016	May 31, 2015	May 31, 2014
Valuation and Qualifying Accounts
Balance at Beginning of Year	$ 4,834	$ 3,267	$ 1,984
Additions - Charged to costs and expenses	44,433	2,313	8,161
Deductions	(2,686)	(746)	(6,878)
Balance at End of Period	46,581	4,834	3,267
Allowance for deferred tax asset
Valuation and Qualifying Accounts
Balance at Beginning of Year	1,791	1,531	712
Additions - Charged to costs and expenses	40,685	467	819
Deductions	(267)	(207)	0
Balance at End of Period	42,209	1,791	1,531
Allowance for sales returns and doubtful accounts
Valuation and Qualifying Accounts
Balance at Beginning of Year	3,043	1,736	1,272
Additions - Charged to costs and expenses	3,748	1,846	7,342
Deductions	(2,419)	(539)	(6,878)
Balance at End of Period	$ 4,372	$ 3,043	$ 1,736